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ABSTRACT 
ENGINEERING NANOPARTICLES SURFACE FOR BIOSENSING:  
“CHEMICAL NOSES’ TO DETECT AND IDENTIFY PROTEINS, 
BACTERIA AND CANCEROUS CELLS 
 
FEBRUARY 2011 
 
OSCAR R. MIRANDA, B.E., NATIONAL UNIVERSITY OF ENGINEERING 
  
MBA (POST-GRADUATE), CENTRAL AMERICAN UNIVERSITY 
 
M.Sc., VILLANOVA UNIVERSITY, PENNSYLVANIA 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS-AMHERST 
 
Directed by: Professor Vincent M. Rotello 
 
 
Rapid and sensitive detection of biomolecules is an important issue in nanomedicine. 
Many disorders are manifested by changes in protein levels of serum and other biofluids. 
Rapid and effective differentiation between normal and cancerous cells is an important 
challenge for the diagnosis and treatment of tumor. Likewise, rapid and effective 
identification of pathogens is a key target in both biomedical and environmental 
monitoring. Most biological recognition processes occur via specific interactions. Gold 
nanoparticles (AuNPs) feature sizes commensurate with biomacromolecules, coupled 
with useful physical and optical properties. A key issue in the use of nanomaterials is 
controlling the interfacial interactions of these complex systems. Modulation of these 
physicochemical properties can be readily achieved by engineering nanoparticles surface. 
Inspired by the idea of mimicking nature, a convenient, precise and rapid method for 
sensing proteins, cancerous cells and bacteria has been developed by overtaking the 
superb performance of biological olfactory systems in odor detection, identification, 
tracking, and location.   On the fundamental side, an array-based/‘chemical nose’ sensor 
composed of cationic functionalized AuNPs as receptors and anionic fluorescent 
conjugated polymers or green fluorescent proteins or enzyme/substrates as transducers 
that can properly detect and identify proteins, bacteria, and cancerous cells has been 
successfully fabricated. 
 ix
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CHAPTER 1 
INTRODUCTION 
The detection and quantification of cells, proteins, and other biosystems in complex 
matrices is important for disease detection. There are wide varieties of methods available 
to approach this goal, including antibodies used in ELISA-type tests, proteomics and 
related approaches coupled with mass spectrometry, as well as widely employed 
techniques such as gel electrophoresis to detect serum imbalances in patients with liver 
failure or other gross metabolic problems.1 For the detection of microorganisms, plating 
and culturing as well as PCR are standard; viral infections are generally detected by 
ELISA type tests, or in the case of early detection of HIV also by PCR.2 Other methods 
for the detection of microorganisms, including electrochemical assays, have been 
suggested.3 However, the field is open when it comes to simple and rapid assays that 
indicate the presence of an analyte by color or fluorescence change; in such a case one 
“strip” might even contain a small library of indicators, the combined responses of which 
would indicate the presence or absence of specific analytes. The combination of selective 
instead of specific sensors or indicators into a sensor array generates a chemical nose or 
tongue, in which the combined response of the library of these sensors identifies analytes 
or disease states.  
This dissertation will focus on array-based sensing using gold nanoparticles (AuNPs) and 
fluorescent conjugated polymer or green fluorescent proteins or enzyme/substrate 
complexes as ‘chemical noses’ to detect and identify protein, bacteria and cancerous cell. 
The read-out of these systems is based on optical methods i.e fluorescence or  UV-vis 
spectroscopy. 
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1.1 Nanoparticles Surfaces: An Excellent Scaffold for Biological Applications 
Nanobiotechnology has emerged as a new exciting field in recent years with much 
promise.4 The use of nanomaterials in nanomedicine merges the interfaces among the 
fields of material science, chemistry and biology. Gold nanoparticles (AuNPs) used as 
receptors, offer a useful platform for biomolecular surface recognition, providing unique 
properties with potentially wide-ranging therapeutic applications.5 The utility of AuNPs 
arises from a variety of desirable structural attributes, including the similar size of 
nanoparticles and biomolecules such as proteins and polynucleic acids (Figure 1.1).6 The 
size of the asotropic NPs core can be tuned from 1.5 to more than 10 nm which can 
provides a suitable platform for the interaction of AuNPs with protein and other 
biomolecule surfaces  
 
 
Figure 1.1 Schematic representation of a 2 nm core gold nanoparticle with 11-mercaptoundecanoic acids 
monolayer and relative sizes of aspirin crystal (small molecule), lysozyme and -chymotrypsin (proteins), 
and a 24-mer DNA duplex (Reproduced from Ref. 6). 
 
Nanoparticles can be fabricated with a wide range of surface functionality providing a 
versatile system for creation of surface-specific receptors and can be fashioned with a 
wide range of metal and semiconductor core materials that impart useful properties such 
as fluorescence and magnetic behavior.7 The applicable properties of some well known 
core materials and corresponding possible ligands used for surface functionalization with 
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their possible applications are summarized in Table 1.1. From Table 1.1, 3 metallic and 2 
non-metallic nanoparticles (i.e. Au, Ag etc.) are become more popular for molecular 
recognition, delivery and sensing where as semiconductor and magnetic nanoparticles are 
drawing interest as imaging agents.8 
Table 1.1: Characteristics, ligands and representative applications for various metal and semiconductor 
materials (Reproduced from Ref. 8). 
  
Core material Characteristics  Ligand Applications 
Au Optical absorption, 
fluorescence and 
fluorescence quenching, 
stability 
Thiol, disulfide, 
phosphine, amine
Biomolecular 
recognition, 
delivery, sensing 
Ag Surface-enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic property Thiol, phosphine, 
amine, 
isocyanide 
Bio-catalyst, sensing
CdSe Luminescence, photo-
stability 
Thiol, phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic property Diol, dopamine 
derivative, amine
MR imaging and 
biomolecule 
purification, sensing
SiO2 Biocompatibility Alkoxysilane Biocompatible by 
surface coating,  
 
Finally, the self-template nature of this system to guest molecules is allowing an increase 
in the affinity and selectivity upon incubation with the guest molecules. Applying these 
characteristic to the selective recognition of biomacromolecules, however, requires 
suitable surface functionality which can be solved by using reported synthetic methods. 9  
There are several examples on nanoparticle-biomolecule interactions have been reported 
based on various biological and diagnostic applications.8 Nanoparticles can be made-up 
with a diverse array of metal, alloy, oxide and semiconductor materials, using standard 
reported procedure available in literatures which already mention before (Table 1.1). As 
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an example Brust and coworkers have developed a widely used particle preparation 
procedure for metallic nanoparticles by the reduction of metal salt in the presence 
surfactant and coating ligands (Figure 1.2).10 This synthetic approach, known as Brust-
Schiffrin method, involves the transfer of hydrogen tetrachloroaurate from aqueous phase 
to toluene phase by using surfactant TOAB and the subsequent reduction by sodium 
borohydride in the presence of alkanethiols to generate nanoparticles that are soluble in 
organic solvents. This reaction leads to the relatively monodisperse AuNPs protected by 
thiol ligands with diameters ranging from 1.5 to 5 nm.  The alkanethiols generally 
possess a footprint of ca. 0.2 nm2, while sterically bulky thiol ligands require much larger 
footprints for encapsulation on gold surfaces.  The nanoparticle size might be readily 
controlled by varying the reaction conditions including gold-to-thiol ratio, reduction rate 
and reaction temperature, etc.11  Thiol-protected AuNPs possess superior stability due to 
the synergic effect of strong thiol-gold interactions and van der Waals attractions of 
neighboring ligands.   The nanoparticles of this kind can then be thoroughly dried and 
redispersed in solution without any aggregation.  Single-phasic reduction of gold salts by 
sodium borohydride in the presence of thiols has also been developed,12 through which 
water-soluble AuNPs could be prepared in a single step.  In the biphasic reduction 
protocol, the absence of thiol ligands can lead to slightly larger nanoparticles stabilized 
by quaternary ammonium, which show considerable stability in solution and serve as 
excellent precursors for other functionalized nanoparticles.13 
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Figure 1.2. Synthesis of metal core gold nanoparticles through Brust-Schiffrin reduction. This synthesis 
involves transfer of hydrogen tetrachloroaurate from aqueous phase to toluene phase by using surfactant 
TOAB and the subsequent reduction by sodium borohydride in the presence of alkanethiols to generate 
nanoparticles that are soluble in organic solvents. The diameters of this asotropic gold nanoparticles 
ranging from 1.5 to 5 nm. 
 
Using this method various metallic nanoparticles (such as Ag, Pt, Pd, Cu etc.) have been 
prepared. In this protocol the size of the particle can be controlled by varying the metal-
ligand ratio and reaction conditions. For efficient biological applications, the most 
important requirements of the nanoparticle are surface functionality and water-solubility.  
To introduce the surface functionality, the most acceptable method is the Murray’s place-
exchange process (Figure 1.3a),14 where the initial ligands on the nanoparticle surface are 
replaced by external ligands of similar functionality as an instance, thiol or disulfide 
ligands for gold and silver particle. The other well known method is direct synthesis of 
metallic nanoparticles in presence of corresponding ligand to generate monolayer-
protected clusters (MPCs) and mixed monolayer-protected clusters (MMPCs). 
According to the necessity further functionality can be introduced through conventional 
organic protocols.15 Recently, another kind of watersoluble functionalized nanoparticles 
were reported by the incorporation of hydrophobic nanoparticles into the hydrophobic 
interiors of surfactant micelles.16,17 To improve the biocompatibility oligo(ethylene 
glycol) (OEG) and poly(ethylene glycol) (PEG) are commonly incorporated into the 
monolayers.12 The OEG or PEG are hydrophilic in nature to improve the water solubility 
with the added benefit these ligand resist the nonspecific interactions with biomolecules. 
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Therefore the slandered nanoparticle for controlled biomolecular interactions consists of 
hydrophobic interior, an OEG or PEG layer, and recognition elements on the surface 
(Figure 1.3b). 
 
Figure 1.3 a) Construction of nanoparticles through Brust reduction and subsequent modification such as 
Murray place-exchange reaction (i), (ii) and encapsulation of hydrophobic MPCs into surfactant micelles 
(iii). b) Multifunctional particle monolayers featuring a hydrophobic core for stability, OEG or PEG layer 
for biocompatibility, and recognition elements on the surface for interaction with biomolecules 
(Reproduced from Ref. 14).  
 
 
1.2 Physical Properties of Gold Nanoparticles 
 AuNPs possess unique optical, magnetic and electronic properties that are vitally 
related to their size and shape.  Solutions of spherical AuNPs exhibit colors ranging from 
dark brown to burgundy red to red violet with the core size increase (from 1 to 100 nm).  
UV/vis investigation reveals that AuNPs generally show an intensive absorption peak 
from 500 to 550 nm.18  This absorption band is usually referred to as “surface plasmon 
band”, which arises from the collective oscillation of the conduction electrons due to the 
resonant excitation by the incident photons (Figure 1.4).  This surface plasmon band is 
absent in both small nanoparticles (d < 2 nm) and bulk materials.  Mie theoretically 
interpreted the surface plasmon resonance (SPR) phenomena in 190819 and his theory has 
been extensively correlated with the experimental results.20,21  The SPR is sensitive not 
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only to nanoparticle size, but also to the surrounding environment such as ligand, solvent 
and temperature.  Particularly, the SPR frequency is dependent on the proximity to other 
nanoparticles.  Thus, under nanoparticle aggregation the surface plasmon band shows 
significant red-shifting (to ca. 650 nm) and broadening and the solution displays red-to-
blue color change due to the interparticle plasmon coupling.22  This phenomenon 
constitutes the cornerstone for their application in colorimetric sensing, which will be 
discussed in detail in the following sections. 
 
 
Figure 1.4 Schematic representation of the oscillation of conduction electrons across the nanoparticle in the 
electromagnetic field of the incident light (Reproduced from Ref(s). 22 and 23). 
  
For the application of AuNPs in solution, it is not a trivial task to determine their 
concentrations.  As the molar extinction coefficient of colloid gold (520 nm) is around 
4000 M-1 cm-1 per gold atom,23  the nanoparticle concentration can then be roughly 
estimated based on the number of gold atoms.  The extinction coefficients of AuNPs with 
different sizes and capping ligands have also been measured experimentally.24  A linear 
relationship is observed between logarithms of molar extinction coefficient () and core 
diameter (d), essentially irrespective of the ligands and solvents: 
                                                         ln  = k ln d + c                                                      (1.1) 
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where k = 3.32 and c = 10.8 ( = 506 nm).  Therefore, the nanoparticle concentrations 
can be readily deduced from Beer-Lambert Law once the nanoparticle size is known 
(from TEM).  According to equation (1.1), it is estimated that the AuNP of 20 nm 
diameter has a molar extinction coefficient of 1109 M-1 cm-1.  This value is at least three 
orders higher than that of common organic dyes (104-106 M-1 cm-1), indicating that 
AuNPs may serve as excellent light collectors.25  
 AuNPs show photoluminescence under certain conditions26,27 and they can also 
enhance fluorescence at appropriate fluorophore-to-metal distances on solid substrates.28  
Nevertheless, much attention has been focused on the superb quenching ability of AuNPs 
to the proximal fluorescent molecules.  Fluorescence resonance energy transfer (FRET) is 
an important deactivation pathway for the excited fluorophores on the nanoparticle 
surfaces in case of a good overlap between the donor’s emission spectrum and the gold 
surface plasmon band.29  The energy transfer efficiency is correlated not only with the 
spectral overlap, donor-acceptor distance and mutual orientation as those existing in the 
conventional FRET systems, but also with the size and shape of the AuNPs used.30  Both 
radiative and nonradiative decay rates of fluorescent molecules are distinctly affected, so 
that highly efficient fluorescence quenching is observed even in the presence of small 
nanoparticles of 1 nm diameter.  Photoinduced electron transfer (PET) makes great 
contribution to the deactivation of the fluorophores in the vicinity of AuNPs, where the 
nanoparticles act as electron acceptors.31  The electron transfer process can be modulated 
by charging/discharging the gold core, providing an interesting opportunity for sensor 
fabrication.32  
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 In contrast to bulk metals, a band gap exists between the valence and the 
conduction bands of metal nanoparticles.  Small metal nanoparticles would therefore 
display size-dependent quantization effects, leading to the discrete electron-transition 
energy levels.  For example, 15 redox states have been observed for hexanethiol-capped 
AuNPs (Au147, r = 0.81 nm) at room temperature due to the quantized double layer 
charging.33  This result explicitly indicates that molecular-protected AuNPs are 
multivalent redox species which display molecule-like redox properties.34  The quantized 
capacitance charging behavior of AuNPs is distinctly affected by electrolyte ions, 
external ligands, and magnetic field applied.  Such unique electrochemical properties 
expand their practical interests of applications in electronic devices and electrochemical 
labels.35  Furthermore, the conductivity of AuNP assemblies relies on the interparticle 
space as well as the chemical environment, providing another important handle over 
tailoring electronic and electrochemical sensors. 
 
1.3 Nanoparticle-Biomolecule Surface Interactions 
Creation of nanoparticle-based artificial receptors for biomacromolecular surface 
recognition provides a potential tool for controlling cellular and extracellular processes in 
numerous biological applications such as enzymatic inhibition, transcription regulation, 
delivery and sensing.  
The conjugation of nanoparticles with biomolecules, such as proteins and DNA, 
can be done using two different approaches: direct covalent linkage and non-covalent 
interactions.36,37,38,39,40 The most direct approach involves covalent attachment.41 This 
conjugation can be achieved through either chemisorption of the biomolecule to the 
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particle surface or through the use of heterobifunctional linkers. Chemisorption of 
proteins onto the surface of nanoparticles (usually containing a core of Au, ZnS, CdS and 
CdSe/ZnS) can be done through cysteine residues that are present on the protein surface 
(e.g. oligopeptide, serum albumin),42 or chemically using 2-iminothiolane (Traut’s 
reagent).43,44 Bifunctional linkers provide a more versatile means of bioconjugation. 
Biomolecules are often covalently linked to ligands on the NP surface via traditional 
coupling strategies such as carbodiimide-mediated amidation and esterfication.45 For 
biological applications, OEG or PEG is used in the linker to enhance the stability of the 
attached biomolecules and minimize non-specific adsorption of other materials.  
Non-covalent assembly provides a highly modular approach to the 
biofunctionalization of nanoparticles. The use of cationic ligands on the nanoparticle 
surface provides a complementary surface for binding the negatively charged backbone 
of DNA, for example the use of NP1 to bind to a 37-mer DNA duplex (Figure 1.5a).46 
Another approach to DNA conjugation exploits the high affinity and specificity of base-
paring between DNA strands (Figure 1.5b).47 It has been reported that cationic tetra-alkyl 
ammonium functionalized AuNPs recognize the surface of an anionic protein through 
complementary electrostatic interaction and inhibit its activity. The activity was 
recovered due to release of free protein by treating the protein–particle complex with 
GSH, showing AuNPs as potential protein transporters (Figure 1.5c).48 In another 
approach has been demonstrated that cationic gold mixed monolayer protected clusters 
(MMPCs) with ~2 nm core diameter were used to induce folding of negatively charged 
peptide (tetraaspartate peptide, TAP) into an -helix conformation (Figure 1.5d).49 
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Figure 1.5 The DNA-nanoparticle interactions. (a) Structure of NP1 scaffold and the DNA backbone. The 
interaction is directed by electrostatic interaction. b) Binding of DNA thtough complementay 
oligonucleotide hybridization. c) AuNPs interact with the surface of an anionic protein through 
complementary electrostatic interaction and inhibit its activity. d) Schematic depiction of the peptide 
binding in helical conformation on MMPCs surface (Reproduced from Ref(s). 47-50). 
 
1.4. Poly(paraphenyleneethynylene)s (PPEs): A Multivalent Water Soluble 
Conjugate Polymer as a Tranducer  
 
Water soluble poly(paraphenyleneethynlene)s conjugated polymers (PPEs) have 
received much attention and have shown great promise as highly sensitive fluorescent 
sensory materials for chemical analytes and biomolecules.  The multivalent capabilities 
and sensitivity of conjugated polymers to minor conformational or environmental 
changes make them ideal candidates for biosensing applications. The electrochemical and 
optoelectronic properties of -conjugated polymers can be modified by environmental 
stimuli to detect chemical or bioactive species. Water-soluble PPEs are accessible by 
introducing ionic side groups to solubilize the otherwise hydrophobic polymer 
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backbones. These polymers can have high fluorescence quantum yields in aqueous 
solution, unique solution behavior, ability to interact electrostatically with other charged 
species, and display an extraordinarily high sensitivity to fluorescence quenchers 
(picomolar level) because of the “molecular wire effect”.50 Ionic groups such as 
carboxylic, sulfonic, ammonium or phosphonate have been grafted on the side chains of 
these conjugated polymers as well as neutral groups such as sugars51 and highly branched 
hydroxyls.52 A number of useful sensor applications for ions, peptides and proteins, 
bacteria and nucleic acids have been reported using such polymers.53  
Compared to quenching of the corresponding monomers, only one recognition 
element binding to a quencher is enough to shut down the fluorescence of a whole 
polymer chain, creating strong signal amplification. This “amplified quenching” or 
“superquenching” process of the PPE fluorescence is caused by either electron or energy 
transfer and is useful to transmit information and monitor binding events either directly 
or by displacement assays through removal of the pre-bound quencher and turning on the 
fluorescence of a conjugated polymer. Many groups have utilized the intrinsic 
fluorescence signal amplification properties of PPEs, and developed sensitive assays for 
biologically relevant targets including proteins, DNA, glycopeptides and carbohydrates. 
Fluorescent “superquenching” of PPEs by oppositely charged analytes was discovered in 
1998 by Whitten et al.54 and opened a new door to specific sensing applications by 
PPEs.55 They are used in direct or competitive assay technology for high-throughput 
screening of protease enzyme activity,56 nucleic acid hybridization57 and kinase58 and 
phosphatase activities by metal ion mediation.59 Ionic PPEs were employed to detect 
conformational changes of biomolecules (Figure 1.6)60 or negatively charged nucleic 
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acids,61 differentiate ssDNA from dsDNA,62 and recognize the DNA’s tertiary structure. 
In the case of the detection of conformational change of biomolecule, a negatively 
charged conjugated polyelectrolyte (poly(thiophene acetic acid), PTAA-Li) when 
interaction with native bovine insuline (nBI) or  bovine insuline in amyloid fibrillar (fBI) 
form a complex, displaying different characteristic optical changes that can be detected 
visually or by absorption and emission, the absorption maximum is red shifted to 463 nm. 
This result strongly suggests that binding of PTAA to amyloid fibrils of BI will force the 
polyelectrolyte backbone to adopt a more rod-shaped conformation. The planarization of 
the polymer backbone might be a result of the change in the secondary structure of the 
BI, as the polyelectrolyte will most likely interact differently with the α-helical nBI 
molecule and the fBI molecule that contains more β-sheet structure. Hence, the alteration 
of the optical properties from the conjugated polyelectrolyte should be due to a change in 
the secondary structure of the protein molecule. Interestingly, the shift in absorption for 
the two different solutions is clearly visible for the human eye. The PTAA/nBI solution is 
yellow, and the PTAA/fBI solution is orange (Figure 1.6).  
 
Figure 1.6 Structure of the insulin monomer (right), chemical structure of the repeating unit of 
poly(thiophene acetic acid) (PTAA-Li) (middle) and  the microtiter plate wells (right) containing 
PTAA/nBI (top) and PTAA/fBI (bottom) (Reproduced from Ref. 61). 
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PPEs form stable complexes with some proteins. However, even with simple 
electrostatic interactions, Heeger et al.63 and Bunz et al.51c showed that proteins can be 
distinguished by their overall charges and electron transfer reactivities.  Recently, Swager 
et. al.51b showed that E. coli can be detected in moderately concentrated cell suspensions 
by using a water-soluble, carbohydrate functionalized PPEs. Fluorescent cell clusters 
formed in 10-15 min. through multivalent interactions with mannose receptors located on 
the bacterial pili of E. coli with the mannosylated polymer.64  
PPEs are typically synthesized according to Heck-Cassar-Sonogashira-Hagihara 
(HCSH) reaction conditions which employs a palladium catalyzed process to yield 
moderate to high molecular weight PPEs (Scheme 1.1).65 This method is advantageous 
due to its tolerance of monomer functionality, variability of reaction conditions, and 
simplicity of  reaction workup.       
 
 
Scheme 1.1 General synthetic scheme for PPEs under HCSH reaction conditions (Reproduced from Ref. 
67). 
 
Due to the ease of synthesis, PPEs can be synthesized in large quantities with high 
purities.  Typically, the PPEs are a yellow-orange solid and exhibit a blue-green 
fluorescence (λemission = 455-465 nm).  With the incorporation of heterocyclic monomers 
such as benzothiadiazole, PPEs with a yellow-orange emission (λemission = 500-550 nm) 
can be easily achieved.    
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1.5. Nanoparticles in Biosensing 
Sensors are a class of devices that produce measurable responses to changes in physical 
conditions or chemical concentration.66  Biosensors, first reported in 1962,67 are generally 
defined as sensors that consists of two components: 1) biological recognition element for 
target binding, often called bioreceptors, 2) transduction element for signaling the 
binding event that produces a signal proportional to the analyte concentration. The large 
surface to-volume ratio with the electronic and optical properties makes the nanoparticles 
as a potential system in sensor application. Nanoparticles are applied in the detection of 
various biomolecules such as, oligonucleotides, proteins, microorganisms and 
mammalian cells. Based on the regulating properties such as absorbance, quenching, 
conductivity etc. the nanoparticle based biological sensing can be sub-categorized in 
several group, such as, 1) colorimetric sensing,68 2) fluorescence sensing69 3) 
electrochemical sensing 70 4) surface enhanced raman scattering (SERS),71 etc. Some of 
the very interesting studies of each group have been highlighted here.  In the first group, a 
colorimetric method of sensing proteins using aptamer and gold nanoparticles 
functionalized with citrate was used.68 In this study, the specific recognition of a 
particular protein is realized through the aptamer structure change which occurs during 
the binding process. This structural change is then detected by the color change of gold 
nanoparticles (Figure 1.7). The analyte thrombin and its 29-mer binding aptamer (TBA) 
were taken as model. Significant color change is visible at as low as 83 nM using this 
calorimetric aptasensor, with UV-visible spectroscopic measurement used to obtain this 
detection limit. 
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Figure 1.7 AuNPs colometric strategy for thrombin detection.  By exploiting interactions between AuNPs 
and the DNA sequences, color changes could sensitively differentiate the conformational change of TBA 
before and after adding thrombin.  Photographs of 200 mL 13 nm AuNPs stabilized by the aptamer (30 mL 
4.59 mM) after the addition of salt (100 mL 0.5 M NaCl) in the presence and absence of target protein 
(from left to right: 83 nM thrombin, 83 nM BSA and water as control) (Reproduced from Ref. 70). 
 
In the second group, for the develop of a fluorescent biosensor the high quenching ability 
of gold nanoparticles was used for molecular beacons construction for sensing the DNA 
strands using the intensity of fluorescence responses.69 According to the reported design, 
initially the dye molecule remains close to the nanoparticle surface due to hairpin 
structure of the attached DNA, resulting in an effective fluorescence quenching through 
FRET (Figure 1.8). As shown in the hybridization of target DNA opens up the hairpin 
structure and increase the distance between nanoparticle and dye, results in a significant 
increase in fluorescence. As the fluorescent intensity was only depends on the 
concentration of the target DNA, this system was used for DNA sensing. A range of 
ssDNA and DNA cleavages ware detected using this molecular beacon approach. 
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Figure 1.8 Schematic representation of molecular beacon for the detection of target DNA (Reproduced 
from Ref. 71).  
In the third group, a bioelectrocatalytic system was constructed by connecting the 
redox enzyme glucose oxidase (apo-GOx) onto a gold nanoparticle that was 
functionalized with N6-(2-aminoethyl) flavin adenine (FAD) (Figure 1.9).70 This enzyme-
nanoparticle hybrid system was linked to the electrode through dithiols, or alternatively 
the FAD-functionalized nanoparticle was assembled onto the electrode followed by the 
addition of apo-GOx. This system exhibited a highly efficient electrical communication 
with the enhanced turnover rates as compared to native Gox, and provided an effective 
sensor for glucose in the physiological concentration regime. An analogous electron 
transfer from protein to nanoparticles was used for monitoring hydrogen evolution from 
zinc-substituted cytochrome c immobilized TiO2 nanoparticles as reported by Yeni Astuti 
et al.72  
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Figure 1.9 a) Fabrication of GOx electrode by the reconstitution of apo-enzyme on a FAD-functionalized 
gold nanoparticle. b) Plot of the current developed by the reconstituted GOx electrode in the presence of 
different concentrations of glucose (Reproduced from Ref. 72).  
 
 The last group of sensing system, SERS, an ultra-sensitive ‘bio-barcode’ 
biosensor for proteins and nucleic acids has been developed by Mirkin’s group, where the 
oligonucleotide is amplified and then detected either by surface hybridization or by PCR 
amplification, providing a means for detection of both proteins and DNA (Figure 1.10). 
In case of DNA detection, a magnetic microparticle carrying partially complementary to 
target DNA was hybridized with bio-barcoded gold nanoparticles in presence of target 
DNA (Figure 10.a). After the magnetic separation of the sandwich assemblies and 
thermal dehybridization, the barcode was released for analysis. The detection limit of this 
method was found at 500 zeptomolar, comparable to many PCR-based approaches. For 
protein detection the magnetic microparticles carry antibodies that specifically bind the 
target protein (Figure 10.b). The magnetic microparticle-bound protein subsequently 
interacts with gold nanoparticles by antigen-antibody interaction. The detection limit for 
the chip-based sandwich hybridization process was observed at 30 attomolar, which was 
reduced using PCR amplification to 3 attomolar.73 This approach is also used for 
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multiplexed detection of protein and DNAs by using mixture of different biobarcoded 
gold nanoparticle probes. 74  
 
Figure 1.10 Schematic illustration of ‘bio-barcode’ assays for a) DNA and b) proteins (Reproduced from 
Ref. 73). 
 
1.6 Chemical Tongue/Nose Sensors  
Most biomolecular recognition processes in biology occur via specific interactions. 
Sensory processes such as taste and smell, however, use “differential” binding where the 
receptors bind to their analytes by different binding characteristics that are selective 
rather then specific.75 These arrays, a.k.a. “electronic tongues”76 provide highly versatile 
sensors (Figure 1.11). They have been used to sense calcium and metal ions, pH levels, 
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sugars as well as cholesterol levels in blood, cocaine in urine, and toxins in water.77 A 
variety of other analytes such as including metal ions,78 volatile agents,79 aromatic 
amines,80 amino acids,81,82 and carbohydrates.83,84 have also been successfully identified 
using this approach.  
 
 
Figure 1.11. A Representative scheme of an molecularly imprinted polymers (MIP) sensor array that uses a 
dye-displacement strategy to give an easily visualized and unique colorimetric response pattern for each 
analyte (Reproduced from Ref. 82). 
1.7 Protein Sensing using Chemical Noses 
The emergence of abnormal proteins and/or irregular protein concentrations are 
indicative of cancers and diseases.85,86 Therefore, sensitive, convenient, and precise 
protein sensing methods are required to obtain early diagnosis of diseases and successful 
treatment of patients. Currently, the most extensively used detection method for proteins 
is enzyme-linked immunosorbent array (ELISA).87 In this system, the capture antibodies 
immobilized onto surfaces bind the antigen through a “lock-key” approach and another 
enzyme-coupled antibody is combined to react with chromogenic or fluorogenic 
substrates to generate detectable signals. Despite of the high sensitivity, the application of 
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this method is restricted due to its high production cost, instability, and challenges for 
quantification. On the other hand, synthetic agents with high affinity and specificity for 
proteins are scarcely available although they possess better chemical and thermal 
stability.  
Recently, the “chemical nose/tongue” approach  has been applied to protein sensing. 
Hamilton’s group has used eight tetra-meso-carboxylphenyl-porphyrins carrying 
peripheral amino acid functionalities to identify four metal and nonmetal-containing 
proteins, with a detection limit between 7.5 ~ 15 M (Figure 1.12a).88,89 Anslyn et al. 
have employed 29 boronic acid-containing oligopeptide functionalized resin beads to 
differentiate 5 proteins and glycoproteins through an indicator-uptake colorimetric 
analysis, with a limit of detection of 355 M (Figure 1.12b).90 
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Figure 1.12 a) A library of tetra-meso-carboxylphenylporphyrin (TCPPs) conjugated with amino acids or 
amino acid derivatives used for protein sensing by Hamilton’s group. b) Structure of receptors which 
incorporates one of 19 natural amino acids at each of three sites that are biased towards particular analyte 
classes. Bromopyrogallol red is used for the indicator-uptake colorimetric analysis (Reproduced from 
Ref(s). 90-92). 
 
It has more recently been shown that non-selective electrostatic interaction in 
combination with covalently or non-covalently bound fluorophores are sufficient to 
differentiate between a number of biological relevant metalloproteins. Thayumanavan et 
al. exploited eight different fluorescence dye molecules non-covalently bound to the 
micellar interiors of an amphiphilic homopolymer to generate a pattern and differentiate 
four different metalloproteins, with limits of detection between 1-200 M (Figure 1.12).91  
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Figure 1.13  a) Schematic of the differential transducer approach using amphiphilic homopolymer 
micelles. b) Fluorescence quenching response for a hypothetical analyte. c) Structure of polymer P1 
(Reproduced from Ref. 93). 
1.8 Chemometric Analysis: A Powerful Tool to Discriminate Biomolecules in Chemical 
Noses Approach 
As a consequence of having an array of differentially selective, rather than specific, 
responses to protein, bacteria, cancerous cells or other analytes, the raw PPE fluorescence 
responses of the sensor arrays are a matrix of noiselike signals from which we must 
accurately and quickly extract patterns with which to classify bacteria, cancerous cells or 
changed protein levels in serum samples. As there is no universally accepted optimal 
chemometric technique for chemical sensor array processing and pattern recognition, it is 
invariably necessary to be flexible and pragmatic in the application and evaluation of any 
such technique thought, a priori, to be a suitable starting point. Neural nets have 
previously been shown to be effective in the processing of fluorescence sensor array 
data.92 Subsequently, Shaffer et al. performed quantitative comparisons of seven well-
regarded chemometric techniques for chemical sensor array pattern recognition.93 They 
used speed, training difficulty, memory requirements, robustness to outliers, and ability 
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to produce an uncertainty measure as qualitative performance measures, classification 
accuracy as the quantitative measure and concluded that the two neural network 
techniques they tested, i.e., learning vector quantization (LVQ) and probabilistic neural 
network (PNN), were clearly superior in performance. These measures, and their results, 
are directly relevant to our proposed work. Subsequent work by Shaffer and Rose-
Pehrssen resulted in an improved probabilistic neural network (IPNN)94 that reduced 
computational requirements, speeded training and decreased the false alarm rate. Further 
improvement can be obtained using the IPNN chemometric methodology of Shaffer and 
Rose-Pehrssen with a complementary filters provided by applying additional analysis 
techniques.95  
As described before, there is no universally accepted optimal chemometric technique 
for chemical sensor array processing and pattern recognition. However, in this 
dissertation the discrimination of biomolecules was carried out using classical linear 
discriminant analysis (LDA) using SYSTAT software (version 11).96 This statistical 
analysis method is used to recognize the linear combination of features that differentiate 
two or more classes of objects or events. Stepwise analysis with different sensor set(s) 
gives certain separatability between all the analytes through jackknifed classification and 
it is possible to be maximizing it using several analysis combinations to determine which 
sensor set can best differentiate between the biomolecules. The Jackknifed classification 
matrix is an attempt to approximate cross-validation. The Jackknifed classification matrix 
use functions computed from all of the data except the case being classified. 
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1.9 Concluding Remarks 
 To achieve highly efficient sensors, it is crucial to engineering the nanoparticle 
surface functionality for selective target analytes. AuNPs present a versatile scaffold for 
the creation of biological sensors.  On the one hand, the particles provide an adaptable 
platform for the incorporation of various functionalities ranging from small organic 
ligands to giant biomacromolecules, allowing the binding of target molecules with 
appropriate affinity and selectivity.  On the other hand, the physical attributes of AuNPs 
such as their environment-sensitive optoelectronic properties can be harnessed to realize 
the transduction of the binding events. Based on the results presented in this dissertation, 
it is apparent that nanoparticle-based sensors provide a powerful platform for analysis of 
proteins and cell surfaces. Through variation of sensor design it would appear that almost 
any system could be differentiated through appropriate sensor design. As we learn the 
strategies required for this differentiation, however, we will have to address the 
complexity of the target systems. Biofluids, such as undiluted human serum, contains a 
large amount of various proteins, salts, and cells that not only can inhibit or alter the 
sensing elements’ ability to detect target analytes, but also complicate pattern generation. 
Clearly, creation of clinically useful sensor will require co-evolution of chemical and data 
analysis strategies.  
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CHAPTER 2 
INTERACTION OF NANOPARTICLES WITH CONJUGATED POLYMER: 
BUILDING “CHEMICAL NOSES” 
 
 
 
2.1 Introduction 
 
 The combination of gold nanoparticles (AuNPs) with conjugated polymers (CPs) is 
a powerful one that has lead to novel biomolecular and bio-inspired materials with 
hierarchical structures.1  This alliance is attractive not only from a structural standpoint, as 
the properties of both components are easily modified, but from an electronic one as well: 
AuNPs and CPs interact by energy transfer and both have transitions in the visible or in the 
UV-vis range.  These interactions are examplified by reported combinations of poly(p-
phenylenevinylene)s (PPV), polyfluorenes (PF) and poly(p-phenyleneethynylene)s (PPE) 
with AuNPs.2,3  A seminal study on the interaction of CPs and AuNPs was published by 
Heeger and Bazan.2 They observed that electrostatic interactions between a negatively 
charged AuNP and positively charged conjugated polymers of the PPV and the PF types 
lead to efficient binding between the AuNP and the CP as indicated by the AuNPs’ ability 
to quench the fluorescence of the CP.  
 In this dissertation, we have employed hydrophobically functionalized AuNPs in 
combination with CPs Sw-CO2/PPECO2 as powerful constructs to discern biomolecules 
and cell surfaces (Chapters 3, 6 and 8) through fluorescence recovery via displacement 
assays. In the course of these investigations we noted significant variance in the binding of 
the positively charged AuNPs to negatively charged CPs depending on the structural 
features of the AuNP. 
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 It is not clear how the hydrophobicity of a monolayer protected AuNP influences 
the magnitude of the interaction between AuNP and CP (in this case the highly fluorescent 
Sw-CO2 with a quantum yield (ΦF greater than 0.3).  As such, we were interested in 
preparing a  series of nanoparticles (NP1-NP11) that differed only in the size and structure 
of their exterior ammonium group (Figure 2.1). Though there has been a thorough study on 
the quenching of AuNPs by CPs by Bazan and Heeger, these authors used citrate-coated 
AuNPs that interacted with positively charged CPs; modulation of the binding between 
AuNP and CP by changing the exposed end of the protective monolayer has not been 
reported.  A technical issue we have found necessary to address is how to perform the data 
analysis pertaining to the quenching experiments between AuNPs and CPs.  Results of 
quenching experiments involving CPs are analyzed using a simple Stern-Volmer 
formalism,4 by which, if static quenching can be assumed,5 the binding constant between 
an AuNP and a fluorophore is extracted from the following equation (Eq. 2.1): 
                                                                                    (Eq. 2.1)          
 I0/I[Q] is the quotient of the fluorescence intensity in the absence (I0) and the 
presence of a specific concentration [Q] of the quencher Q (I[Q]). Ksv represents the binding 
constant between AuNP and CP.  From this simple equation Heeger and Bazan calculated 
binding constants between AuNP and conjugated polymer that were in excess of KSV = 
1010 M-1.   While this data workup is simple, it is not without problems (vide infra).  The 
highly efficient quenching process brought on by  complexation of the AuNP and the CP is 
of  unusually large magnitude and may be a consequence of both the molecular wire effect 
and the efficient Förster type energy transfer from the excited state of the conjugated 
polymer to the plasmon band of the AuNP.  Polyvalency6,7 is probably also involved, as it 
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can be reasonably assumed that multiple electrostatic interactions occur between polymer 
chain and a single AuNP.  Despite the strength of the interaction between CP and AuNP, 
their affinity for one another can be modulated by varying the structure of the positively 
charged monolayer ensheathing the AuNP. 
 AuNPs are easily synthesized8,9,10 and monolayer functionalized with different and 
suitably substituted thiols or disulfides that chemisorb and oxidatively add to the gold 
surface after AuNP formation.  As the number of potential disulfide and thiol ligands is 
essentially unlimited, different ligand coating can give AuNP unique physical and 
chemical properties; AuNP-conjugated polymer constructs form when the two components 
are mixed. Upon addition of a sufficient amount of nanoparticle to the system, the 
fluorescence of the conjugated polymer is fully quenched.11  These AuNP-PPE complexes 
can be disrupted by the introduction of a suitable, charged analyte, which leads to free PPE 
chains in solution and a subsequent  fluorescence turn-on. 
 We have exploited this principle for the successful sensing of proteins (Chapter 
3),11 bacteria (Chapter 6)12 and cancerous cells (Chapter 8).13 As we have created libraries 
of nanoparticles, we can influence both the binding of the employed PPE as well as its 
decomplexation from the AuNP by an analyte.  
As an example for AuNP-PPE conjugate sensing system, we employing three and 
six simple AuNP-PPE constructs showed impressive selectivity (Chapters 3, 6, and 8); 
however, it is also helped to illustrate the effect of increasing salt concentration on the 
binding between AuNP and conjugated polymers, as well as to demonstrate the influence 
of the hydrophobic character of the monolayer protected AuNPs on the binding constant 
KB between AuNP and CP.  Herein we investigate the influence of increasing 
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hydrophobic character on the AuNP/CP binding and examine its dependence upon ionic 
strength.    
2.2 Results and Discussion 
 
The Ligands L1-L11 were synthesized according to Scheme 2.1 through 
quaternization of the tertiary amines 1-11 by the mesylate L0.  Deprotection with 
trifluoroacetic acid in the presence of triisopropylsilane as a reducing agent gave L1-L11 
as yellowish oils.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1. Synthesis of the thiols L1-L11.  Yields of L1-L11 are above 95% in all cases starting from L0. 
 
 
The NP1-NP11 were synthesized by dissolving pentanethiol-protected AuNPs 
generated from a literature procedure3 in dried dichloromethane (DCM) and subsequently 
adding thiols L1-L11 respectively. Removal of solvent, dialysis in water and 
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lyophilization afforded NP1-NP11 as brownish-red powders, which freely re-dispersed in 
water (Figure 2.1).     
 The PPE Sw-CO2 was prepared according to a literature procedure14 and used as a 
5 micromolar solution in buffer. The polymer had a degree of polymerization (Pn) of 12 
and a molecular weight (Mn) of 14 KDa with a polydispersity index (PDI) of 1.8.  
 
 
Figure 2.1 Monolayer protected gold nanoparticles (AuNPs) and structure of PPE Sw-CO2 investigated in 
this study.  
 
 
 The quenching of Sw-CO2 by the AuNP is a static process in terms of the Stern-
Volmer formalism, as the emission lifetimes of the PPEs are generally between 150 and 
450 ps.15 Hence, any dynamic quenching effects, while present, have only a minute 
influence. We have recently developed the following binding model, which we exploit to 
investigate the quenching processes of the PPE by the AuNPs (Eq. 2.2).16 
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(Eq. 2.2) 
I0 is the fluorescence intensity of the PPE at a concentration [F]0 in the absence of 
quencher [Q] (in this case nanoparticles), I[Q] is the fluorescence intensity of the PPE in 
the presence of a concentration [Q] of gold nanoparticle, [Q]tot is the total concentration 
of the added quencher, and  n denotes the valency of the AuNP, i.e. how many sites the 
AuNP has to quench multiple PPE chains.  The term  is used to correlate the 
fluorescence intensities and concentrations of the two species. This factor is constant if 
the instrumental variables (e.g. slit width, excitation wavelength, sensitivity, etc.) and the 
nanoparticle and polymer identities are fixed. 
  In obtaining the Stern-Volmer binding constant, the current form of the equation 
(Eq. 2.2) allows us to approximate Ksv by performing a curve fitting analysis using ten 
different concentrations of nanoparticle quencher. 
 The formula in Eq. 2.2 is considerably more complex than Eq. 2.1, as the Stern-
Volmer formalism makes assumptions that do not hold well in the high binding regimen we 
are investigating.  In these cases, the SV-plots curve upward and are not linear as would be 
expected. One of the reasons for the non-linear behavior is the expression of the term [Q] in 
Eq. 3.1, as it refers to the concentration of free quencher and not to the easily measured 
total concentration of quencher [Q]tot. If [F]0/Ksv < 1 the assumption that [Q]free ≈ [Q]tot is 
justified and the Stern-Volmer approximation provides a simple and convenient but 
powerful tool for extracting binding constants in an analytical way.  If [F]0/Ksv > 1, the 
assumption  that [Q]free ≈ [Q]tot breaks down and the observed Stern-Volmer plots are 
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invariably upwardly sloped.  An analytical expression for the concentration of free 
quencher is unfortunately not available and most literature studies make use of [Q]total 
instead of [Q]free.  Consequently, one finds an innate upward curvature to the Stern-Volmer 
plot if [F]0/Ksv > 1. While this upward curvature is often attributed to superquenching or 
other effects such as Dexter energy transfer, we suspect that it is due, at least in part, to the 
incorrect use of [Q]total instead of [Q]free.17  There is a second minor issue with the Stern-
Volmer formalism in that it assumes the formation of a 1:1 complex that is fully quenched 
and does not display any residual fluorescence.  Use of Eq. 2.2 resolves all of these issues. 
 In our first experiments we explored the influence of different buffers on the 
binding strengths between AuNP and Sw-CO2.  As shown in Figure 2.2 the binding curves 
are nearly superimposable in PB, PIPES, HEPES and TRIS-HCl buffers at a 5 mmol 
concentration.  In the case of phosphate buffered saline (PBS) the binding constant is lower 
and there is a significant final residual fluorescence at high AuNP concentration.   As Sw-
CO2 has a Pn of 12 and a PDI of 1.8, there is expected to be a fraction of short oligomers in 
such polymer solutions. Since shorter polymer chains do not support polyvalent 
interactions to the AuNP as well, their binding will be considerably less efficient, and 
addition of salt will screen the electrostatic attractions between polymer and AuNP more so 
for short polymer chains than for longer ones.  
 In another series of experiments we investigated the influence of PPE concentration 
on Ksv.  Figure 2.3 shows the dependence of the binding constant upon the concentration of 
the PPE. Binding constants obtained from a 10 nM solution of PPE are identical to those 
obtained from a 1 M solution of PPE as predicted by Eq. 2.2, because they are not 
affected by the Stern-Volmer equation.  
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Figure 2.2  Fluorescence titration curves for the complexation of NP3 with Sw-CO2 in PB (top left), PIPES 
(top right), HEPES (middle left), Tris-HCl (middle right), and PBS (bottom left) 
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 After performing these preliminary studies, we investigated the eleven 
nanoparticles NP1-NP11 (Figure 2.1) for their ability to quench the fluorescence of Sw-CO2 
in the presence of 0, 100, 250, 500 and 1000 mM of NaCl to determine and evaluate the 
relationship between electrostatic and hydrophobic effects (Figure 2.2).  Figure 2.1 shows 
that NP1-NP4 display increasingly long hydrocarbon tails while NP5-NP7 feature cyclic 
hydrophobic substituents on the ammonium functionality.  The NP8-NP11 contain aromatic 
residues and are therefore grouped together. 
 
 
 
 
Figure 2.3 Quenching of PPE by NP3 for a PPE concentration of 1 µm (top; 8.5 x 107 M-1) and 10 nm 
(bottom; 8.6 x 107 M-1).  Experimental values for Ksv’s are nearly concentration independent.  
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NP1 NP2 NP3 NP4 NP5 NP6 NP7 NP8 NP9 NP10 NP11
Ks 0.5
Ks 0.25
Ks 0.1
Ks no salt1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
1.E+09
1.E+10
1.E+11
Ks 0.5
Ks 0.25
Ks 0.1
Ks no salt
 
Figure 2.4 Logarithmic plot of binding constants between NP1-NP11 and Sw-CO2 in the presence of 
different concentrations of sodium chloride.    
 
 
Table 2.1 and Figure 2.4 display the results of the binding studies of NP1-NP11 to 
Sw-CO2 in the presence of increasingly concentrated sodium chloride solutions.  The 
binding between the negatively charged PPE and the positively charged AuNPs is 
dependent upon the structure of the AuNP and the salt concentration.   
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Table 2.1. Binding ratio “n” and binding constant Ka values for the complexation NP1-NP11 with Sw-CO2 
in PB with 0, 100, 250, 500, and 1000 mM NaCl. At higher NaCl concentrations, values could not be 
accurately determined for all nanoparticle-conjugated polymer constructs. 
 
 
 
Increasing ionic strength screens the electrostatic interactions between AuNP and 
PPE. In a 1 molar NaCl solution binding between PPE and AuNP is weak, as the 
electrostatic interaction between AuNP and PPE is greatly attenuated.  Static quenching 
is interrupted by the addition of salt, but dynamic quenching should be independent of the 
presence of binding sites or salt concentration. At high salt concentrations we observe 
values of Ksv of around 1 x 103 M-1 for NP1-NP7 while the binding constants for NP8-
NP11 are negligible.  From these experiments we can conclude that the contribution of 
dynamic quenching to the overall quenching process is minor and that it does not 
influence the outcome of the binding experiments done at low salt concentrations. 
According to Eq. 2.2 the analysis of the binding curves gives the number of binding sites 
n that are available on a single nanoparticle.  The aromatic nanoparticles NP8-NP11 give 
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values for n of around 6, i.e. 6 repeat units with 12 carboxylate functionalities are bound 
to one nanoparticle.   
NP1 NP2 NP3 NP4 NP5 NP6 NP7 NP8 NP9 NP10 NP11
N 0.5
N 0.25
N 0.1
N no salt0
2
4
6
8
10
12
14
N 0.5
N 0.25
N 0.1
N no salt
 
 
Figure 2.5 Number of binding sites n as obtained from Eq. 2.2. This value n refers to the binding sites 
of the AuNP-PPE construct.  
 
 
As we have a degree of polymerization of 12 for the PPE, this means that either 
several PPE molecules could interact using only one or two of their carboxylate groups, 
or that only one PPE chain is bound per AuNP but with up to six contacts.  From this 
model it is not possible to discern between these two scenarios.  Overall, the n-values 
vary from 2-12, with the least hydrophobic AuNPs having the least number of binding 
sites.  Figure 2.5 depicts the obtained results. 
In the absence of salt, the AuNPs with aromatic ammonium species bind by far 
the strongest to the conjugated polymer.  We rationalize this as a prevalence of --
interactions, i.e. the phenyl groups of the nanoparticle ligands bind strongly to the 
aromatic backbone of the PPE.     
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 Although the partition coefficient P of a molecule alone does not provide an 
understanding of hydrophobic interactions of AuNPs to Sw-CO2, it does offer a means of 
characterizing the effect of hydrophobicity when it is combined with another parameter.  
Therefore, we explored the relation between logKa and logP to elucidate the interaction 
between the hydrophobicity of the AuNPs and Sw-CO2. As shown in Figure 2.6, NP10 and 
NP11 that display aromatic units on their surface are the most efficient at quenching the 
fluorescence of the Sw-CO2. As mentioned before, we presume that this is due to --
interactions between the aromatic groups on the surface of the AuNP and the hydrophobic 
backbone of the PPE.  In the case of the cyclic units, NP5 (R = cyclohexyl), NP6 (R= tert-
butyl) and NP7 (R= cyclododecyl) the binding interaction in terms of logKa is lower by 
orders of magnitude, and this is assumed to be the result of two factors: a) they do not have 
aromatic units to interact with PPE and b) they feature bulky cyclic functionalities that 
reduce the electrostatic interaction with Sw-CO2. However, a phenyl addition to the 
cyclohexane unit (NP8) increases the binding interaction. In the case of NP1 (R= ethyl), 
NP2 (R= butyl) and NP3 (R= hexyl) the elongation of the aliphatic R group on the 
quaternary amine increases sligthly the strength of the binding. This is not the case for NP4 
(R = decyl) where a weak binding interaction with Sw-CO2 is observed.    
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Figure 2.6. Logarithmic relation of binding constants (Ka, AuNP-SwCO2) and partition coefficient of NP1-
NP11 (NP9 is not plotted due to the force field interaction).  
 
Surprisingly, the strongest binding AuNPs (NP10 and NP11) also display the 
highest sensitivity towards the addition of sodium chloride, while NP5 is the least 
sensitive to an increase in ionic strength.  Conclusions that might be drawn to aid in the 
development of further AuNP-CP constructs are: 1) Electrostatic interactions between 
PPE and AuNP can be modulated and even turned off by an increase in ionic strength. 2) 
Aromatic side chains are more sensitive towards interruption of binding than aliphatic 
and specifically cycloaliphatic ammonium groups are. 3) Aromatic ammonium side 
chains display the highest association constants and promote the interaction between PPE 
and AuNP, presumably through aromatic stacking with the PPE backbone. 
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2.3 Conclusion 
 
 In conclusion, we have investigated the quenching of Sw-CO2 by 11 monoloayer 
protected, ammonium-functionalized nanoparticles (NP1-NP11) with varying hydropho-
bicity. AuNPs that feature aromatic units on their surfaces are most effective in quenching 
the fluorescence of the PPE perhaps due to efficient edge to face interactions between the 
aromatic groups on the surface of the AuNP and the hydrophobic backbone of the PPE in 
the fashion explained by Hunter and Sanders.18  In all cases, however, increasing the ionic 
strength of the medium dramatically decreases the strength of the interaction between the 
two oppositely charged species i.e. AuNP and CP.  
 In the aliphatic systems, an increase in hydrophobicity is counterbalanced by a 
decrease in the electrostatic interactions, thus it does not lead to an increase in binding 
between AuNP and CP.  In the aromatic AuNPs, however, the binding constant between 
AuNP and Sw-CO2 correlates well with the hydrophobicity of the aromatic tail on the 
ammonium group, suggesting that at low salt concentrations the contribution of the 
hydrophobic arenes is significant.  Overall, we demonstrated that simple manipulation of 
the surface functionality of AuNPs by varying their hydrophobicity allows for a large range 
of binding constants to be attained by molecular tailoring, particularly if ammonium salts 
with aromatic substituents are employed to stabilize the AuNPs. 
 
 
2.4 Experimental Section 
 
2.4.1 Instrumentation and Materials.  Swallowtail-substituted carboxylate PPE (Sw-
CO2) was synthesized according to published procedure.14  Fluorescence intensity 
changes at 465 nm were recorded in 96-well plates (300 µL Whatman Glass Bottom 
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microplate) on a Molecular Devices SpectraMax M5 micro plate reader with an 
excitation wavelength of 405 nm.  Phosphate buffer (PB), phosphate buffered saline 
(PBS), piperazine-1,4-bis(2-ethanesulfonic acid) (PIPES), N-2-hydroxyethylpiperazine-
N’-2-ethanesulfonic acid (HEPES), and tris(hydroxymethyl)aminomethane hydrochloride 
(Tris-HCl) were purchased from Sigma-Aldrich.  The buffers were diluted to a 
concentration of 5 mM and a pH of 7.2 with DI H2O.  To calculate log P, computational 
program Maestro 8.0 was used. 
 
2.4.2 General Procedure for the Synthesis of Cationic  Ligands11 
 
 
 
 
Scheme 2.2. Synthesis of ligands11 
 
General procedure: Compound 2 bearing ammonium end groups were synthesized 
through the reaction of 1,1,1-triphenyl-14,17,20,23-tetraoxa-2-thiapentacosan-25-yl 
methanesulphonate (1) with corresponding substituted N,N-dimethylamines during 48 h 
at ~35 oC. The trityl protected thiol ligand (2) was dissolved in dry dichloromethane 
(Methylene Chloride, DCM) and an excess of trifluoroacetic acid (TFA, ~ 20 
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equivalents) was added. The color of the solution was turned to yellow immediately. 
Subsequently, triisopropylsilane (TIPS, ~ 1.2 equivalents) was added to the reaction 
mixture. The reaction mixture was stirred for ~5 h under Ar condition at room 
temperature. The solvent and most TFA and TIPS were distilled off under reduced 
pressure. The pale yellow residue was further dried in high vacuum. The product (L) 
formation was quantitative and their structure was confirmed by NMR. The yields were 
>95%.  
Compound L1: 1H NMR (400MHz, CDCl3, TMS):  3.94 (br, 2H, -CH2N-), 3.69-3.56 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.44 (t, 2H, -CH2O-), 3.40-3.32 (m, 2H,-NCH2-), 
3.23 (s, 6H, -(CH3)2N-), 2.78 (s, 3H, -CH3SO-3-), 2.51 (q, 2H, -CH2S-), 1.69-1.149 (m, 
4H, (SCH2)CH2  + -CH2(CH2O)-) , 1.44-1.24 (m, 18H, -SH + -CH2-  + -(NCH2)CH3). 
 
Compound L2: 1H NMR (400MHz, CDCl3, TMS):  3.96 (br, 2H, -CH2N-), 3.68-3.57 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.49 (t, 2H, -CH2O-), 3.39-3.33 (m, 2H,-NCH2-), 
3.17 (s, 6H, -(CH3)2N-), 2.91 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.78-1.52 (m, 6H, 
-(NCH2)CH2-) + (SCH2)CH2  + -CH2(CH2O)-) , 1.44-1.24 (m, 17H, -SH + -(NCH2CH2-
)CH2-) + -CH2-), 0.98 (t, 3H, - CH3-). 
 
Compound L3: 1H NMR (400MHz, CDCl3, TMS):  3.95 (br, 2H, -CH2N-), 3.68-3.56 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.46 (t, 2H, -CH2O-), 3.40-3.33 (m, 2H,-NCH2-), 
3.19 (s, 6H, -(CH3)2N-), 2.87 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.76-1.53 (m, 6H, 
-(NCH2)CH2-) + (SCH2)CH2  + -CH2(CH2O)-) , 1.41-1.22 (m, 21H, -SH + -(NCH2CH2-
)CH2-) + -CH2-), 0.89 (t, 3H, - CH3-). 
 
Compound L4: 1H NMR (400MHz, CDCl3, TMS):  3.94 (br, 2H, -CH2N-), 3.67-3.54 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.48 (t, 2H, -CH2O-), 3.41-3.32 (m, 2H,-NCH2-), 
3.17 (s, 6H, -(CH3)2N-), 2.90 (s, 3H, -CH3SO-3-), 2.51 (q, 2H, -CH2S-), 1.78-1.52 (m, 6H, 
-(NCH2)CH2-) + (SCH2)CH2  + -CH2(CH2O)-) , 1.45-1.15 (m, 29H, -SH + -(NCH2CH2-
)CH2-) + -CH2-), 0.87 (t, 3H, - CH3-). 
 
Compound L5: 1H NMR (400MHz, CDCl3, TMS): 3.95 (br, 2H, -CH2N-), 3.81-3.72 
(m, 1H, HCyclo), 3.69-3.53 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.49 (t, 2H, -CH2O-), 
3.11 (s, 6H, -(CH3)2N-), 2.91 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 2.23 (d, 2H, 
HCyclo), 1.99 (d, 2H, HCyclo), 1.78-1.52 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.51-1.12 
(m, 21H, SH + -CH2-  + HCyclo). 
Compound L6: 1H NMR (400MHz, CDCl3, TMS):  3.96 (br, 2H, -CH2N-), 3.79-3.75 
(m, 1H, HCyclo), 3.66-3.57 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.46 (t, 2H, -CH2O-), 
3.12 (s, 6H, -(CH3)2N-), 2.89 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 2.28 (d, 2H, 
HCyclo), 2.01 (d, 2H, HCyclo), 1.64-1.54 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.47 (q, 
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2H, HCyclo), 1.33 (t, 3J = 8.0 Hz, 1H, -SH), 1.30-1.22 (m, 14H, -CH2-), 1.16 (q, 2H, 
HCyclo)  1.04 (td, 1H -CHC-), 0.86 (s, 9H, -C(CH3)3-). 
 
Compound L7: 1H NMR (400MHz, CDCl3, TMS):  3.98 (br, 2H, -CH2N-), 3.78-3.75 
(m, 1H, HCyclo), 3.64-3.55 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.46-3.42 (dt, 2H, -
CH2O-), 3.16 (s, 6H, -(CH3)2N-), 2.86 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.93-
1.40 (m, 26H, SCH2)CH2  + -CH2(CH2O)- + HCyclo), 1.33 (t, 3J = 7.82 Hz, 1H, -SH), 
1.29-1.24 (m, 14H, -CH2-). 
 
Compound L8: 1H NMR (400MHz, CDCl3, TMS):  7.4-7.2 (m, 4H, HAr), 7.17 (d, 1H, 
HAr), 3.95 (d and br, 2H, -CH2N-), 3.79-3.52 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.45 
(q, 2H, -CH2O-),3.29-3.22 (m and br, 1H, HCyclo), 3.01-2.92 (m and br, 1H, HCyclo) 2.87 
(s, 3H, -CH3SO-3-), 2.81 (d and br, 6H, -(CH3)2N-), 2.52 (q, 2H, -CH2S-), 2.39-2.26 (m, 
2H, HCyclo), 2.19-2.06 (m, 2H, HCyclo), 1.96-1.84 (m, 4H, HCyclo), 1.72-1.53 (m, 4H, -
(SCH2)CH2  + -CH2(CH2O)-), 1.42-1.1.19 (m, 15H, -SH + -CH2-). 
 
Compound L9: 1H NMR (400MHz, CDCl3, TMS):  7.82 (d, 2H, HAr), 7.66-7.51 (m, 
3H, HAr), 4.24 (br, 2H, -CH2N-), 3.78 (s, 6H, -(CH3)2N-), 3.68-3.52 (m, 14H, -CH2O- + -
OCH2-(CH2N)-), 3.47-3.36 (m, 2H, -CH2O-), 2.87 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -
CH2S-), 1.70-1.46 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.42-1.1.16 (m, 15H, -SH + -
CH2-). 
 
Compound L10: 1H NMR (400MHz, CDCl3, TMS):  8.37 (d, 1H, HAr), 7.98 (d, 1H, 
HAr), 7.69-7.61 (m, 3H, HAr), 7.59-7.48 (m, 1H, HAr), 4.38 (br, 2H,-NCH2-Ar)), 3.76 (br, 
2H, -CH2N-) 3.72-3.62 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.61-3.55 (m, 2H, -CH2O-
), 3.23 (s, 6H, -(CH3)2N-), 3.07 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.67-1.51 (m, 
4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.35-1.21 (m, 15H, -SH + -CH2-). 
 
Compound L11: 1H NMR (400MHz, CDCl3, TMS):  7.42 (d, 2H, HAr), 7.37-2.27 (m, 
8H, HAr), 7.25-7.18 (t, 2H, HAr), 5.13 (s, 1H, HAr), 4.12 (br, 2H, -CH2N-)), 3.96 (br, 2H, -
NCH2(CH2OCAr), 3.64-3.51 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.45 (t, 2H, -CH2O-), 
3.29-3.34 (m, 2H, -CH2OCAr-), 3.28 (s, 6H, -(CH3)2N-), 2.86 (s, 3H, -CH3SO-3-), 2.52 
(q, 2H, -CH2S-), 1.60-1.48 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.34-1.16 (m, 15H, -
SH + -CH2-). 
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2.4.3 General Procedure for the Synthesis of Cationic Nanoparticles 
 
 
Scheme 2.3 Synthesis of cationic gold nanoparticles (NP1-NP11) 
 
General Procedure: 1-Pentanethiol coated gold nanoparticles (d = ~2 nm) were 
prepared according to the previously reported protocol.9 Place-exchange reaction19 of 
compound Ls dissolved in DCM with pentanethiol-coated gold nanoparticles (d~2 nm) 
was carried out for 3 days at environmental temperature. Then, DCM was evaporated 
under reduced pressure. The residue was dissolved in a small amount of distilled water 
and dialyzed (membrane MWCO = 1,000) to remove excess ligands, acetic acid and the 
other salts present with the nanoparticles. After dialysis, the particles were lyophilized to 
afford a brownish solid. The particles (NPs) are redispersed in water and/or ionized water 
(18 M-cm). 1H NMR spectra in D2O showed substantial broadening of the proton 
signals and no free ligands were observed. 
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CHAPTER 3 
NANOPARTICLES-FLUORESCENT POLYMER “CHEMICAL NOSE” 
SENSOR:  DETECTION AND IDENTIFICATION OF PROTEINS 
 
 
3.1 Introduction 
 
The presence of biomarker proteins and/or irregular protein concentrations is a 
consequence of cancer and other disease states.1,2 Sensitive, convenient, and precise 
protein sensing methods provide crucial tools for the early diagnosis of diseases and 
successful treatment of patients. However, protein detection is a challenging prospect due 
to the structural diversity and complexity of the target analytes. Currently, the most 
extensively used detection method for proteins is enzyme-linked immunosorbent assay 
(ELISA).3  In this system, the capture antibodies immobilized onto surfaces bind the 
antigen through a “lock-key” approach and another enzyme-coupled antibody is 
combined to react with chromogenic or fluorogenic substrates to generate detectable 
signals. Despite its high sensitivity, the application of this method is restricted due to its 
high production cost, instability, and challenges for quantification. While synthetic 
systems would alleviate some of these concerns, obtaining high affinity and specificity is 
quite challenging. 
The “chemical nose/tongue” approach provides an alternative to the sensing protocol 
on the basis of exclusive analyte-receptor binding pairs.4  In this strategy, a sensor array 
featuring selective receptors, as opposed to ‘lock-key’ specific recognition, is used for 
analyte detection.  Strategically, the array presents chemical diversity to respond 
differentially to a variety of analytes.  During the past few years, this approach has been 
harnessed to detect a wide range of analytes including metal ions,5 volatile agents,6 
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aromatic amines,7 amino acids,8,9 and carbohydrates.10,11 There have been preliminary 
studies into the application of this strategy to protein sensing,  including  Hamilton’s 
porphyrin-based sensors used to identify four metal and nonmetal-containing 
proteins,12,13  and  Anslyn’s use of 29 boronic acid-containing oligopeptide functionalized 
resin beads to differentiate 5 proteins and glycoproteins through an indicator-uptake 
colorimetric analysis.14 
 The first key challenge for effective protein sensors is the creation of materials 
featuring appropriate surface areas for binding protein exteriors, coupled with the control 
of structure and functionality required for selectivity. Nanoparticles provide versatile 
scaffolds for targeting biomacromolecules that feature sizes commensurate with 
proteins,15,16,17 a challenging prospect with “small molecule”-based systems. Moreover, 
the self-assembled monolayer on these systems allows facile tuning of a range of surface 
properties in a highly divergent fashion, enabling diverse receptors to be rapidly and 
efficiently produced. For example, charged ligand-protected clusters can effectively 
recognize the protein surface through complementary electrostatic and hydrophobic 
interactions.18,19,20   
The second challenge in protein sensing is the transduction of the binding event. Our 
strategy for the creation of protein sensors is to use the particle surface for protein 
recognition, with displacement of a fluorophore generating the output.  As depicted in 
Figure 3.1a, the nanoparticles associate with charge complementary fluorescent dyes to 
give quenched complexes.  The subsequent binding of protein analytes displaces the 
dyes, regenerating the fluorescence.  By modulating the nanoparticle-protein and/or 
nanoparticle-dye association, distinct signal response patterns can then be employed to 
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differentiate the proteins (Figure 3.1b).  The fluorescent indicator displacement assay 
does not require special instruments and its sensitivity (due in large part to the high 
surface area provided by nanoparticles) and rapidity facilitates protein detection.   
 
Figure 3.1 Fluorophore displacement-based protein sensor array. a) Displacement of quenched fluorescent 
polymer by protein analyte with concomitant restoration of fluorescence. b) Pattern generation through 
differential release of fluorescent polymers from gold nanoparticles.  
 
In the current study, we employed six readily fabricated structurally related cationic 
gold nanoparticles (NP1-NP6) to create protein sensors (Figure 3.2a).  These particles 
serve as both selective recognition elements as well as quenchers for the polymer. For our 
studies, we chose gold relative to other potential core materials (e.g. silver) due to its 
extraordinary stability, in particular resistance to exchange by amines (e.g. lysine 
residues) 21 and strong quenching ability.22 The nanoparticle end groups carry additional 
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hydrophobic, aromatic or hydrogen-bonding functionality engineered to tune 
nanoparticle-polymer and nanoparticle-protein interactions.  For the fluorescent 
transduction element we used a highly fluorescent poly(p-phenyleneethynylene) 
(PPE)23,24 derivative, PPE-CO2,25 as a fluorescence indicator. Seven proteins with 
diverse structural features (Mw, pI) were used as the target analytes (Figure 3.2b).  Using 
these components, we have created a competent sensor array, rendering distinct 
fluorescence response fingerprints for individual proteins. Linear discriminant analysis 
(LDA) was performed to identify the protein patterns with a high degree of accuracy. 
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Figure 3.2 Structural features of protein receptors, signal transducer, and target analytes. a) Chemical 
structure of cationic gold nanoparticles (NP1-NP6) and anionic fluorescent polymer PPE-CO2 (n ~ 12).  b) 
Surface structural feature and relative size of seven proteins and the nanoparticles used in the sensing study. 
Color scheme for the proteins: non-polar residues (gray), basic residues (blue), acidic residues (red) and 
polar residues (green).  
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3.2 Results and Discussion 
 
 Fluorescence titration was first conducted to assess the complexation between 
anionic PPE-CO2 and cationic gold nanoparticles NP1-NP6. The intrinsic fluorescence 
of PPE-CO2 was significantly quenched and slightly blue shifted upon addition of all 
nanoparticles (Figure 3.3 for NP3, for the others refer Figure 3.S1). The absorption effect 
of gold cores was obtained through control experiments using neutral particles26 and the 
normalized fluorescence intensities of PPE-CO2 at 465 nm were subsequently plotted 
versus the ratio of nanoparticle to polymer. The complex stability constants (KS) and 
association stoichiometries (n) were obtained through nonlinear least-squares curve-
fitting analysis (Table 3.1). 24 Complex stabilities vary within ca. one order of magnitude 
(G ~ 6 kJ mol-1), while the binding stoichiometry ranges from 0.8 for NP6 to 2.9 for 
NP2.  The observation indicates that the subtle structural changes of nanoparticle end 
groups significantly affect their affinity for the polymer. Significantly, all particle-
polymer conjugates were optically transparent over the concentration range studied.  
 
 59
 
Figure 3.3 Fluorescence intensity changes of PPE-CO2 (100 nM) at 465 nm upon addition of cationic 
NP3.  To eliminate the absorption effect of gold core, the fluorescence intensity was calibrated with that in 
the presence of respective concentrations of tetra(ethylene glycol)-functionalized gold nanoparticle which 
does not associate with PPE-CO2.  Inset shows the fluorescence spectra and the images of PPE-CO2 
solution before and after addition of NP3.  
 
Table 3.1 Binding constants (log KS) and binding stoichiometries (n) between polymer PPE-CO2 and 
various cationic nanoparticles (NP1-NP6) as determined from fluorescence titration. 
 
 
 Once the different binding characteristics of PPE-CO2 with NP1-NP6 were 
established, the particle-polymer conjugates were used to sense proteins. The proteins 
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were chosen to display a variety of sizes and charges: the isoelectric points (pI) of the 
seven proteins vary from 4.6 to 10.7 and molecular weights range from 12.3 to 540 kDa.  
Within this set there are several pairs of proteins that have comparable molecular weights 
and/or pI values, providing a challenging testbed for protein discrimination. In the initial 
sensing study, 200 L of fluorescent polymer PPE-CO2 (100 nM) and stoichiometric 
nanoparticles NP1-NP6 (the stoichiometric values were taken from Table 3.1) were 
respectively loaded onto 96-well plates for recording the initial fluorescence intensities at 
465 nm.  Under these conditions, it is estimated that > 80% of polymer is bound to the 
nanoparticles based on the binding constants listed in Table 3.1, allowing fluorescent 
enhancement via subsequent displacement.  As illustrated in Figure 3.4a, addition of 
aliquots of protein (5 M) resulted in a variety of fluorescence responses.  By contrast, 
the addition of proteins (5 M) into PPE-CO2 (100 nM) induces only marginal 
fluorescence changes (Figure 3.S2 in experimental data), confirming the disruption of 
nanoparticle-PPE-CO2 interactions by proteins.  BSA, -galactosidase, acid phosphatase 
and alkaline phosphatase induce different levels of fluorescence increase, while 
cytochrome c, the only metal-containing protein, further attenuates the fluorescence of 
the systems presumably via an energy or electron transfer process.27  Lipase and subtilisin 
A lead to smaller but still significant fluorescence changes for most nanoparticle-PPE 
systems.  Notably, each protein possesses a unique response pattern.  Such an outcome is 
reasonable since their interaction with the protein-detecting array is dependent on their 
surface characteristics such as the distribution of hydrophobic, neutral, and charged 
amino acid residues.  For each protein, we have tested its fluorescence responses against 
the six nanoparticle-PPE assemblies for six times, generating a 6  6  7 matrix. 
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Figure 3.4 Array-based sensing of 5 M protein analytes. a) Fluorescence response (I) patterns of the 
NP-PPE sensor array (NP1–NP6) against various proteins (CC: cytochrome c, -Gal: -galactosidase, 
PhosA: acid phosphatase, PhosB: alkaline phosphatase, SubA: subtilisin A).  Each value is an average of 
six parallel measurements. b) Canonical score plot for the first two factors of simplified fluorescence 
response patterns obtained with NP-PPE assembly arrays against 5 M proteins. The canonical scores were 
calculated by LDA for the identification of seven proteins. The 95% confidence ellipses for the individual 
proteins are also shown. 
 
 The raw data obtained were subjected to linear discriminant analysis (LDA) to 
differentiate the fluorescence response patterns of the nanoparticle-PPE systems against 
the different protein targets.28  LDA can maximize the ratio of between-class variance to 
the within-class variance in any particular data set thereby enabling maximal separability.  
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This analysis reduced the size of the training matrix (6 nanoparticles  7 proteins  6 
replicates) and transformed them into canonical factors that are linear combinations of the 
response patterns (5 factors  7 proteins  6 replicates).  The five canonical factors 
contain 96.4%, 1.9%, 0.8%, 0.6%, and 0.3% of the variation, respectively.  The first two 
factors were visualized in a two-dimensional plot as presented in Figure 3.4b.  In this 
plot, each point represents the response pattern for a single protein to the nanoparticle-
PPE sensor array. 
The canonical fluorescence response patterns of 5 M proteins against the 
nanoparticle-PPE sensor array are clustered to seven distinct groups according to the 
protein analyte, with no overlap between the 95% confidence ellipses (Figure 3.4a, see 
also Table 3.S1 in experimental data). This result demonstrates that LDA allows the 
discrimination of very subtle differences in protein structure. Moreover, LDA provides 
in-depth quantitative analysis of the fluorescence responses of protein analytes.  The 
assignment of the individual case was based on its Mahalanobis distances to the centroid 
of each group in a multidimensional space. The 42 training cases (7 proteins  6 
replicates) can be totally correctly assigned to their respective groups using LDA, giving 
a 100% accuracy.  Furthermore, another 56 protein samples were prepared randomly and 
used as unknowns in a “blind” experiment, i.e. the individual performing the analysis did 
not know the identity of the solutions. During LDA analysis, the new cases were 
classified to the groups generated through the training matrix according to their 
Mahalanobis distances.  Out of 56 cases, 54 were correctly classified, affording an 
identification accuracy of 96.4%.  This result confirms not only the reproducibility of our 
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fluorescence patterns, but also the feasibility of practical application of such nanoparticle-
conjugated polymer sensor array in detection and identification of proteins. 
Real-world applications, however, require identification of proteins at varying 
concentrations. Varying protein concentrations would be expected to lead to the drastic 
alteration of fluorescence response patterns for the proteins, making identification of 
proteins with both unknown identity and concentration challenging. To enable the 
detection of unknown proteins, we have designed a protocol combining LDA and UV 
measurements.  In this approach, a set of fluorescence response patterns were generated 
at analyte protein concentrations that generated a standard UV absorption value at 280 
nm (A280 = 0.005), the lowest concentration that the proteins could be substantially 
differentiated using the given sensor array followed by LDA.  Therefore, this 
concentration could also be treated as the detection limit of this assay, with molar 
concentrations ranging from 4 nM for -galactosidase to 215 nM for cytochrome c (see 
Figure 3.5 for other proteins).  In our unknown identification protocol, the A280 value of 
the protein was determined, and an aliquot subsequently diluted to A280 = 0.005 for 
recording the fluorescence response pattern against the NP-PPE sensing array. Once the 
identity of the protein was established by LDA, its initial concentration could be 
determined from the initial A280 value and corresponding molar extinction coefficient 
(280) according to Beer-Lambert Law. 
The fluorescence response patterns where the protein concentration is A280 = 0.005 
are distinctly different from those generated from 5 M of proteins, but retain a high 
degree of reproducibility (Figure 3.5a, see also Table 3.S2 in experimental data).  As 
before, LDA accurately differentiate the protein patterns.  As shown in Figure 3.5b, the 
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canonical fluorescence response patterns display excellent separation, except for a minor 
overlap between lipase and subtilisin A.  According to the Jackknifed classification 
matrix, only one subtilisin A sample is misclassified, affording a classification accuracy 
of 97.6% (41 out of 42).  As a control, analogous analyses were performed using polymer 
([PPE-CO2] = 100 nM) in the absence of nanoparticles.  These studies show that the 
polymer itself can only substantially differentiate cytochrome c,27 the metalloprotein, 
from the other proteins (see ESI).  For the other six proteins, merely 50% classification 
accuracy is obtained on the basis of 6 replicates of measurement, only modestly higher 
than the statistical possibility (i.e. 17%).  A further in-depth examination on the 
classification accuracy of the polymer in the absence and presence of individual 
nanoparticles revealed that the latter generally afforded better differentiation abilities than 
the former (see Tables 3S3 and 3S4 in Experimental data), demonstrating the role of the 
nanoparticle in providing selectivity, and hence the differentiation between proteins 
required for effective sensing. 
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Figure 3.5 Array-based sensing of protein analytes with identical absorbance at 280 nm.  a) Fluorescence 
response (I) patterns of the NP-PPE sensor array. b) Canonical score plot for the first two factors of 
simplified fluorescence response patterns obtained with NP-PPE assembly arrays against proteins with 
identical absorption values of A = 0.005 at 280 nm. The canonical scores were calculated by LDA for the 
identification of seven proteins, with 95% confidence ellipses for the individual proteins shown. [BSA] = 
110 nM; [cytochrome c] = 215 nM; [β-galactosidase] = 4 nM; [lipase] = 90 nM; [acid phosphatase] = 20 
nM; [alkaline phosphotase] = 80 nM; [Subtilisin A] = 190 nM. 
 
A series of unknown protein solutions were subsequently used for quantitative 
detection.  To facilitate solution preparation and UV-vis measurement, the unknown 
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proteins were prepared at varying concentrations (120 nM - 50 M).  In principle, lower 
concentrations can also be employed since the detection limit of this method is 
nanomolar (vide supra).  The unknown protein solutions were submitted to the testing 
procedures including determination of A280, dilution of solution to A280 = 0.005, 
fluorescence response recording against the sensor array, and LDA.  Of the 52 unknown 
protein samples; only 3 samples were incorrectly identified, affording an identification 
accuracy of 94.2% (see Table 3.S5 for original data).  In addition, the protein 
concentration was assessed generally within ±5% once it was identified (Table 3.S5).  
This result unambiguously manifests that our sensor array holds substantial promise for 
both the identification and quantification of protein analytes. 
 
3.3 Conclusion 
In conclusion, we have demonstrated that the assemblies of gold nanoparticles with 
fluorescent PPE polymer provide efficient sensors of proteins, achieving both detection 
and identification of analytes.  This strategy exploits the size and tunability of the 
nanoparticle surface to provide selective interactions with proteins, and the efficient 
quenching of fluorophores by the metallic core to impart efficient transduction of the 
binding event. Through application of linear discriminant analysis, we are able to use 
these fluorescence changes to identify and quantify proteins in a rapid, efficient, and 
general fashion. The robust characteristics of the nanoparticle and polymer components 
coupled with diversity of surface functionality that can be readily obtained using 
nanoparticles makes this array approach a promising technique to biomedical diagnostics. 
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3.4 Experimental Section 
 
3.4.1 Metods, Instrumentation and Materials 
Carboxylate-substituted PPE (PPE-CO2) was synthesized according to the reported 
procedure.25 The weight and number average molecular weights of the polymer are 6600 
and 3500, respectively.  The polydispersity index (PDI) and degree of polymerization of 
the conjugated polymer are 1.88 and 12, respectively.  Thiol ligands bearing ammonium 
end groups were synthesized through the reaction of 1,1,1-triphenyl-14,17,20,23-
tetraoxa-2- thiapentacosan-25-yl methanesulfonate with corresponding substituted N,N-
dimethylamines followed by deprotection in the presence of trifluoroacetic acid (TFA) 
and triisopropylsilane (TIPS).  Subsequent place-exchange reaction with petanethiol-
coated gold nanoparticles (d ~ 2 nm)29 afforded cationic gold nanoparticles NP1-NP6 in 
high yields.  1H NMR investigation revealed that the place-exchange reaction proceeds 
almost quantitatively and the coverage of cationic ligands on the nanoparticles is near 
unit.  Bovine serum albumin (BSA), cytochrome c (from horse heart), -galactosidase 
(from E. coli), lipase (from Candida rugosa), acid phosphatase (from potato), alkaline 
phosphatase (from bovine intestinal mucosa), and subtilisin A (from Bacillus 
licheniformis) were purchased from Sigma-Aldrich and used as received.  Phosphate 
buffered saline (PBS, pH 7.4, 1) was purchased from Invitrogen and used as the solvent 
throughout the fluorescence assays. 
In the fluorescence titration study, fluorescence spectra were measured in a 
conventional quartz cuvette (10  10  40 mm) on a Shimadzu RF-5301 PC 
spectrofluorophotometer at room temperature (ca. 25 °C).  During the titration, 2 mL of 
PPE-CO2 (100 nM) was placed in the cuvette and the initial emission spectrum was 
 68
recorded with excitation at 430 nm.  Aliquots of a solution of PPE-CO2 (100 nM) and 
nanoparticles were subsequently added to the solution in the cuvette.  After each addition, 
a fluorescence spectrum was recorded.  The normalized fluorescence intensities 
calibrated by respective controls (tetra(ethylene glycol)-functionalized neutral 
nanoparticle with the same core) at 465 nm were plotted against the molar ratio of 
nanoparticle to PPE-CO2.  Nonlinear least-squares curve-fitting analysis was conducted 
to estimate the complex stability as well as the association stoichiometry using a 
calculation model in which the nanoparticle is assumed to possess n equivalent and 
independent binding sites.19 
 In the protein sensing study, fluorescent polymer PPE-CO2 and stoichiometric 
nanoparticles NP1-NP6 (determined by fluorescence titration, ref. Table 1) was placed 
into six separate glass vials and diluted with PBS buffer to afford mixture solutions where 
the final concentration of PPE-CO2 was 100 nM.  Then each solution (200 L) was 
respectively loaded into a well on a 96-well plate (300 L Whatman Glass Bottom 
microplate) and the fluorescence intensity value at 465 nm was recorded on a Molecular 
Devices SpectraMax M5 micro plate reader with excitation at 430 nm.  Subsequently, 10 
L of protein stock solution (105 M) was added to each well (final concentration 5 M) 
and the fluorescence intensity values at 465 nm were recorded again.  The difference 
between two reads before and after addition of proteins is treated as the fluorescence 
response.  Such process was repeated for seven protein targets to generate six replicates 
of each.  Thus, the seven proteins were tested against the six nanoparticle array (NP1-
NP6) six times to give a 6  6  7 training data matrix.  The raw data matrix was 
processed using a classical linear discriminant analysis (LDA) in SYSTAT (version 
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11.0).  Similar procedures were also performed to identify 56 randomly selected protein 
samples.   
In the studies featuring unknown analyte protein concentrations, the sensor array was 
tested against 7 proteins (A280 = 0.005) for 6 times to generate the training data matrix. 
Fifty-two unknown protein solutions were subjected successively to UV absorption 
measurement at 280 nm, dilution to A280 = 0.005, fluorescence response pattern recording 
against the sensor array, and LDA.  After the protein identity was recognized by LDA, 
the initial protein concentration (c) was deduced from the A280 value and corresponding 
molar extinction coefficient (280) on the basis of Beer-Lambert Law (c = A280/(280l)).  In 
the experimental setup, the protein samples were randomly selected from the 7 protein 
species and the solution preparation, data collection and LDA analysis were performed 
by different persons. 
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3.4.2 Experimental data 
 
 
 
Figure 3.S1 Fluorescence titration curves for the complexation of PPE-CO2 (100 nM) with various 
cationic gold nanoparticles.  The intensity changes at 465 nm were followed by the addition of various 
concentrations of NPs with an excitation wavelength of 430 nm.  The red solid lines represent the best 
curve-fitting using a calculation model of single set of identical binding sites. 
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Figure 3.S2 Fluorescence intensities of PPE-CO2 (100 nM, 200 L) in the 96-well microplate upon 
addition of PBS (10 L) or various protein solutions (10 L, 105 M).  The intensities were recorded at 
465 nm with an excitation wavelength of 430 nm. 
 
 
Table 3.S1 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1 – NP6) against 
various proteins (5 M). Table continues on the next page. 
Protein NP1 NP2 NP3 NP4 NP5 NP6 
BSA 257.301 225.6705 264.481 414.337 232.6915 271.8175 
BSA 340.96 306.497 286.159 389.051 255.113 289.169 
BSA 286.309 269.784 298.041 375.189 277.446 266.679 
BSA 274.95 230.364 270.385 385.978 270.743 255.996 
BSA 248.114 227.807 219.887 406.811 118.506 205.777 
BSA 289.53 301.474 233.368 411.579 126.498 156.355 
Cytochrome c -173.239 -243.7695 -98.33 -42.106 -67.827 -6.100 
Cytochrome c -212.689 -253.748 -96.444 -50.032 -70.193 -11.864 
Cytochrome c -211.989 -176.255 -96.533 -28.81 -75.472 -10.474 
Cytochrome c -226.049 -249.75 -101.088 -39.883 -56.252 -2.608 
Cytochrome c -218.562 -159.429 -89.063 -45.986 -53.261 -27.726 
Cytochrome c -194.438 -113.668 -48.999 -37.641 -56.521 -22.668 
-Galactosidase 685.72 717.134 675.0985 540.824 669.4222 922.738 
-Galactosidase 799.231 718.938 755.872 658.867 775.697 953.258 
-Galactosidase 749.614 732.453 695.919 734.933 710.618 902.833 
-Galactosidase 889.984 646.159 717.96 637.393 712.389 954.118 
-Galactosidase 864.656 656.946 733.992 661.197 731.902 871.314 
-Galactosidase 805.633 747.617 779.35 744.682 729.5 895.446 
Lipase -43.738 -39.656 91.944 -22.739 -1.6697 106.3148 
Lipase -2.394 -59.968 96.99 1.132 15.709 126.414 
Lipase 89.814 -129.488 89.227 -14.037 -2.891 105.287 
Lipase 3.47 -9.823 111.726 -9.262 5.724 108.542 
Lipase -56.325 -3.53 69.104 -1.982 34.993 88.651 
Lipase -57.092 7.63 63.602 -17.495 0.618 100.479 
Acid phosphatase 94.092 91.365 201.777 175.071 200.925 180.196 
Acid phosphatase 122.214 102.202 199.684 181.79 193.317 214.438 
Acid phosphatase 107.14 109.187 248.382 160.445 177.163 188.247 
Acid phosphatase 127.16 111.545 196.917 174.477 186.309 181.137 
Acid phosphatase 151.778 136.102 183.673 174.045 186.81 202.74 
Acid phosphatase 131.67 99.933 195.84 163.312 194.355 192.107 
Alkaline phosphatase 213.327 147.464 292.456 255.852 318.939 263.11 
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Alkaline phosphatase 190.598 135.389 230.212 279.278 311.824 252.339 
Alkaline phosphatase 160.721 205.114 245.772 285.58 311.061 248.009 
Alkaline phosphatase 142.322 160.667 251.252 272.127 326.608 258.939 
Alkaline phosphatase 175.056 170.559 268.359 287.199 317.05 243.648 
Alkaline phosphatase 184.905 193.269 249.972 297.744 315.026 250.946 
Subtilisin A -30.425 6.563 -22.139 11.007 -3.126 -9.373 
Subtilisin A -36.602 -28.967 4.15 13.281 0.197 -16.321 
Subtilisin A -38.18 -2.424 -10.839 12.274 -6.559 -0.836 
Subtilisin A -18.079 -1.368 -22.089 21.301 -12.414 -11.739 
Subtilisin A -48.413 -38.422 13.29 6.327 -28.12 -13.824 
Subtilisin A -9.517 0.942 -25.906 39.032 -12.308 5.541 
 
 
 
Table 3.S2 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1–NP6) against 
various proteins with identical absorption values of A = 0.005 at 280 nm. Table continues on the next page. 
Protein NP1 NP2 NP3 NP4 NP5 NP6 
BSA -207.251 -80.4074 -41.0494 3.556583 -41.3954 -3.76742 
BSA -152.201 -77.1674 -55.7804 -1.94342 -49.7074 4.588583
BSA -251.316 -0.11142 -31.9444 25.40958 -39.3404 -11.0144 
BSA -98.0724 -65.7634 -43.7164 22.97658 -43.5624 -7.16342 
BSA -211.026 -66.2634 -39.8604 -7.87942 -43.6464 -3.81042 
BSA -105.233 -220.02 -26.8694 10.40658 -33.0744 -9.22942 
Cytochrome c -172.652 -50.1355 -146.265 10.8245 -47.6265 -40.3145 
Cytochrome c -190.972 -82.9625 -137.953 3.2665 -73.4645 -47.1625 
Cytochrome c -232.23 4.8425 -140.34 2.4305 -73.3435 -49.6205 
Cytochrome c -230.869 -122.978 -145.803 34.3415 -67.2365 -57.2915 
Cytochrome c -164.136 10.4385 -122.127 0.3655 -60.3585 -48.4655 
Cytochrome c -163.889 6.6535 -116.073 23.3225 -52.0905 -54.5375 
-Galactosidase 19.0285 107.7135 60.0105 113.7165 83.2875 61.1885 
-Galactosidase 9.1095 96.5955 77.4785 125.5305 53.7755 39.4995 
-Galactosidase -19.4815 101.9385 69.9525 73.7525 94.1465 47.2445 
-Galactosidase 1.2955 41.5925 74.2685 123.5115 94.1875 49.3605 
-Galactosidase -196.846 119.6175 62.6425 61.8325 80.0215 48.0035 
-Galactosidase -11.7785 44.9365 83.1515 92.8155 88.1445 43.2705 
Lipase -79.0774 86.93458 -6.73842 27.82958 2.912583 -6.25842 
Lipase -42.0344 73.02458 -0.80742 24.90658 10.39558 -10.2144 
Lipase -134.166 26.16258 -0.72042 51.70958 12.93158 -13.5724 
Lipase -23.2854 96.48058 -3.04842 32.51358 4.503583 -10.3044 
Lipase -120.295 90.46358 -0.58542 57.46258 18.25058 -2.08742 
Lipase -196.312 86.72058 -4.36842 20.83658 20.81058 -8.69742 
Acid phosphatase -128.351 -188.015 2.1795 -79.1105 -46.9325 31.7065 
Acid phosphatase -77.2075 -44.4985 4.4975 -75.2075 -60.4315 28.5805 
Acid phosphatase -86.9055 -146.495 4.1835 -56.7145 -59.1445 31.3135 
Acid phosphatase -99.9655 -119.904 -8.0655 -62.6845 -42.9485 15.1155 
Acid phosphatase -111.126 -122.595 4.9705 -70.9985 -25.8015 33.4465 
Acid phosphatase -22.4615 -165.882 12.7355 -35.2555 -62.1085 40.8975 
Alkaline phosphatase 28.025 45.951 142.938 71.48 77.665 77.528 
Alkaline phosphatase -14.702 -43.38 118.72 56.961 64.276 97.109 
Alkaline phosphatase -31.212 -32.501 105.815 81.159 62.164 82.984 
Alkaline phosphatase 18.479 -30.982 119.467 63.77 73.137 106.726 
Alkaline phosphatase -13.647 -44.002 151.862 61.725 69.491 90.719 
Alkaline phosphatase 7.936 -26.84 142.162 68.08 76.484 94.309 
Subtilisin A -131.396 25.0715 1.9835 47.1915 -6.7715 -10.0785 
Subtilisin A -2.9055 -10.7465 11.8125 47.2905 -15.1505 -17.8985 
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Subtilisin A -78.4445 -41.6635 -32.2655 29.5855 12.6455 -7.0365 
Subtilisin A -80.4355 -30.6755 -24.3905 33.4205 -10.8945 -24.7975 
Subtilisin A -9.2595 7.0255 -13.5505 43.6225 -0.6355 1.8175 
Subtilisin A -175.215 4.4625 -6.6085 55.0065 -5.0035 -19.8595 
 
 
 
 
 
Figure 3.S3 Fluorescence responses (I) of fluorescent polymer PPE-CO2 (100 nM) against various 
proteins with identical absorbance of A = 0.005 at 280 nm (BSA, 110 nM; CC: cytochrome c, 215 nM; -
Gal: -galactosidase, 4 nM; Lipase, 90 nM; PhosA: acid phosphatase, 20 nM; PhosB: alkaline phosphatase, 
80 nM; SubA: subtilisin A, 190 nM).  Each fluorescence response value is an average of six parallel 
measurements.  There are significant response overlaps between the proteins except for CC, as denoted by 
the shaded regions.  LDA analysis on the raw data affords only a 57% classification accuracy. 
 
 
 
Table 3.S3 LDA classification accuracy of protein analytes (5 M) by using the fluorescent polymer and 
the complexes of the fluorescent polymer with individual nanoparticles as sensors.  The values are taken 
from the Jackknifed classification matrix based on LDA analysis of the raw data (6 replicates) listed in 
Figure 3.S2 and Table 3.S1.  The average classification accuracy of 6 polymer-nanoparticle complexes is 
81.5%. 
 
Proteins Polymer Polymer/NP1 Polymer/NP2 Polymer/NP3 Polymer/NP4 Polymer/NP5 Polymer/NP6
BSA 83 100 100 50 100 33 0 
CC 100 100 83 83 100 100 50 
-Gal 83 100 100 100 83 100 100 
Lipase 100 33 33 100 100 67 100 
PhosA 100 83 83 83 100 83 100 
PhosB 33 83 83 50 100 100 83 
SubA 0 67 67 100 100 83 50 
Total 71 81 79 81 98 81 69 
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Table 3.S4 LDA classification accuracy of protein analytes (A280 = 0.005) by using the fluorescent polymer 
and the complexes of the fluorescent polymer with individual nanoparticles as sensors.  The values are 
taken from the Jackknifed classification matrix based on LDA analysis of the raw data (6 replicates) listed 
in Figure 3.S3 and Table 3.S2.  The average classification accuracy of 6 polymer-nanoparticle complexes is 
61.5%. 
Proteins Polymer Polymer/NP1 Polymer/NP2 Polymer/NP3 Polymer/NP4 Polymer/NP5 Polymer/NP6 
BSA 17 17 67 100 67 83 50 
CC 100 50 17 100 17 67 100 
-Gal 83 17 67 100 67 83 83 
Lipase 83 17 17 83 33 83 50 
PhosA 50 17 83 83 100 17 83 
PhosB 50 83 17 100 100 67 100 
SubA 17 33 67 17 50 83 50 
Total 57 33 48 83 62 69 74 
 
 
 
Table 3.S5 Detection and identification of unknown proteins using LDA combined with UV 
measurements.a Table continues on the next page. 
Fluorescence response pattern Identification Verification # 
NP1 NP2 NP3 NP4 NP5 NP6 Protein A280 Conc. Protein/Conc. Deviation
1 -55.3435 51.7795 -16.3605 26.5705 -4.4815 -2.796 SubA 1.2182 46.8 M SubA/48.6 M -3.7% 
2 -159.922 -200.188 -33.567 -1.8505 -27.8385 15.6485 BSA 0.96539 20.6 M BSA/20.7 M -0.5% 
3 60.447 24.348 -22.804 -51.3415 -27.869 46.857 PhosA 0.28217 1.09 M PhosA/1.15 M -5.2% 
4 18.986 4.8175 30.6935 82.7865 86.03 55.373 -Gal 0.16012 141.9 nM -Gal/132.5 nM +7.1% 
5 -153.174 76.981 -107.443 39.1415 -43.0145 -20.585 CC 0.27177 11.7 M CC/11.6 M +0.9% 
6 140.3665 77.798 125.5305 57.021 29.3225 97.9345 PhosB 1.10921 17.7 M PhosB/18.2 M -2.7% 
7 30.9535 -73.4045 -24.526 -58.722 -32.537 41.9955 PhosA 0.57403 2.23 M PhosA/2.29 M -2.6% 
8 -32.722 -83.1245 1.01 26.369 -16.3085 -6.646 SubA 0.91653 35.2 M SubA/36.4 M -3.3% 
9 -170.571 -176.652 -2.443 -10.5135 -20.1085 4.8575 BSA 0.25960 5.54 M BSA/5.17 M +7.2% 
10 110.9075 75.605 120.6435 58.417 38.8035 96.4325 PhosB 0.84386 13.4 M PhosB/13.7 M -2.2% 
11 -52.4345 -90.4335 -31.8315 39.614 -40.355 7.283 BSA 0.21278 4.54 M BSA/4.27 M +6.3% 
12 132.2205 14.8855 48.0685 88.9575 60.5765 46.69 -Gal 0.30713 272.1 nM -Gal/265.1 nM +2.6% 
13 -53.007 -26.357 2.4935 -0.6355 -18.5085 -2.031 SubA 0.64011 24.6 M SubA/24.3 M +1.2% 
14 -89.257 -30.347 -95.7465 29.4355 -42.224 -25.484 CC 0.51375 22.1 M CC/23.7 M -6.8% 
15 74.92 34.4575 122.4875 58.0585 30.54 90.445 PhosB 0.58285 9.32 M PhosB/9.11 M +2.3% 
16 69.74 -59.9385 -22.9405 -54.0895 -38.892 46.379 PhosA 0.87457 3.39 M PhosA/3.44 M -1.5% 
17 -46.589 -41.161 -45.58 28.9365 -18.155 -5.202 SubA 1.03644 39.8 M BSA/22.2 M Fail 
18 -1.3855 123.234 40.306 104.191 53.1025 60.338 -Gal 0.45375 402.0 nM -Gal/397.6 nM +1.1% 
19 8.744 -47.9015 -10.503 23.4455 -2.786 -0.551 SubA 0.29871 11.5 M SubA/12.1 M -5.0% 
20 -127.88 10.989 -111.602 25.039 -42.7185 -31.055 CC 1.10620 47.4 M CC/47.4 M 0% 
21 80.646 77.4045 122.2085 49.6575 28.364 108.999 PhosB 0.30431 4.85 M PhosB/4.55 M +6.6% 
22 -34.1755 -62.086 -39.003 -49.7855 -42.4565 47.0585 PhosA 1.12450 4.36 M PhosA/4.58 M -4.8% 
23 -171.657 26.51 -108.075 33.099 -54.846 -23.0465 CC 0.22161 9.55 M CC/10.7 M -10.7% 
24 66.1835 65.6285 43.726 85.35 63.9405 58.366 -Gal 0.60837 539.0 nM -Gal/530.2 nM +1.7% 
25 -62.507 -77.425 -13.4925 -67.5525 -53.5785 45.438 PhosA 1.13410 4.40 M PhosA/4.37 M +0.7% 
26 125.019 99.546 94.4245 92.824 95.8115 67.8245 -Gal 0.13440 119.1 nM -Gal/114.6 nM +3.9% 
27 67.929 6.440 -24.355 21.209 5.599 9.609 SubA 0.28359 10.9 M Lipase/5.05 M Fail 
28 -44.821 -8.148 -12.4455 42.5155 -8.811 19.273 SubA 0.31565 12.1 M SubA/11.5 M +5.2% 
29 -1.7445 -53.0475 134.7005 77.0995 26.2465 93.0025 PhosB 1.16620 18.6 M PhosB/18.4 M +1.1% 
30 -12.801 -213.077 -26.6465 14.8225 -20.1955 3.6715 BSA 0.31933 6.81 M BSA/6.40 M +6.4% 
31 113.935 22.192 108.781 67.868 52.256 88.252 PhosB 0.89032 14.2 M PhosB/13.8 M +2.9% 
32 -49.831 -201.661 -13.814 -70.416 -21.3195 42.461 PhosA 0.88471 3.43 M PhosA/3.27 M +4.9% 
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33 120.276 127.391 100.1595 73.635 79.0325 59.9445 -Gal 0.27235 241.3 nM -Gal/229.1 nM +5.3% 
34 -37.397 -27.0225 16.458 27.685 5.337 -5.986 SubA 0.58273 22.4 M SubA/22.9 M -2.2% 
35 4.1795 11.8585 139.236 85.6165 17.748 94.747 PhosB 0.87407 13.9 M PhosB/13.8 M +0.7% 
36 -3.5925 -92.691 -34.049 12.4535 -36.709 19.2155 BSA 0.61183 13.1 M BSA/12.8 M +2.3% 
37 35.837 9.911 -9.081 15.321 6.598 5.385 Lipase 0.58135 10.7 M Lipase/10.1 M +7.9% 
38 30.6755 16.9725 98.9435 63.948 113.2 59.3525 -Gal 0.38936 345.0 nM -Gal/344.8 nM +0.1% 
39 -58.207 -152.25 -15.833 18.004 -25.175 1.521 BSA 0.89327 19.1 M BSA/19.2 M -0.5% 
40 -43.3685 -71.0225 -20.966 -70.314 -44.754 40.6875 PhosA 0.59783 2.32 M PhosA/2.18 M +6.4% 
41 -11.573 -6.737 8.481 18.5585 20.9805 -8.1385 Lipase 0.91641 16.9 M SubA/34.5 M Fail 
42 3.5915 -32.2335 152.74 48.9305 33.6155 98.29 PhosB 0.58425 9.31 M PhosB/9.22 M +1.0% 
43 2.341 69.094 83.720 67.793 64.218 38.548 -Gal 0.27904 247.2 M -Gal/249.7 nM -1.0% 
44 -41.8565 -138.779 -20.7295 -75.9705 -26.236 54.806 PhosA 0.24280 941 nM PhosA/1.09 M -13.7% 
45 9.074 -60.2835 166.391 54.379 35.2185 113.06 PhosB 0.30505 4.86 M PhosB/4.61 M +5.4% 
46 32.227 99.8215 96.609 77.601 94.505 68.7545 -Gal 0.50911 451.1 nM -Gal/458.3 nM -1.6% 
47 27.6605 -39.711 1.79 18.2735 5.9905 -5.728 SubA 1.16410 44.7 M SubA/46.0 M -2.8% 
48 -74.983 -150.324 -70.2795 24.0015 -55.487 -25.0155 BSA 1.30270 27.8 M BSA/25.7 M +8.6% 
49 -29.81 71.8155 3.726 25.9465 2.937 -6.1615 Lipase 1.13742 20.9 M Lipase/20.2 M +3.5% 
50 -61.873 99.490 80.315 81.070 77.443 36.694 -Gal 0.45795 405.8 nM -Gal/374.6 nM +8.3% 
51 2.728 10.573 -9.496 23.268 12.090 15.387 Lipase 0.84971 15.6 M Lipase/15.2 M +2.6% 
52 94.083 -32.448 117.772 74.158 73.077 104.623 PhosB 0.59023 9.40 M PhosB/9.23 M +1.8% 
a BSA: bovine serum albumin,  (280 nm) = 46860 M-1 cm-1; CC: cytochrome c,  (280 nm) = 23200 M-1 
cm-1; -Gal: -galactosidase,  (280 nm) = 1128600 M-1 cm-1; Lipase:  (280 nm) = 54350 M-1 cm-1; 
PhosA: acid phosphatase,  (280 nm) = 257980 M-1 cm-1; PhosB: alkaline phosphatase,  (280 nm) = 62780 
M-1 cm-1; SubA: subtilisin A,  (280 nm) = 26030 M-1 cm-1. 
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CHAPTER 4 
SNIFFING SERUM PROTEIN IN HUMAN SERUM: 
A NANOPARTICLE-GFP CONJUGATE BASED ARRAY SENSING 
 
 
4.1 Introduction 
 
Personalized medicine1 requires personalized diagnostics to achieve personalized 
treatment of specific diseases. While treatment with personalized drugs is the final goal, a 
necessary prerequisite is the early determination of the disease status and causes. It was 
evident that the most acute and chronic disease states will result in subtle or dramatic 
changes in the relative composition of a person’s blood serum.2 This hypothesis has 
strong support from regular clinical tools, where simple electrophoresis of plasma leads 
to the identification and semiquantitative “fingerprinting” of proteins that are abundant in 
blood serum. The presence of specific electrophoresis patterns can interpret by physicians 
to diagnose a significant number of disorders.3 Changes in protein electrophoresis 
patterns are diagnostic for liver and renal failure, as well to states of massive 
malnutrition, systemic shock or other large scale inflammatory events. Simple one-
dimensional agarose electrophoresis of protein serum is an effective but slow and 
insensitive tool for the detection of gross protein imbalances. The reason of the difficulty 
for the detection of protein composition in serum is arising from its complex 
composition. Human blood serum contains >20,000 different proteins, some of which are 
present in concentrations > 50 g/L such as albumin, down to specific disease markers 
including cardiac troponin or natriuretic peptide that are found after a myocardial infarct 
or in patients with congestive heart failure respectively in concentrations of 2-9 μg/L and 
0.6-1.4 μg/L respective. Besides albumin, the other proteins found in plasma at high 
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concentrations are prealbumin (0.2- 0.4 g/L), antitrypsin (a protease inhibitor 0.5 g/L), 
macroglobulin (1.5-3.5 g/L), lipoprotein (3-7 g/L), transferrin (2-4 g/L), and 
immunoglobulins A, D, E, G (8-17 g/L). About 20 proteins constitute 99 weight% of all 
of the serum protein content. Table 4.1 displays the isoelectric point, molecular weight 
and approximate concentrations of the 20 most common proteins in human serum. Most 
of the serum proteins are negatively charged, but their molecular weights vary from 28 to 
900 kDa. It is important to note that some of these proteins such as transferrin display a 
quite significant range in concentration. 
Table 4.1 Approximate Weight Content of High Abundant Proteins in Serum/Plasma. 4 
Protein gL-1 Mwa pIb Protein gL-1 Mwa pIb Protein gL-1 Mwa pIb 
Albumin 50 65 5.2 -Antitrypsin 0.5 52 5.4 Factor H 0.2 139 ? 
IgG 1-4 10 150 7.5-7.8 C3-Complement 0.5 180 5.8 Ceruloplasmin 0.2 135 4.4 
Transferrin 2-4 80 5.6 Haptoglobin 0.2 41 5.1-7 C4-Complement 0.2 200 6 
Fibrinogen 2 340 5.6 Apolipoprotein 
A1 
0.2 28 5.4-5.6 Complement B 0.2 100 5.9-6.1
IgA Total 1.5 350 4.9 Apolipoprotein B 0.2 515 5.0-5.3 Prealbumin  0.2 60 ? 
-Macroglobulin 1.5 750 5.3-6.3 -1-acid 
glycoprotein 
0.2 40 2.7 C9-Complement 0.1 71 5.60 
IgM 0.5 900 5-7 Lipoprotein(a) 0.1 400-700 ?     
a) molecular weight in kDa. b) isoelectric point. 
 
The plasma protein composition can change for various reasons5 such as, i) inter- and 
intradaily changes in serum composition, ii) age related changes in serum composition, 
iii) nutritional status, iv) differences in serum composition for each individual and v) 
disease related changes in serum composition. The detection of the vast number of 
proteins acquired with proteomic techniques such as surface-enhanced laser 
desorption/ionization (SELDI)6 technique allows the determination of patterns of protein 
distribution that in comparison with normal sera may allow to find specific protein 
signatures for specific diseases. But here the instrumentation is expensive, the throughput 
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is low and the dynamic range is limited. If specific fractions of proteins are removed from 
the serum, then mass spectrometry is more sensitive and a tool for the discovery of 
hitherto unknown serum proteins. However mass spectrometry is at the moment not well 
suited as a high throughput tool for the economical screening of large numbers of serum 
samples, and is certainly unrealistic as a tool for personalized diagnostics. 
With 2-D-SDS-PAGE electrophoresis, the specific proteins identified may also be 
sequenced.7 Isoelectric focusing allows separation of proteins according to their charge, 
while in the second dimension the proteins are separable according to their molecular 
weight. This technique has led to the discovery of signature protein patterns in patients 
with ovarian carcinomas and in patients with inflammatory bowel disease.8 But these 
chromatograms are examined by eye and therefore only significant changes in serum 
composition are recognized. Plasma proteins that are present in much smaller amounts 
are specifically detected by monoclonal antibodies, with enhanced troponin or myoglobin 
levels being used to diagnose myocardial infarcts and increased PSA antigen used to 
detect prostate cancers.9 The third group is composed of specific disease markers that are 
present in smallquantities to signal the early stage of a specific disease or a group of 
disorders. In such a case the gross plasma composition may be changed either 
significantly or subtly. Classic examples for such markers include those for neoplastic 
diseases, where the debris produced by the large number of dead and therefore lysed cells 
significantly increases the DNA content of the plasma.10 While the use of monoclonal is 
powerful, each monoclonal antibody has to be raised and can only detect one specific 
protein. Moreover, the technical difficulties as regards to quantification are significant.11 
We pose the hypothesis that most disease states will leave their “fingerprint” in the 
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overall plasma composition, leading to an altered serum content of specific proteins or 
protein groups. The development of generalized and easy access “serum sensors” should 
give fast, reliable, and accurate readings of a person’s health status.  A “chemical 
nose/tongue” strategy12,13 provides an alternative strategy to the above methods for 
protein sensing. In the “nose” approach, differential interactions of analytes with a 
receptor array generate a pattern that is used for identification. A variety of scaffolds 
have been employed for array-based sensing of proteins, including oligopeptide-
functionalized resins14, substituted porphyrins15, polymers16, 17 and synthetic polymer-
nanoparticle systems18, 19. While highly effective at identifying proteins, these systems 
generally feature high limits of detection (generally 8-40 M) and require a large number 
of detector elements relative to the number of proteins sensed. Moreover, these methods 
have not been applied to sensing in challenging matrices such as biofluids. 
 
4.2 Results and Discussion 
In gold nanoparticle-fluorescent conjugated polymer based array we used six 
different functionalized cationic nanoparticles and a fluorescent polymer to detect seven 
target proteins at detection limit of 4 nM for β-galactosidase (β-gal) with the accuracy of 
94%.18 To provide a more effective system suitable for protein sensing in serum, we 
created hybrid synthetic-biomolecular sensor elements. In the sensing process an array of 
green fluorescent protein (GFP)-nanoparticle (NP) complexes generates a signature that 
can be employed to identify proteins in human serum. Compared to our previous sensor 
array using polymers, the biocompatibility of both the nanoparticles and GFP allows us to 
use this system without affecting the target protein conformation during their 
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detection20,21. In addition, the GFP-NP conjugate mimics protein-protein surface 
interactions, which is instrumental in reaching much lower detection limits and thus 
enabling detection of biomedically relevant changes in protein concentration in undiluted 
human serum.   
 Our sensing strategy relies on the electrostatic complementarity between GFP 
and the NPs. GFP is a beta barrel shaped marker protein that is negatively charged at 
physiological conditions (3.0 diameter x 4.0 nm length, MW = 27 KDa, pH 7.4, pI = 
5.92) 22, 23, with an excitation peak at 490 nm and emission peak at 510 nm (Figure 4.1a). 
Due to their positive charges, the gold NPs complex the anionic GFP, resulting in 
fluorescence quenching. We hypothesized that in the presence of analyte proteins the 
binding equilibrium between GFP and NP would be altered due to competitive binding, 
thus modulating the fluorescence response (Figure 4.1b). The fluorescence response can 
be positive or negative depending on the binding affinity of analyte proteins towards NPs 
and GFP. The higher affinity to NPs produces positive response and otherwise generates 
negative response as a result of analyte protein-GFP aggregation (Figure S17).   
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Figure 4.1  Modes of sensor response. a) Structure, absorbance and fluorescence spectra of GFP in 5 mM 
sodium phosphate buffer, pH 7.40.  b) Schematic illustration of the competitive binding between protein 
and quenched nanoparticle-GFP complexes and protein aggregation leading to the fluorescence light-up or 
further quenching. 
 
To confirm this hypothesis, five cationic gold NPs (NP1–NP5) were fabricated as 
sensor elements.  In addition to their cationic charges, the ligand shells of these NPs 
differ in hydrophobicity, aromaticity, and hydrogen bonding ability (Figure 4.2).  
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Figure 4.2 Structural features of nanoparticles . Chemical structure of cationic gold nanoparticles. NP1 
features only cationic charge, NP2 and NP4 feature groups capable of hydrophobic interaction, NP3 
features groups capable of hydrogen bonding and NP5 has aromatic recognition unit capable of π-π 
interaction. 
 
Roughly 20 serum proteins with different charge and molecular weights constitute 
99% by mass of the serum protein content24. We choose five of the most abundant serum 
proteins for our studies: albumin, IgG, transferrin, fibrinogen and -antitrypsin (Table 
4.2). 
Table 4.2 Molecular weight, isoelectric point and concentration of five analyte serum proteins24 in human 
serum. 
Protein ML-1 Mwa pIb %c 
Albumin 769 65 5.2 70 
IgG 66.7 150 7.5-7.8 14 
Transferrin 25-50 80 5.6 5.7 
Fibrinogen 5.9 340 5.6 2.8 
-Antitrypsin 9.6 52 5.4 0.7 
a) molecular weight in kDa. b) isoelectric point. c) weight percent in human serum. 
 
Preliminary studies were performed in buffer. We optimized the binding ratio 
between GFP and nanoparticles (NP1–NP5) through fluorescence titration. The 
fluorescence of GFP was significantly quenched for all nanoparticles and the change of 
fluorescence intensity against increasing nanoparticle concentrations was plotted (Figure 
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4.4, Figure 4.S16). The complex stability constants (KS) and association stoichiometries 
(n) were obtained through nonlinear least-squares curve-fitting analysis (Table 4.S1)25. 
The variation in complex stabilities and the binding stoichiometry demonstrate the 
significant effect of head groups in nanoparticle-protein affinity. 
Once the binding ratio that provided maximum quenching of fluorescence was 
determined, we tested the ability of our sensor to detect serum proteins in 5 mM sodium 
phosphate buffer using a solution of 100 nM of both particle and GFP. Testing at varying 
protein concentrations demonstrated that complete differentiation of the five analyte 
proteins was obtained at 25 nM (Figure 4.4a).  
Linear discriminant analysis (LDA) was used to quantitatively differentiate the 
fluorescence response patterns of the nanoparticle-GFP conjugates with the serum 
proteins26. We generated the fluorescence responses six times for each protein against the 
five nanoparticle-GFP conjugates for this purpose. After the analysis, four canonical 
factors were generated (91.5%, 6.8%, 1.2% and 0.5%) that are linear combination of the 
response matrices obtained from fluorescence response pattern (5 nanoparticle-GFP 
conjugates × 5 proteins × 6 replicates). The 30 training cases (5 proteins × 6 replicates) 
are separated in five respective groups with 100% accuracy according to the jackknifed 
classification matrix and the most significant two factors are plotted in 2D (Figure 4.3b). 
This detection efficiency was validated through identification of unknowns from our 
training set, where a randomized set of the five proteins from the training set were 
identified with 97% accuracy (Table 4.S6).  
 85
 
Figure 4.3 Array based sensing of five serum proteins in 5 mM sodium phosphate buffer (pH 7.40). (a) 
Fluorescence response (I) patterns of the five nanoparticle-GFP adducts in the presence of five high 
abundant serum proteins at 25 nM concentration (average of six measurements). (b) Canonical score plot 
for the fluorescence patterns as obtained from LDA against five protein analytes at fixed concentration of 
25 nM, with 95% confidence ellipses. 
  
Protein sensing in human serum provides a far more demanding testbed than pure 
proteins in solution. The high overall protein content (~1 mM, 71 mg/mL) and 
multianalyte nature of human serum generates a complex matrix that is challenging for 
sensor design. To provide a controlled model for testing our methodology, we spiked 
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physiologically relevant concentrations of the above five proteins into commercially 
available human serum. We first optimized the concentration and ratio of nanoparticle-
GFP conjugates. Because of the optical density of pure human serum, a higher 
concentration of GFP (250 nM) was required to get sufficient response. The titration data 
(Figure 4.4) indicates that saturation in fluorescence quenching was not observed even at 
a 8:1 NP/GFP ratio due to the presence of the other proteins in human serum that 
compete with GFP for nanoparticle binding. To provide reproducible quenching and a 
high level of sensitivity, we used a particle concentration of 500 nM, corresponding to the 
inflection point observed in the titration curves (Figure 4.4).  
 
Figure 4.4 Determination of the optimum ratio of fluorophore to nanoparticle. The changes of fluorescence 
intensity of GFP (250 nM) at 510 nm were measured after the addition of cationic nanoparticles (0-2 M) 
with an excitation wavelength of 475 nm. The absorption effect from gold core was subtracted by using 
non-interacting tetra(ethylene glycol)-functionalized gold nanoparticles. Inset shows the change of 
Fluorescence intensity of GFP (100 nM) at 510 nm upon addition of cationic NP3 in 5 mM sodium 
phosphate buffer. The red solid lines represent the best curve fitting using the model of single set of 
identical binding sites and the arrow indicates the optimum binding ratio used for our study. 
 
Using the conditions optimized above, 500 nM was the minimum amount of spiked 
analyte required for reproducible differentiation of the target proteins. We created a 
training matrix (5 nanoparticle-GFP conjugates  5 proteins  6 replicates) with GFP-
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nanoparticle conjugates and each of the proteins. Similar to the buffer studies, each of the 
proteins generated distinct fluorescence response (Figure 4.5a). As before, these patterns 
were further subjected to LDA analysis, providing a 97% identification accuracy, as -
antitrypsin slightly overlaps with IgG. The four canonical factors are 76.9%, 20.3%, 
2.7%, 0.1% and the plot of the first two factors with 95% confidence ellipses is presented 
in Figure 4.5b. We next tested the system against unknowns taken from the training set. 
Out of 30 samples 28 samples were correctly identified affording a 93% identification 
accuracy (see Table 4.S7 for original data).  We identified target proteins in the complex 
serum matrix at physiologically relevant submicromolar concentrations. As a point of 
reference, we were able to detect and identify the analyte proteins between 0.06 to 8.4% 
(by molarity) of total serum protein concentration (Table 4.3).  
 
Table 4.3 Change of protein concentration as a percentage of its typical concentration in normal serum 
detected by the sensor array. 
 
Protein ML-1 %a 
Albumin 769 0.06 
IgG 66.7 0.75 
Transferrin 25-50 1-2 
Fibrinogen 5.9 8.4 
-Antitrypsin 9.6 5.2 
a Change in protein concentrations in molarity. 
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Figure 4.5 Array based sensing of five serum proteins in human serum. a) Fluorescence response (I) 
pattern of the five nanoparticle-GFP adducts in the presence of serum proteins spiked in human serum 
at 500 nM concentration (responses are average of six measurements and  error bars are standard 
deviations of the measurements from the mean). b) Canonical score plot for the fluorescence patterns 
as obtained from LDA against five protein analytes at fixed concentration (500 nM) with 95% 
confidence ellipses. 
 
After successful detection of serum proteins in human serum, the next challenge 
arises from the detection of a protein at variable concentration level and in mixture with 
other proteins. One of the limitations of the antibody and other approaches is the 
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differentiation between the variable concentration levels of a single protein. To find out 
the ability of our system over in this regard, we performed the similar experiments with 
HSA and IgG at different concentrations (500 nM, 1 µM and 2 µM). It is observed that 
the LDA plots for various concentrations are not random rather follow certain patterns 
and can be differentiated from each other with certain extent (Figure 4.6a). Essentially, 
clusters around a common center that are distinct from each other can be observed for 
proteins with variable concentrations (Figure 4.6b). 
 
Figure 4.6 Discrimination of HSA and IgG at different concentrations and mixture of proteins. a) 
Canonical score plot for the fluorescence patterns as obtained from LDA for human serum albumin (HSA) 
and immunoglobulin G (IgG) at different concentrations (500 nM, 1 µM and 2 µM) with 95% confidence 
ellipses. b) Clustering of all the data for the three concentrations mentioned for each protein as obtained 
from LDA analysis.   
 
After getting the differentiation at varying level of protein concentration we 
continued our investigation towards the detection of mixture of proteins in serum. We 
mixed HSA and IgG in serum at 1:1 molar ratio with 250 nM each as well as 500 nM 
each and compared with 500 nM of individual proteins. When subjected to the LDA 
analysis of the fluorescence responses, it shows that the canonical score plots revolve 
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around the HSA and IgG plots and clearly distinct from them (Figure 4.7). Although we 
can discriminate the mixture of proteins at different concentration from each other, no 
correlation between the plots could be drawn since the complex equilibrium among the 
serum proteins, GFP and NP make the system behave differently. However, a profile of 
mixture of proteins can be generated that could enable detection of diseased states caused 
by an elevated level of proteins which are being developed. 
 
Figure 4.7 Differentiation of mixture of proteins. HSA and IgG were mixed at 1:1 molar ratio with 250 nM 
each and 500 nM each and added to the five GFP-NP complexes.  The canonical score plots obtained from 
LDA analysis were compared with that for the 500 nM of the individual proteins. 
 
4.3 Conclusion 
In conclusion, we have demonstrated a nanoparticle-GFP array based biosensor that can 
effectively identify most abundant serum proteins rang at very low concentration with 
higher efficiency. We also successfully extend this efficiency in detection of proteins in 
highly complex system i.e., human serum which is composed of several proteins with 
variable concentrations. This result indicate that the simple nanoparticle-GFP array can 
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efficiently recognize biological analyst in serum simply and instantaneously with reliable 
fashion. In this approach the competitive complexation between GFP and analyte proteins 
with nanoparticles makes this system comparable to natural protein-protein interaction, 
providing potential for further optimization via engineering of both the synthetic and 
biological components. We also believe that optimization of this methodology potentially 
modernize the medical diagnostics, both in the clinic and as a tool for personalized 
diagnostics. 
 
4.4 Experimental Section 
4.4.1 Methods, Instrumentation and Materials 
Green fluorescence protein (GFP) was expressed according to known procedure27. In 
brief, starter cultures from a glycerol stock of GFP in BL21(DE3) was grown overnight 
in 50 ml culture media at 37 oC. The following day, 5 ml of the starter cultures was added 
to a Fernbach flask containing 1 L culture media and shaken until the OD600 = 0.6 - 0.7.  
The culture was then induced by adding isopropyl--D-thiogalactopyranoside (IPTG) (1 
mM final concentration) and shaken at 28 oC.  After three hours, the cells were harvested 
by centrifugation and the pellet was then resuspended in lysis buffer. Once lysed, the 
solution was pelleted and the supernatant was further purified using HisPur Cobalt 
columns. The analyte proteins, serum albumin (HSA), immunoglobulins (IgG), 
transferrin, fibrinogen and -antitrypsin all from human serum were purchased from 
Sigma-Aldrich and used as received. Cationic nanoparticles NP1, NP2 were synthesized 
according to the reported procedure and NP3-NP5 were prepared following the similar 
procedure which is elaborately described in supporting information. 5 mM sodium 
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phosphate buffer, pH 7.4 was used as a solvent for the experiment in buffer solution. The 
commercial human serum from untransfused male donors was purchased from MP 
Biomedicals, LLC and used without further treatment.  
In the fluorescence titration between nanoparticles and GFP, the change of 
fluorescence intensity at 510 nm was measured with an excitation wavelength of 475 nm 
at various concentrations of nanoparticles from 0 to 100 nM on a Molecular Devices 
SpectaMax M5 microplate reader at 25 C in 5 mM sodium phosphate buffer. The change 
of fluorescence intensity against increasing nanoparticle concentrations was plotted 
(Figure 4.S2), using a non-interacting gold nanoparticle (e.g. PEG-NP) as a control to 
compensate for particle absorption. Nonlinear least-squares curve-fitting analysis was 
employed to estimate the binding constant (Ks) and association stoichiometry (n) using 
the model in which the nanoparticle is assumed to possess n equivalent of independent 
binding sites. In case of human serum, similar procedure was followed, but the only 
modification was the concentration of GFP (250 nM) and the nanoparticles (0-2 M). 
To create the training matrix, GFP and nanoparticles are mixed in the ratio obtained 
from fluorescence titration. In case of 5 mM sodium phosphate buffer solution the final 
concentration of nanoparticle and GFP were 100 nM each. On the other hand, in serum 
solution study the final concentration of nanoparticle and GFP were 500 nM and 250 nM 
respectively. After 30 min of incubation 200 L of each solution was loaded into a well 
on a 96-well plate (300 L Whatman black bottom micropalte) and the fluorescence 
intensity at 510 nm recorded using fluorescence microplate reader (Molecular Devices 
SpectraMax M5). Subsequently, 10 L of protein solution, 0.525 M for buffer solution 
and 10.5 M for serum solution, was added so that the final concentrations were 25 nM 
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and 500 nM in buffer and serum respectively. After incubation for 30 min the 
fluorescence intensity at 510 nm was recorded again. The difference between the two 
intensities before and after addition of proteins was considered as the fluorescence 
response (Table 4.S1 and 4.S3). This process was repeated for five serum proteins with 
five selective cationic nanoparticles in six replicates. This data was used to generate the 6 
 5  5 (6 replicates  5 proteins  5 nanoparticles) training matrix. This training matrix 
was used for classical linear discriminant analysis (LDA) in SYSTAT (version 11.0). 
For the unknown detection, we prepared the protein solutions (0.525 M or 10.5 
M) out of the five serum proteins according to buffer or serum study. From this 
prepared solution we randomly choose 30 samples for each system (buffer or serum) and 
the same method was followed using the nanoparticle-GFP motif. We replicated each 
unknown samples three times instead of six for preparing training matrix. We considered 
the average response of three replicates for a single unknown sample and analyzed with 
five known proteins in LDA analysis. 
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4.4.2 Experimental Data 
4.4.2.1 Synthesis of Ligands and Nanoparticles. 
 
 
 
Scheme 4.S1 Synthesis of ligands.  
 
General procedure: Compound 2 bearing ammonium end groups were synthesized by 
the reaction of 1,1,1-triphenyl-14,17,20,23-tetraoxa-2- thiapentacosan-25-yl 
methanesulphonate (1) with corresponding substituted N,N-dimethylamines with stirring 
for 48 hours at ~35 oC. The trityl protected thiol ligand (2) was dissolved in dry 
dichloromethane (Methylene Chloride, DCM) and an excess of trifluoroacetic acid (TFA, 
~20 equivalents) was added. The color of the solution was turned into yellow 
immediately. Subsequently, triisopropylsilane (TIPS, ~1.2 equivalents) was added to the 
reaction mixture. The reaction mixture was stirred for ~5 h under Ar-atmosphere at room 
temperature. The solvent, most of the TFA and TIPS were distilled off under reduced 
pressure. The pale yellow residue was further dried in high vacuum. The product (L) 
formation was quantitative and their structure was confirmed by NMR and mass 
spectroscopy. The yields were >95%. 
Compound L1: 1H NMR (400MHz, CDCl3, TMS):  3.95 (br, 2H, -CH2O-), 3.70-3.58 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.49 (t, 2H, -CH2N-),  3.25 (s, 9H, -N(CH3)3-), 
2.90 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.64-1.51 (m, 4H, (SCH2)CH2  + -
CH2(CH2O)-) , 1.36-1.22 (m, 15H, -SH + -CH2-). 
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13C NMR (400 MHz, CDCl3) δ(ppm): 71.58, 70.56, 70.49, 70.34, 70.24, 70.15, 70.04, 
65.13, 54.72, 39.25, 31.07, 29.76, 29.65, 29.62, 29.57, 29.53, 29.51, 29.27, 28.56, 26.10. 
ESI-MS (m/z): calculated for C22H48NO4S+ [M+], 422.33; found 421.1. 
 
Compound L2: 1H NMR (400MHz, CDCl3, TMS):  3.95 (br, 2H, -CH2O-), 3.68-3.56 
(m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.46 (t, 2H, -CH2N-), 3.40-3.33 (m, 2H,-NCH2-), 
3.19 (s, 6H, -(CH3)2N-), 2.87 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.76-1.53 (m, 6H, 
-(NCH2)CH2-) + (SCH2)CH2  + -CH2(CH2O)-) , 1.41-1.22 (m, 21H, -SH + -(NCH2CH2-
)CH2-) + -CH2-), 0.89 (t, 3H, - CH3-). 
13C NMR (400 MHz, CDCl3) δ(ppm): 71.59, 70.54, 70.51, 70.44, 70.33, 70.15, 70.00, 
66.42, 64.82, 63.50, 51.90, 34.07, 31.18, 29.59, 29.54, 29.52, 29.49, 29.09, 28.39, 26.07, 
25.84, 24.68, 22.71, 22.37, 13.85. 
ESI-MS (m/z): calculated for C27H58NO4S+ [M+], 492.41; found 492.0. 
 
Compound L3: 1H NMR (400MHz, CDCl3, TMS):  4.78 (br, 1H, -CHOH(CH2OH)-), 
4.59 (br, 1H, -CH2OH-), 4.50-4.45 (m, 1H, -CHOH(CH2OH)-), 4.43 (d and br, 2H,-
NCH2-),  3.95 (d and br, 2H, -CH2O-), 3.86-3.76 (d and br, 2H, -CH2-OH), 3.75-3.55 (m, 
14H, -CH2O- + -OCH2-(CH2N)-), 3.48 (t, 2H, -CH2N-), 3.34 (s, 6H, -(CH3)2N-), 2.99 (s, 
3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.71-1.51 (m, 4H, + (SCH2)CH2  + -CH2(CH2O)-), 
1.42-1.21 (m, 15H, -SH + -CH2-). 
13C NMR (400 MHz, CDCl3) δ(ppm): 71.65, 70.45, 70.37, 70.19, 69.97, 68.07, 66.79, 
66.47, 64.89,  64.81, 64.42, 63.83, 60.42, 53.59, 53.15, 45.41, 42.76, 39.51, 34.14, 29.55, 
29.30, 29.16, 29.02, 28.74, 28.59, 28.46, 26.08, 24.74, 23.54. 
ESI-MS (m/z): calculated for C24H58NO4S+ [M+], 482.35; found 482.0. 
 
Compound L4: 1H NMR (400MHz, CDCl3, TMS):  3.96 (br, 2H, -CH2O-), 3.79-3.75 
(m, 1H, HCyclo), 3.66-3.57 (m, 14H, -CH2O- + -OCH2-(CH2N)-), 3.46 (t, 2H, -CH2N-), 
3.12 (s, 6H, -(CH3)2N-), 2.89 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -CH2S-), 2.28 (d, 2H, 
HCyclo), 2.01 (d, 2H, HCyclo), 1.64-1.54 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.47 (q, 
2H, HCyclo), 1.33 (t, 3J = 8.0 Hz, 1H, -SH), 1.30-1.22 (m, 14H, -CH2-), 1.16 (q, 2H, 
HCyclo)  1.04 (td, 1H -CHC-), 0.86 (s, 9H, -C(CH3)3-). 
13C NMR (400 MHz, CDCl3) δ(ppm): 74.52, 71.71, 70.58, 70.54, 70.38, 70.31, 70.09, 
64.90, 62.26, 49.05, 46.79, 39.61, 34.16, 32.30, 29.60, 29.34, 29.19, 28.65, 28.49, 27.49, 
26.46, 26.24, 26.16, 25.73, 25.64, 24.78. 
ESI-MS (m/z): calculated for C31H64NO4S+ [M+], 546.46; found 546.0. 
 
Compound L5: 1H NMR (400MHz, CDCl3, TMS):  7.82 (d, 2H, HAr), 7.66-7.51 (m, 3H, 
HAr), 4.24 (br, 2H, -CH2O-), 3.78 (s, 6H, -(CH3)2N-), 3.68-3.52 (m, 14H, -CH2O- + -
OCH2-(CH2N)-), 3.47-3.36 (m, 2H, -CH2N-), 2.87 (s, 3H, -CH3SO-3-), 2.52 (q, 2H, -
CH2S-), 1.70-1.46 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.42-1.1.16 (m, 15H, -SH + -
CH2-). 
13C NMR (400 MHz, CDCl3) δ(ppm): 144.04, 130.89, 120.88, 116.50, 113.65, 71.71, 
70.60, 70.50, 70.40, 70.19, 70.03, 69.90, 65.32, 56.47, 39.61, 34.13, 29.64, 29.60, 29.52, 
29.17, 29.04, 28.69, 28.47, 26.07, 24.76. 
ESI-MS (m/z): calculated for C27H50NO4S+ [M+], 484.35; found 484.0. 
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Figure 4.S1 400 MHz 1H NMR spectra of compound L1 in CDCl3 (D, 99.8%).  
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Figure 4.S2 400 MHz 13C NMR spectra of compound L1 in CDCl3 (D, 99.8%). 
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                         Figure 4.S3 ESI-MS spectra of compound L1. 
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Figure 4.S4 400 MHz 1H NMR spectra of compound L2 in CDCl3 (D, 99.8%).  
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Figure 4.S5 400 MHz 13C NMR spectra of compound L2 in CDCl3 (D, 99.8%). 
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                       Figure 4.S6 ESI-MS spectra of compound L2. 
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Figure 4.S7 400 MHz 1H NMR spectra of compound L3 in CDCl3 (D, 99.8%). 
 103
 
 
Figure 4.S8 400 MHz 13C NMR spectra of compound L3 in CDCl3 (D, 99.8%). 
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                          Figure 4.S9 ESI-MS spectra of compound L3. 
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Figure 4.S10 400 MHz 1H NMR spectra of compound L4 in CDCl3 (D, 99.8%). 
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Figure4. S11 400 MHz 13C NMR spectra of compound L4 in CDCl3 (D, 99.8%). 
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                         Figure 4.S12 ESI-MS spectra of compound L4. 
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Figure 4.S13 400 MHz 1H NMR spectra of compound L5 in CDCl3 (D, 99.8%). 
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Figure 4.S14 400 MHz 13C NMR spectra of compound L5 in CDCl3 (D, 99.8%). 
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                           Figure 4.S15  ESI-MS spectra of compound L5. 
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Scheme 4.S2 Fabrication of cationic gold nanoparticles. 
General procedure: 1-Pentanethiol coated gold nanoparticles (d = ~2 nm) were prepared 
according to the previously reported protocol.28  Place-exchange reaction29 of compound 
Ls (s = 1, 2, 3, 4, 5) dissolved in DCM with pentanethiol-coated gold nanoparticles (d~2 
nm) was carried out for 3 days at room temperature and the DCM was then evaporated 
under reduced pressure. The residue was dissolved in a small amount of distilled water 
and dialyzed (membrane MWCO = 1,000) to remove excess ligands, acetic acid and 
other salts present with the nanoparticles. After dialysis, the particles were lyophilized to 
afford a brownish solid. The nanoparticles are redispersed in ionized water (18 M-cm). 
1H NMR spectra in D2O showed substantial broadening of the proton signals and no free 
ligands were observed. 
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Figure 4.S16 Fluorescence titration curves for the complexation of GFP with four different cationic gold 
nanoparticles (NP1, NP2, NP4, NP5). The changes of fluorescence intensity at 510 nm were measured 
following the addition of cationic nanoparticles (0-100 nM for 5 mM sodium phosphate buffer (inset) and 
0-2 M for serum solution) with an excitation wavelength of 475 nm.  
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Figure 4.S17 Change in fluorescence responses (I) of GFP (100 nM, 200 L) in absence and presence of 
various protein solutions (25 nM). The intensities were recorded at 510 nm with an excitation wavelength 
of 475 nm. Each fluorescence response value is an average of six parallel measurements. 
 
Table 4.S1 Binding constants (KS), Gibbs free energy changes (-ΔG) and binding stoichiometries (n) 
between GFP and various cationic nanoparticles (NP1-NP5) as determined from fluorescence titration. 
Nanoparticle KS / 109 M-1 G / kJ mol-1 n 
NP1 22.7 59.11 3.9 
NP2 51.3 61.13 2.2 
NP3 0.5 49.65 4.7 
NP4 1.1 51.61 7.9 
NP5 0.2 47.38 3.3 
 
 
Table 4.S2 Training matrix of fluorescence response patterns of NP-GFP sensor array (NP1-NP5) against 
five serum proteins (25 nM) in 5 mM sodium phosphate buffer pH 7.4. Table continues on the next page. 
Protein NP1 NP2 NP3 NP4 NP5 
HSA -18.532 -45.298 -17.948 -16.819 0.972 
HSA -16.378 -29.25 -3.996 -11.575 7.191 
HSA -20.397 -36.076 -13.112 -13.901 1.021 
HSA -27.604 -24.953 -4.779 -13.927 4.034 
HSA -26.745 -25.183 -7.76 -3.6 0.781 
HSA -31.166 -28.784 -11.191 -2.124 8.168 
IgG -18.457 -20.497 -49.215 -6.814 6.723 
IgG -15.73 -12.767 -37.362 -5.608 3.726 
IgG -21.065 -5.392 -35.549 -6.856 1.957 
IgG -26.809 -7.699 -33.717 0.141 10.623 
IgG -20.746 -17.59 -42.568 -4.747 -7.43 
IgG -28.262 -21.65 -34.032 -8.2 1.772 
Fibrinogen -46.994 -20.427 44.239 -4.885 56.329 
Fibrinogen -72.301 -12.394 44.329 -8.931 73.802 
Fibrinogen -65.488 -22.13 49.268 -5.994 55.743 
Fibrinogen -78.38 -16.268 39.119 -4.24 71.327 
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Fibrinogen -70.348 -15.801 58.2 -5.209 57.553 
Fibrinogen -88.654 -16.339 37.888 -3.165 79.429 
-Antitrypsin 1.832 -39.973 -8.15 -23.802 0.592 
-Antitrypsin 18.936 -40.204 -6.233 -26.518 12.63 
-Antitrypsin 15.499 -35.087 -9.344 -34.81 -2.162 
-Antitrypsin -0.404 -37.903 -4.798 -23.846 -1.586 
-Antitrypsin 7.433 -39.452 -7.332 -25.163 -5.362 
-Antitrypsin 37.739 -41.178 -11.925 -23.795 1.874 
Transferrin -5.005 -30.502 -28.348 -14.971 -3.383 
Transferrin -12.869 -21.725 -18.571 -4.516 6.385 
Transferrin 17.4 -19.154 -20.139 -11.815 4.825 
Transferrin -15.011 -14.219 -10.778 -2.678 2.904 
Transferrin -33.286 -11.069 -18.755 -2.382 5.71 
Transferrin 8.789 -14.704 -23.331 2.752 2.368 
 
 
Table 4.S3 LDA classification accuracy of protein analytes by using the individual GFP-nanoparticle 
complexes as sensor in 5 mM sodium phosphate buffer, pH 7.4. The values are considered from the 
Jacknifed classification matrix based on LDA analysis of the 6 replicated data listed in Table S1. The 
maximum classification accuracy was obtained 100% using all five GFP-nanoparticle combinations. 
Proteins NP1 NP2 NP3 NP4 NP5 All 
HSA 67 83 67 100 67 100 
IgG 100 33 100 0 100 100 
Fibrinogen 50 33 33 67 17 100 
-Antitrypsin 67 50 100 0 0 100 
Transferrin 33 33 83 0 0 100 
Total 63 47 77 33 37 100 
 
Table 4.S4 Training matrix of fluorescence response patterns of NP-GFP sensor array (NP1-NP5) against 
five serum proteins (500 nM) in human serum. Table continues on the next page. 
Protein NP1 NP2 NP3 NP4 NP5 
HSA -25.185 35.308 37.975 60.525 15.908 
HSA 33.69 43.494 29.986 45.685 18.705 
HSA -34.553 33.198 11.311 54.613 10.012 
HSA 79.313 26.839 15.565 49.973 28.507 
HSA 14 13.784 25.269 33.235 13.216 
HSA 50.658 43.361 19.192 31.82 29.904 
IgG -22.482 9.723 37.008 -2.621 -10.262 
IgG -110.788 11.703 -9.019 -7.571 -29.802 
IgG -55.84 -38.686 7.998 -74.414 -29.679 
IgG -122.045 -75.776 16.632 -2.424 -13.585 
IgG -184.384 -2.881 -14.023 -2.117 -7.345 
IgG -22.34 -36.442 -25.241 -6.95 -9.373 
Fibrinogen 151.28 -119.741 -24.122 20.872 -53.202 
Fibrinogen 147.351 -98.086 10.442 43.628 -32.968 
Fibrinogen 133.975 -30.237 -12.07 26.133 -84.102 
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Fibrinogen 142.781 -112.046 -19.16 30.523 -31.204 
Fibrinogen 114.114 -121.229 22.276 27.292 -28.001 
Fibrinogen 113.864 -68.836 -51.75 30.508 -31.968 
-Antitrypsin -76.466 42.259 -92.872 40.603 13.961 
-Antitrypsin -24.938 42.652 -52.578 21.521 -0.383 
-Antitrypsin -57.408 12.85 -16.545 29.464 6.252 
-Antitrypsin -45.808 22.305 -67.508 13.642 10.035 
-Antitrypsin -36.381 35.745 -20.054 30.49 12.917 
-Antitrypsin -40.913 -23.131 -19.906 35.097 0.942 
Transferrin 126.388 125.495 134.738 67.01 20.049 
Transferrin 91.008 95.072 109.441 44.165 54.314 
Transferrin -34.963 54.258 -18.764 59.91 44.024 
Transferrin -60.551 101.613 71.836 45.938 41.313 
Transferrin 56.279 62.391 -14.756 62.015 56.356 
Transferrin 52.154 51.712 38.793 39.582 51.462 
 
 
Table 4.S5 LDA classification accuracy of protein analytes by using the individual GFP-nanoparticle 
complexes as sensor in human serum. The values are considered from the Jacknifed classification matrix 
based on LDA analysis of the 6 replicated data listed in Table S3. The maximum classification accuracy 
was obtained 97% using all five GFP-nanoparticle combinations. 
Proteins NP1 NP2 NP3 NP4 NP5 All 
HSA 100 83 50 33 67 100 
IgG 17 67 83 17 67 100 
Fibrinogen 50 50 17 100 67 100 
-Antitrypsin 33 67 67 50 83 83 
Transferrin 83 33 50 0 67 100 
Total 57 60 53 40 70 97 
 
 
Table 4.S6 Detection and identification of unknown serum proteins in 5 mM sodium phosphate buffer, pH 
7.4 using LDA. Table continues on the next page. 
Fluorescence response pattern # 
NP1 NP2 NP3 NP4 NP5 
Identification Verification 
1 4.684 -28.3937 19.506 -27.4577 11.22733 -Antitrypsin -Antitrypsin 
2 46.656 -29.2637 82.70033 -20.0467 113.517 Fibrinogen Fibrinogen 
3 0.349667 -29.862 -2.26733 -16.38 8.249 HSA HSA 
4 -26.234 -25.408 -33.522 -11.8157 0.307 IgG IgG 
5 -34.857 -21.2593 -23.4117 -5.48767 0.645 Transferrin Transferrin 
6 -2.04767 -34.0037 16.88767 -30.4097 17.768 -Antitrypsin -Antitrypsin 
7 94.439 -35.8293 104.2083 -5.826 59.99233 Fibrinogen Fibrinogen 
8 6.559667 -36.6427 -4.05033 -13.9613 6.927667 HSA HSA 
9 -33.871 -29.9463 -34.289 0.394667 0.741 IgG IgG 
10 -20.8303 -33.143 -27.1667 -10.0173 10.93633 Transferrin Transferrin 
11 -1.30033 -38.4287 10.827 -30.4497 5.354 -Antitrypsin -Antitrypsin 
12 66.78667 -35.138 73.21167 -4.52233 69.67133 Fibrinogen Fibrinogen 
13 1.165 -31.2983 -6.651 -11.6873 4.368 HSA HSA 
14 -17.0693 -17.9457 -23.7473 -7.08333 2.182667 IgG IgG 
15 -14.286 -25.4467 -20.7507 -4.872 -1.316 Transferrin Transferrin 
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16 -8.64067 -31.4013 1.129 -22.642 8.385667 -Antitrypsin -Antitrypsin 
17 55.38367 -25.565 74.23333 -20.926 66.45067 Fibrinogen Fibrinogen 
18 11.715 -20.1727 2.882667 -15.2097 17.61033 HSA HSA 
19 -15.221 -37.6677 -23.318 -3.65267 1.684 Transferrin IgG 
20 -7.368 -20.7963 -13.128 -3.69333 6.640667 Transferrin Transferrin 
21 20.64133 -54.8697 50.54767 -17.1707 5.697333 -Antitrypsin -Antitrypsin 
22 146.8727 -43.762 111.4403 -5.83633 84.02133 Fibrinogen Fibrinogen 
23 6.840333 -48.6713 -3.30867 -7.54967 12.15967 HSA HSA 
24 -26.0133 -36.3093 -55.214 -1.13267 8.987 IgG IgG 
25 -11.3223 -16.426 -11.915 -7.36633 -0.62667 Transferrin Transferrin 
26 -6.78233 -18.0977 -13.793 -7.216 -2.137 Transferrin Transferrin 
27 3.568667 -31.5797 16.57667 -26.5613 4.504667 -Antitrypsin -Antitrypsin 
28 61.24267 -23.491 96.51133 -3.24867 58.63267 Fibrinogen Fibrinogen 
29 -15.2647 -29.7037 -15.109 -14.0513 4.040667 HSA HSA 
30 -11.202 -20.7027 -36.554 -3.775 2.106333 IgG IgG 
 
 
Table 4.S7 Detection and identification of unknown serum proteins in serum using LDA. 
Fluorescence response pattern # 
NP1 NP2 NP3 NP4 NP5 
Identification Verification 
1 74.75433 104.6627 52.88533 84.07 80.909 Transferrin Transferrin 
2 17.40667 44.292 33.522 4.037667 -7.886 -Antitrypsin -Antitrypsin 
3 -13.745 28.82867 27.56867 6.555667 8.313 -Antitrypsin -Antitrypsin 
4 -5.53367 56.73867 4.019333 19.02633 -94.1843 Fibrinogen Fibrinogen 
5 29.45633 28.211 41.33567 30.58633 -24.767 IgG -Antitrypsin 
6 37.92233 -41.37 -103.575 23.30433 14.967 HSA HSA 
7 -16.582 26.09967 58.272 29.37633 38.515 HSA HSA 
8 -133.057 -23.643 7.877 -32.3313 -15.9957 IgG IgG 
9 -71.5627 -89.7873 -32.8967 -9.00367 18.158 IgG IgG 
10 62.023 38.60267 79.416 115.327 -35.331 Fibrinogen Fibrinogen 
11 122.1453 313.654 116.8473 148.417 131.8263 Transferrin Transferrin 
12 33.05733 23.643 37.877 32.33133 15.99567 HSA HSA 
13 5.293 33.464 36.257 28.801 30.66933 HSA HSA 
14 35.161 28.953 -0.567 30.251 -13.2193 -Antitrypsin -Antitrypsin 
15 -84.374 -90.1397 -34.6433 -75.8787 -110.12 IgG IgG 
16 48.80367 59.975 69.75367 61.452 74.422 Transferrin Transferrin 
17 54.00333 42.20967 73.615 56.78233 66.12933 Transferrin Transferrin 
18 240.9683 163.627 -28.523 -94.3863 -68.9923 IgG IgG 
19 31.52067 34.94333 43.77767 32.40133 -8.79367 -Antitrypsin HSA 
20 60.67 48.87633 40.28167 16.78233 16.12933 HSA HSA 
21 41.82767 -32.953 -10.2337 31.91767 -39.0913 Fibrinogen Fibrinogen 
22 140.408 112.4333 -51.4157 11.00167 -97.6823 Fibrinogen Fibrinogen 
23 73.74133 45.76667 110.2757 77.66833 94.349 Transferrin Transferrin 
24 3.306 28.175 33.11667 42.325 -25.147 -Antitrypsin -Antitrypsin 
25 67.07967 9.277333 159.2897 32.82267 -123.864 Fibrinogen Fibrinogen 
26 87.183 43.376 157.9987 94.48633 117.043 Transferrin Transferrin 
27 -127.011 -271.885 -55.832 -204.422 58.93333 IgG IgG 
28 71.85633 32.289 16.79167 10.11067 8.785 HSA HSA 
29 -52.1673 37.82967 -31.4483 15.21 15.23333 -Antitrypsin -Antitrypsin 
30 115.5963 97.18933 131.6317 118.673 -99.101 Fibrinogen Fibrinogen 
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Table 4.S8  Training matrix of the fluorescence responses of NP-GFP sensor array (NP1-NP5) against two 
serum proteins at different concentrations in undiluted serum. 
Proteins  NP1 NP2 NP3 NP4 NP5 
HSA 500 nM 36.779 93.68 35.538 21.085 47.776 
HSA 500 nM 115.101 98.987 32.628 58.455 50.073 
HSA 500 nM 75.371 89.106 56.712 36.143 34.554 
HSA 500 nM 53.123 99.375 74.79 38.711 27.076 
HSA 500 nM 79.465 88.404 55.727 51.131 25.436 
HSA 500 nM 86.788 109.041 23.629 36.368 -2.934 
HSA 1 µM 81.835 77.727 81.756 90.558 114.885 
HSA 1 µM 48.202 94.133 100.135 55.811 102.966 
HSA 1 µM 98.508 129.882 73.469 111.341 91.465 
HSA 1 µM 88.247 77.25 50.121 57.31 102.692 
HSA 1 µM 80.577 74.521 91.315 83.783 111.878 
HSA 1 µM 103.679 119.859 86.81 63.374 91.567 
HSA 2 µM 109.752 120.75 101.79 117.751 123.175 
HSA 2 µM 68.678 124.737 123.571 94.761 77.74 
HSA 2 µM 108.234 113.567 85.116 113.809 64.965 
HSA 2 µM 91.207 88.023 84.701 114.75 66.563 
HSA 2 µM 37.45 74.441 58.563 71.76 72.212 
HSA 2 µM 36.984 54.034 101.945 72.592 61.694 
IgG 500 nM -20.535 -47.869 -1.231 20.578 -6.899 
IgG 500 nM -10.142 -3.756 -86.993 -51.978 0.955 
IgG 500 nM -32.613 -22.642 -90.484 -90.113 -29.181 
IgG 500 nM -17.667 -30.918 -55.741 -35.685 1.682 
IgG 500 nM 10.918 -21.06 -19.7 -40.112 -22.847 
IgG 500 nM -12.79 -28.653 -39.975 19.348 -29.316 
IgG 1 µM -79.722 -18.975 -71.669 -28.268 -59.102 
IgG 1 µM -96.852 -61.204 -99.069 -27.075 -36.127 
IgG 1 µM -96.549 -34.248 -84.156 -62.283 -58.991 
IgG 1 µM -86.457 -72.164 -119.259 -69.132 -50.836 
IgG 1 µM -58.259 -54.634 -98.298 -33.522 -31.563 
IgG 1 µM -89.147 -265.236 -100.153 -35.929 -77.421 
IgG 2 µM -51.724 -83.283 -83.946 -84.5 -78.542 
IgG 2 µM -78.383 -100.504 -123.046 -65.95 -65.118 
IgG 2 µM -43.095 -65.418 -141.393 -72.145 -35.054 
IgG 2 µM -55.417 -99.826 -146.527 -47.284 -117.778 
IgG 2 µM -84.478 -60.019 -129.572 -11.872 -97.409 
IgG 2 µM -22.036 -80.941 -30.569 -61.74 -86.066 
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Table 4.S9 Training matrix of the fluorescence responses of NP-GFP sensor array (NP1-NP5) against 
mixtures of serum proteins (HSA and IgG 250 nM each; HSA and IgG 500 nM each) and individual 
proteins (HSA and IgG 500 nM each) in undiluted serum.  
Protein(s) NP1 NP2 NP3 NP4 NP5 
HSA0.5 µM 36.779 93.68 35.538 21.085 47.776 
HSA0.5 µM 115.101 98.987 32.628 58.455 50.073 
HSA0.5 µM 75.371 89.106 56.712 36.143 34.554 
HSA0.5 µM 53.123 99.375 74.79 38.711 27.076 
HSA0.5 µM 79.465 88.404 55.727 51.131 25.436 
HSA0.5 µM 86.788 109.041 23.629 36.368 -2.934 
IgG0.5 µM  -20.535 -47.869 -1.231 20.578 -6.899 
IgG0.5 µM -10.142 -3.756 -86.993 -51.978 0.955 
IgG0.5 µM -32.613 -22.642 -90.484 -90.113 -29.181 
IgG0.5 µM -17.667 -30.918 -55.741 -35.685 1.682 
IgG0.5 µM 10.918 -21.06 -19.7 -40.112 -22.847 
IgG0.5 µM -12.79 -28.653 -39.975 19.348 -29.316 
HSA0.5-IgG0.5 µM 136.065 88.088 66.951 81.659 120.204 
HSA0.5-IgG0.5 µM 24.462 33.528 69.531 77.042 56.269 
HSA0.5-IgG0.5 µM 81.669 101.369 64.058 56.326 88.377 
HSA0.5-IgG0.5 µM 59.897 70.35 46.265 -0.201 93.308 
HSA0.5-IgG0.5 µM 103.92 50.723 74.781 34.042 79.045 
HSA0.5-IgG0.5 µM 108.286 78.441 91.725 62.458 59.168 
HSA0.25-IgG0.25 µM -97.334 -184.659 -139.598 -61.371 -87.43 
HSA0.25-IgG0.25 µM -43.757 -124.828 -130.223 -91.557 -42.496 
HSA0.25-IgG0.25 µM -44.588 -80.317 -86.414 -108.216 -104.818 
HSA0.25-IgG0.25 µM -63.207 -64.866 -124.171 -97.906 -64.233 
HSA0.25-IgG0.25 µM -56.32 -137.994 -116.131 -73.141 -67.603 
HSA0.25-IgG0.25 µM -84.824 -83.432 -87.4 -63.884 -59.937 
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CHAPTER 5 
ENZYME AMPLIFIED ARRAY SENSING (EAAS): 
CHEMICAL NOSE DETECTING PROTEIN IN HUMAN URINE 
 
 
 
5.1Introduction 
 
Irregular protein concentration levels in biofluids, e.g. serum, urine, and saliva provide 
essential information for the early diagnosis of many pathological conditions such as 
hypoalbuminemia, cancers, Alzheimer’s disease, prostatisis, HIV, and other disease 
states.1 The development of strategies for monitoring protein levels remains a major issue 
in medical diagnostics, pathogen detection and proteomics.2 Substantial efforts have been 
devoted to develop precise and efficient methods for protein sensing,3 including enzyme-
labeled immunoassays,4 electrophoresis methods,5 and analytical techniques.6  
   The "chemical nose/tongue" approach7 presents a potential alternative to specific 
recognition and separations techniques. In this approach a sensor array is generated to 
provide differential interaction with analytes via selective receptors, generating a stimulus 
response pattern that can be statistically analyzed and used for the identification of 
individual target analytes8,9 and also analysis of complex mixtures.10 Over the past few 
years, this technology has been successfully applied for protein detection using array-
based approaches, including porphyrins,11  oligopeptide-functionalized resins,12 and 
polymers.13 In a real word example, a single functional conjugated polymer poly 
(thiophene) has been successfully applied as a food freshness sensor to detect biogenic 
amines in fish associated with food poisoning (e.g. histamine) with increasing 
concentrations from 22.5 M to 4.5. Recently, we have developed nanoparticle-GFP 
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based “chemical nose” strategy for protein detection in biofluid that is highly sensitive 
(500 nM)14 as compared to other reported similar approaches (1-350 M).11,12,13c,d We 
have also developed a sensor array composed of gold nanoparticles and fluorescent 
polymers that can identify proteins through a fluorophore-displacement mechanism.15 
This sensor array achieved detection limits of 215 nM for low Mw proteins.  
   The increased sensitivity required for many diagnostic uses16 presents a challenging 
goal for array-based sensor because the detection process generally relies on fluorescence 
responses that are restricted by the inherent emissivity of the fluorophores used. To 
overcome this limitation, we have explored the use of enzymes to provide array-based 
sensors with enhanced sensitivity. In this Enzyme Amplified Array Sensing (EAAS) 
approach, the sensitivity of the array is amplified through an enzymatic reaction. This 
approach couples the signal amplification process of ELISA with the versatility of the 
“chemical nose” approach. In this dissertation, the use of this method to sense and 
identify a range of biomedically relevant proteins at 1 nM in both buffer and desalted 
human urine is reported.  
Our EAAS features three components: a) -galactosidase (-Gal) as the enzyme, b) 4-
Methylumbelliferyl-beta-D-Galactopyranoside (MUG) as a fluorogenic substrate to 
provide “turn on” sensing, and c) gold nanoparticles (AuNPs) as the receptors to provide 
differential protein affinity, and hence discrimination. In practice, cationic AuNPs 
electrostatically bind the anionic -Gal, inhibiting the enzyme without denaturation.17 
Displacement of the particle by analyte proteins restores -Gal activity, generating a 
fluorescent readout signal (Figure 5.1) that is amplified through enzymatic catalysis. 
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Figure 5.1  A schematic representation of sensors comprised of -Galactosidase (-Gal) and cationic 
AuNPs. In a) supramolecular adducts of -Gal and AuNP formed through complementary electrostatic 
interactions, inhibiting the enzymatic activity of -galactosidase. As shown in b) -Galactosidase is 
displaced from the -Gal/AuNP complex by protein analytes, restoring the catalytic activity of -Gal 
towards the fluorogenic substrate 4-methylumbelliferyl--D-Galactopyranoside, resulting in an amplified 
signal for detection. 
 
5.2 Results and Discussion 
The anionic tetrameric enzyme -Gal (17.513.59 nm, pI = 4.6, Mw = 465 kDa),  was 
chosen as the amplifying element due its stability to a wide range of temperature, pH, and 
ionic strength conditions.18,19  Gold nanoparticles (~2 nm core diameter) with a positive 
surface charge were used to bind efficiently to the anionic -Gal trough electrostatic 
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complementary and electrostatic charge interactions (see Figures 5.S29, 5.S31, and 5.S33 
for zeta potential and DLS measurements). These AuNPs feature a tetraethylene glycol 
unit in the ligand shell to minimize the denaturation of the bound enzyme/analyte protein 
and variable terminal functionality to generate the differential affinity required for 
sensing (Figure 5.2).20  
 
 
Figure 5.2  Structure features of the cationic gold nanoparticles (NP1-NP6). The transmission electron 
microscopy (TEM) and histogram plot show the morphology, monodispersity, and sizes of the metallic 
core gold nanoparticles.  
 
As a starting point, we focused on the optimization on the binding ratio between 
AuNPs (NP1-NP6) and -Gal through inhibition activities in phosphate buffer. We 
conducted an activity assay of -Gal-catalyzed hydrolysis at various concentrations of 
nanoparticles (see Figure 5.S26).  Typically, a concentration of 0.5 nM of -Gal in 
phosphate buffer solution (5 mM, pH = 7.4) was incubated with various concentration of 
NP1-NP6 for 30 minutes and 1 mM of the fluorogenic substrate (MUG, exc = 455 nm) 
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was added to AuNP-enzyme complexes for the inhibition and enzyme-substrate reaction 
studies. As a control, the enzyme inhibition was also studied with neutral tetra(ethylene 
glycol) functionalized nanoparticles. The normalized first-order rate of fluorogenic 
substrate hydrolysis was plotted versus the ratio of nanoparticles to -Gal, and showed a 
tendency to decrease upon addition of nanoparticles, as shown for NP2 in Figure 5.3. 
This result clearly indicates that activity of -Gal is inhibited by nanoparticle binding. 
This inhibition of -Gal activity depends on subtle structural changes of peripheral 
ligands on the AuNPs with the linear end group (NP1) exhibiting less suppression than a 
branched isomeric structure (NP2). 
 
Figure 5.3 Normalized inhibition activity of -Gal (0.5 nM) against 1 mM substrate MUG upon addition of 
cationic NP2 in 5 mM phosphate buffer. The inset shows the kinetics of the fluorescence spectra before and 
after addition of NP2. The arrow in the inset indicates the direction of activity (0 nM indicates free enzyme 
and 5 nM indicates inhibited enzyme with NPs). 
 
A total of nine proteins of various sizes, surface charges, molecular weights, and 
isoelectric points were chosen to test generality and limitations of our sensor, (Table 5.1, 
see Table 5.S6 for zeta potentials, rh values and extinction coefficients at 280 nm of the 
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analyte proteins).  Fluorogenic substrate hydrolysis for the -Gal/AuNP conjugates 
against individual proteins in buffer is summarized in Figure 5.4. The individual target 
proteins generated distinguishable and highly reproducible rates of the fluorogenesis, 
indicating the potential for protein discrimination.  
Table 5.1 Physical properties of the proteins used as sensing targets in phosphate buffer solution at pH 
7.4.13a  
Protein‡ Mw (kDa) pI 
-Amylase (-Am) 50.0 5.0 
Bovine serum albumin (BSA) 66.3 4.8 
Cytochrome c (CytC) 12.3 10.7 
Ferritin (Fer) 750.0 4.5 
Human serum albumin (HSA) 69.4 5.2 
Lipase (Lip) 58.0 5.6 
Lysozyme (Lys) 14.4 11.0 
Myoglobin (Myo) 17.0 7.2 
Alkaline phosphatase (PhosB)  140.0 5.7 
                           ‡ Proteins in italics are commonly found in human urine. 
All proteins were tested using a fluorescence displacement assay of six -Gal/AuNP 
assemblies array for six replicate measurements, providing a data set as a 6  6  9 
matrix.  The resulting data was analyzed through linear discrimination analysis (LDA) 
using SYSTAT software (version 11)21 and transformed into five canonical factors. This 
statistical analysis method is used to recognize the linear combination of features that 
differentiate two or more classes of objects or events.  The five canonical factors contain 
42.2%, 34.1%, 12.1%, 5.8%, and 4.9% of the variation, respectively.  The canonical 
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score plot of the first three factors is presented in Figure 5.5, where each dot represents 
the fluorescence response pattern of a single protein target to the -Gal/AuNP sensor 
array.  The canonical plot reveals nine distinct clusters corresponding to individual target 
proteins that give rise to a 100% classification accuracy obtained from a Jackknifed 
matrix in LDA. This result demonstrates that the -Gal/AuNP sensor array is sensitive 
enough to differentiate target proteins in the 1 nM range, significantly more sensitive than 
prior methods, including our previous fluorescent polymer-nanoparticle conjugates 
systems.11,12,13,15 
 
Figure 5.4  Fluorescence response patterns ratio of -Gal and six AuNP adducts against various target 
proteins. Each value represents an average of six parallel measurements with standard deviation. 
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Figure 5.5 Canonical score plot of the first three factors of fluorescence response patterns obtained through 
-Gal/AuNP sensor array against nine target proteins in 1 nM concentration. 
 
The high sensitivity of our -Gal/AuNP sensor array can be attributed to signal 
amplification through the enzyme-substrate reaction of -Gal.  Significantly, the same 
training matrix analyzed using only one nanoparticle  structure gives rise to classification 
accuracies of 33%, 44%, 37%, 31%, 44%, and 35% for NP1 to NP6 respectively, 
indicating almost equal ability of each particle to discriminate between protein targets 
(Table 5.S3).  
To investigate the robustness identification accuracy of the -Gal/AuNP sensor array, 
we prepared sixty unknown protein samples at 1 nM randomly chosen from the training 
set for identification.  The fluorescence response patterns obtained for each unknown 
against the sensor array were analyzed through LDA analysis. The resulting patterns were 
classified through the canonical score plot by the first two factors of simplified 
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fluorescence patterns based on the Mahalanobis distances of unknowns to the centroid of 
the respective protein clusters in the canonical score plot.  An identification accuracy of 
92% (55 correct out 60) demonstrates reproducibility of our enzyme-nanoparticle sensor 
system for identification.  
Sensing of proteins in real world biofluids such as protein in human urine provides a 
far more demanding test than sensing in simple buffer solutions. The overall protein 
content (>1.5 M, 0.150 g/L) and the multianalyte nature of the human urine (>1500 
proteins as competing biomolecules) generate a complex matrix that is challenging for 
sensor design.22 An additional complication that arises is variation in ionic strength, an 
issue that addressed biomedically through desalting using the standard spin column 
chromatography, a technique we employed in our studies that would complicate real-
world analysis, human urine was used for medical analysis (see Figures 5.S27 and 
5.S28). 22,23   
The complexation between -Gal and cationic AuNPs in human urine (Bioreclamation 
Inc.) solution desalted via spin column chromatography was also determined by the 
hydrolysis of MUG by -Gal in the presence of various concentrations of AuNPs (Figure 
6, additional information see Figures 5.S34 and 5.S35). In this experiment, -Gal was 
dissolved in human urine protein solution (~1.5 M, see SI for details) buffered to pH = 
7.4 using 5 mM phosphate buffer. This solution was then equilibrated with a 
stoichiometric amount of nanoparticles for 15 min.  Then, an excess amount of the MUG 
solution (1 mM) was added to initiate the enzymatic reaction. The activity of -Gal was 
directly correlated with the AuNPs concentration, indicating that the activity of -Gal is 
inhibited by AuNPs complex formation. 
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Figure 5.6 Normalized inhibition activity of -Gal (0.5 nM) against 1 mM substrate MUG upon addition of 
cationic NP2 in the presence of desalted human urinary proteins. The inset shows the kinetics of the 
fluorescence spectra before and after addition of NP2. The arrow in the inset indicates the direction of 
activity. 
 
Using the conditions optimized above described, it was established that 1 nM 
concentration of spiked proteins was required for reproducible differentiation of the 
target analytes (Table 5.1). As before, we created a training matrix (six -Gal/AuNP 
adducts  nine proteins  six replicates) with -Gal/AuNP adduct and each of the 
proteins. Each protein in the human urine protein solution generated a distinct 
fluorescence response. The rates of fluorogenic substrate hydrolysis for -Gal/AuNP pair 
in the presence of individual protein analytes are summarized in Figure 7, showing that 
NP1 and NP4 exhibit stronger affinity for -Gal than for other proteins, producing 
smaller hydrolysis rates and less fluorescence response.  As before, this fluorescent 
response pattern was subjected to further LDA analysis producing a 6  6  9 matrix.  
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This matrix was transformed into five canonical factors.  The five canonical factors 
contain 62.3%, 20.7%, 9.1%, 4.3%, and 0.9% of the variation, respectively. 
 
 
Figure 5.7  Fluorescence response patterns ratio of -Gal and six AuNP adducts against various target 
proteins.  Each value represents an average of six parallel measurements. 
 
The canonical score plot of the first three factors is presented in Figure 5.8, where each 
dot represents the fluorescence response pattern of a single protein target to the -
Gal/AuNP sensor array.  The canonical plot reveals nine distinct clusters corresponding 
to individual target proteins, giving rise to a 100% classification accuracy based on the 
 132
Jackknifed matrix in LDA.  This result demonstrates that the -Gal/AuNP sensor array is 
sensitive enough to differentiate each of the target proteins at 1 nM in the biofluid matrix 
(0.067% of the total protein content in urine), comparable with the preliminary study 
carried out in buffer. This sensitivity is improved as described before 4-215 fold in 
comparison with simple fluorophore displacement15 and it is also comparable with the 
preliminary study carried out in buffer. The particles in this study are well suited for 
differentiation: the same training matrix analyzed using a single nanoparticle gives rise to 
classification accuracies of 33%, 52%, 41%, 43%, 48%, and 31% from NP1 to NP6, 
respectively (Table 5.S10). This indicates almost an equal contribution of each particle in 
the discrimination of the examined protein targets. 
 
Figure 5.8 Canonical score plot of the first three factors of fluorescence response patterns ratio obtained 
through -Gal/AuNP sensor array against nine target proteins at 1 nM in desalted human urine (~1.5 M 
total protein content). 
 
The accuracy of the -Gal/AuNP sensor array was validated by identifying 
unknown proteins in the competitive environment of desalted human urine protein 
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solution. Sixty unknown protein solutions spiked at 1 nM were chosen arbitrarily from 
the training set.  The fluorescence response patterns were newly analyzed through LDA 
analysis, and further classified by the Mahalanobis distances of unknowns to the centroid 
of the respective protein clusters in the canonical score plot.  This process identified 55 
out of 60 unknowns correctly, corresponding to a 92% identification accuracy, 
demonstrating both the feasibility and reproducibility of our enzyme-nanoparticle sensor 
system.   
 
5.3 Conclusion 
In this study, we have demonstrated the use of enzymatic amplification dramatically 
increase the sensitivity of the array-based sensing of proteins. Using this EAAS method, 
we were able to rapidly and reproducibly sense proteins at concentrations of 1 nM in both 
phosphate buffer and desalted human urine protein solution. These studies demonstrate 
that sensing can be achieved with high sensitivity in a complex biomatrix, providing an 
important first step for the creation of array-based biosensors for real-word diagnostic 
applications. In our ongoing studies, we are exploiting both new alternative approaches 
for protein detection and new data analysis strategies to apply this methodology to more 
complex matrices featuring a large diversity of target analytes.  
 
5.4 Experimental Section 
5.4.1 Binding of -Gal to Cationic AuNPs 1-6. Agarose (Type-IB, Sigma Aldrich) gel 
electrophoresis was performed using a FisherBiotech Electrophoresis System (mini-
horizontal unit FB-SB-710). -Gal (2 M) was incubated with cationic AuNPs at 
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different ratio in sodium phosphate buffer (5 mM, pH 7.4) for 15 minutes.  5 L of 80% 
glycerol in deionized water (18 M-cm) was added to 40 L of above solutions and the 
samples were loaded onto the gel. A constant voltage (100 V) was applied to the system 
for 45 min to achieve adequate separation. The gels were then stained in a 0.5% 
Coomassie blue solution (40% volume methanol and 10% volume acetic acid in distilled 
water) for 1 h. Extensive destaining process was carried out with a 40% volume methanol 
and 10% volume acetic acid aqueous solution until the proteins were clearly visible. 
5.4.2 Concentration of desalted human urinary proteins. The male human urine 
sample (Bioreclamation Inc.) was first adjusted to pH 3.5.  Then, the pH-adjusted urine 
sample was applied on a pre-activated maxi spin column (Norgen Biotek Corporation, 
NBC).  A buffer solution (P/N 21602) from NBC was used to wash the column.  At pH 
3.5, the urinary proteins are able to bind to the resin in the column based on their charges; 
while the salts and other related species are removed with the eluent.  The purified urine 
proteins were finally eluted with an elution buffer solution (P/N 21605) from NBC 
(Figures S26 and S27). The concentrated and salt-free human urine proteins were diluted 
at a concentration of 120 g/mL (~1.5 M) in 5 mM phosphate buffer. This complex 
matrix was used to prepare -Gal solutions at 0.5 nM. Experiments using these samples 
need to be processed as soon as possible; delays of more than 2 h might cause unreliable 
results.    
 
 
 
 135
5.4.3 Protein Sensing in Presence of Desalted Human Prinary Proteins. -
galactosidase (-Gal) and the fluorogenic substrate (4-Methylumbelliferyl-beta-D-
galactopyranoside, MUG) were purchased from Sigma-Aldrich.  In the two different 
studies, nanoparticle and -Gal solutions were prepared i) in sodium phosphate buffer 
solution (5 mM, pH 7.4) and ii) 120 g/mL human urinary proteins in 5 mM phosphate 
buffer.  In the activity assay studies, -Gal (0.5 nM) was incubated with various 
concentrations of NP1-NP6 for 30 minutes and 1 mM of the fluorogenic substrate 
(MUG) was added.   As a control experiment, the enzymatic activity of -Gal was also 
monitored in the presence of neutral tetraethylene glycol functionalized nanoparticles. 
The -Gal stock concentration was 275 nM, while the stock concentrations of NP1-NP6 
were prepared in the range of 100 nM and 50 nM. The inhibition studies were carried out 
at pre-determined times by adding 5 L of MUG (42 mM in DMSO) and 5 L of PB 
buffer into 200 L -Gal/AuNP solution.  The enzymatic activity was followed by 
monitoring product formation every 22 s for 15 minutes at 455 nm using a microplate 
reader (EL808 Bio-Tek Instruments, Inc.). The samples were measured in triplicate.  
From the activity/inhibition studies, optimal concentrations of -Gal/AuNP complexes 
were obtained. 
Once the different inhibiting characteristics of the -Gal/AuNP complexes were 
established, stoichiometric amounts of -Gal and NP1-NP6 were used to sense the 
protein targets in two different solutions. In the first solution the analyte targets were 
spiked in 5 mM phosphate buffer (pH 7.4) while the second was spiked in 5 mM 
phosphate buffer containing 120 g/mL human urinary proteins. As a general protocol, 
each solution of the -Gal/AuNP complex (200 L) was placed into a well on the 96-
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well microplate.  After incubation for 30 mins, 5 L of an analyte protein solution (stock 
solution = 42 nM) was added to each well.  After incubation for another 30 min, 5 L of 
MUG (42 mM in DMSO) was added to the sample and the enzyme reaction activity was 
monitored for product formation every 22 s for 15 minutes at 455 nm using a microplate 
reader.  This process was carried out for 9 proteins to generate six replicates for each, 
leading to a training data matrix of 6 nanoparticles  9 proteins  6 replicates that was 
subjected to a classical linear discriminant analysis (LDA) using SYSTAT (version 11.0). 
In the studies of unknown samples, sixty unknown protein solutions were randomly 
selected from nine proteins in the training set, and prepared at 42 nM concentration 
diluted from a stock solution with UV absorbance at 280 nm equal to 0.1.  The sensing 
assay was conducted using the aforementioned procedure with 5 L of unknown, 
affording a final protein concentration of 1 nM into the 96 wells microplate reader. Each 
unknown was performed twice against sensor array to obtain an average of a fluorescence 
response pattern.  Afterward, the protein identity was detected by LDA analysis, with the 
system correctly determining a 92% of accuracy of the unknown samples over the span of 
the experiment. In the experimental setup, the solution preparation, data collection, and 
LDA analysis were operated by different persons to reduce bias and increase 
reproducibility of the unknown experiment. 
5.4.4 Instrumentation.  TEM samples were prepared by depositing 3 L of a diluted 
aqueous solution of cationic AuNPs (5 M) onto a 300 mesh carbon-coated copper grid. 
The samples were dried in air at room temperature. TEM images were obtained on a 
JEOL 100CX electron microscope operated at 100 keV and analyzed using Image J.  
More than 200 AuNPs were taken as target samples to calculate the average diameters 
 137
and size distributions.  -Potential (ZP) and dynamic light scattering (DLS) results were 
used to characterize the charge and the hydrodynamic diameter of both nanoparticles and 
proteins. Cationic gold nanoparticles were dissolved in sodium phosphate buffer (5 mM, 
pH 7.4) to make solutions at 5 M concentrations. The samples were filtered through a 
Millipore syringe-driven filter (0.22 μm) and injected into a folded capillary disposable 
cell.  In the case of the proteins, the samples were filtered through a Millipore syringe-
driven filter (0.22 μm) and injected into the disposable cell. Both ZP and DLS were 
measured on a MALVERN Zetasizer Nano ZS instrument. Each sample was scanned six 
times and an average value was reported. 
5.4.5 Synthesis of AuNPs 1-6.  Pentanethiol-coated AuNPs with core diameter 2 nm 
were synthesized using the Brust-Schiffrin two-phase synthesis method.1 Murray place-
exchange method2 was used to obtain the quaternary ammonium functionalized AuNPs 
1-6 (see Schemes 5.S1, 5.S2, and 5.S3 for synthesis and Figures 5.S1-5.S25 for 
characterization).3  The cationic AuNPs were very stable in aqueous solution. 
5.4.6 Target Proteins. -Amylase (-Amy, from Bacillus licheniformis), bovine serum 
albumin (BSA, from Bovine serum), cytochrome c (CytC, from equine heart), ferritin 
(Fer, from equine spleen), human serum albumin (HAS, from human serum), lipase (Lip, 
from candida rugosa, type VII), lysozyme (Lys, from chicken egg white), myoglobin 
(Myo, from equine heart), and alkaline phosphatase (PhosB, from bovine intestinal 
mucosa) were purchased from Sigma-Aldrich and used as received. The protein 
                                                 
1 a) Kanaras, A. G.; Kamounah, F. S.; Schaumburg, K.; Kiely, C. J.; Brust, M. Chem. Commun. 2002, 2294. b) Brust, M.; Walker, 
M.; Bethell, D.; Schiffrin, D. J.; Whyman, R. J. Chem. Soc. Chem. Commun. 1994, 801. 
2 Templeton, A. C.; Wuelfing, M. P.; Murray, R. W. Acc. Chem. Res. 2000, 33, 27. 
3 You, C. C.; Miranda, O. R.; Gider, B.; Ghosh, P. S.; Kim, I. B.; Erdogan, B.; Krovi, S. A.; Bunz, U. H. F.; Rotello, V. M. Nat. 
Nanotech. 2007, 2, 318. 
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concentrations were standaridized by the absorbance at 280 nm in 5 mM phosphate 
buffer at pH 7.4 using a Hewlett Packard 8452A Diode Array Spectophotometer. 
 
 
 
 
 
Scheme 5.S1 Synthesis of ligands L1, L2, L3, L4, L5 and L6. 4  
 
 
 
General procedure: 
 
Compound 1: Triphenylmethanethiol (7.92 g, 28.66 mmol) was dissolved in a solution 
of ethanol/benzene (1:1, 50 mL) and NaOH (1.43 g, 35.82 mmol) in 15 mL of H2O was 
added.  Then 11-bromo-1-undecanol (6 g, 23.88 mmol) was also dissolved in a solution 
of ethanol/benzene (1:1, 50 mL) and added to the triphenylmethanethiol mixture. The 
new reaction mixture was stirred overnight at room temperature. Once the reaction was 
completed (checked by TLC) all the mixture was poured into a saturated solution of 
NaHCO3 and washed three times. The organic layer was separated and added into another 
solution saturated of NaCl and also washed for three times. Afterward the organic layer 
was separated, dried (Na2SO4), and concentrated using a rotavapor. The crude product 
was purified by column chromatography over silica gel using hexane/ethyl acetate (9:1, 
4:1 and 1:1, v/v) as an eluent. The solvent was removed in vacuum to obtain compound 1 
as a colorless oil (Yield 10.23 g, >95.9 %, see NMR Figure S1). 
 
 
 
                                                 
4 C.-C. You, O. R. Miranda, B. Gider, P. S. Ghosh, I.-B. Kim, B. Erdogan, S. A. Krovi, U. H. F. Bunz, V. M. Rotello, Nat. 
Nanotechnol. 2007, 2, 318-323. 
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Figure 5.S1 400 MHz 1H NMR spectra of compound 1 in CDCl3 (D, 99.8%). 
 
Compound 2:  To a solution of compound 1 (9 g, 20.15 mmol) in dry dichloromethane 
(DCM) at 4 °C, triethylamine (4.08 g, 40.3 mmol) was added. Methylsulfonyl chloride 
(3.46 g, 30.2 mmol) was injected drop by drop to the solution maintaining the 
temperature less that 5 °C. After 30 minutes the reaction mixture was warmed up to room 
temperature and stirred for another 30 minutes. Once the reaction was completed 
(according to TLC), the DCM was evaporated. The viscous compound was again diluted 
with DCM and poured into 0.1 M solution of HCl, and treated twice.  Organic layer was 
poured into a saturated solution of NaHCO3 and washed three times. The organic layer 
was separated and added into another solution saturated of NaCl and also treated three 
times. Afterward organic layer was separated, dried (Na2SO4) and concentrated at 
reduced pressure. The crude product was purified by column chromatography over silica 
gel using hexane/ethyl acetate (1:1, v/v) as an eluent. Solvent was removed in vacuum to 
afford compound 2 as colorless oil (Yield 10.1 g, >95.5 %). The NMR showed an 
additional peak on the spectra of compound 1 around 2.95 ppm confirming the synthesis 
of 11-(tritylthio)undecyl methanesulfonate (see Figure S2).  To synthesize 1,1,1-
triphenyl-14,17,20,23-tetraoxa-2-thiapentacosan-25-ol, NaOH (0.8 g, 20 mmol) in 1 ml 
of H2O was added to 58.26 mL of tetraethyleneglycol (TEG: 52.3 g, 300 mmol) and 
stirred for 1 h at 90 °C.  To this reaction mixture, 11-(tritylthio)undecyl methanesulfonate 
(10 g, was added (by dissolving in TEG) and stirred for 24 h. The reaction mixture once 
completed (according to TLC) was extracted by washing with a solution of hexane/ethyl 
acetate (4:1, v/v) six times (checked by TLC). Afterward, the organic layer was separated 
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and concentrated at reduced pressure. The crude product was purified by column 
chromatography over silica gel (flash running) using hexane/ethyl acetate (1:1 and 0:1, 
v/v) as an eluent. The solvent was removed in vacuum to obtain compound 2 as a 
colorless oil (Yield 7.83 g, >65.0 %, see NMR Figure 5.S3). 
 
 
Figure 5.S2 400 MHz 1H NMR spectra of 11-(tritylthio)undecyl methanesulfonate in CDCl3 (D, 99.8%). 
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Figure 5.S3 400 MHz 1H NMR spectra of compound 2 in CDCl3 (D, 99.8%). 
 
Compound 3:  Compound 2 (7 g, 11.24 mmol) was dissolved in dry dichloromethane 
(DCM) at 4 °C, and was followed by the addition of triethylamine (3.41 g, 33.72 mmol). 
Methylsulfonyl chloride (2.44 g, 16.86 mmol) was injected drop by drop to the reaction 
mixture maintaining the temperature less that 5 °C. After 30 minutes the reaction mixture 
was warmed up to room temperature and stirred for another 30 minutes. When the 
reaction was finally completed (according to TLC), the DCM solvent was evaporated. 
The viscous compound was again diluted with DCM and was poured into 0.1 M solution 
of HCl, and washed twice.  The organic layer was poured into a saturate solution of 
NaHCO3 and treated three times. Organic layer was separated and added into another 
solution saturated of NaCl and also treated for three times. Afterward, the organic layer 
was separated, dried (Na2SO4) and concentrated at reduced pressure. The crude product 
was purified by column chromatography over silica gel (flash running) using 
hexane/ethyl acetate (1:1, 1:4 and 0:1 v/v) as an eluent. Solvent was removed in vacuum 
to afford compound 3 as a colorless oil (Yield 7.31 g, >92.5 %). The NMR results 
showed an additional peak on the spectra of compound 1 around ~2.75 ppm confirming 
the synthesis of 1,1,1-triphenyl-14,17,20,23-tetraoxa-2-thiapentacosan-25-yl 
methanesulphonate (see Figure 5.S4). 
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Figure 5.S4 400 MHz 1H NMR spectra of compound 2 in CDCl3 (D, 99.8%). 
 
Compound 4 (Trt L): Compound 3 (1 g, 1.43 mmol) was added to an available library 
of dimethylamine solutions (28.53 mmol) containing 5% of ethanol. The reaction 
mixtures were stirred at ~35 oC for 48 h. Crude product was checked by TLC and ethanol 
was eliminated at reduced pressure. The light yellow residue was purified by hexane with 
support of both heat and sonication and further dried in a high vacuum system. The 
product formation (4) was quantitative and their structure was confirmed by NMR. The 
yield was >94.6 %. 
 
1H NMR of compound 4 (Trt L) 
 
Compound Trt L1: 1H NMR (400MHz, CDCl3, TMS):  7.43-7.38 (m, 4H, HAr), 7.31-
7.24 (m, 9H, HAr), 7.23-7.17 (m, 2H, HAr), 3.98 (br, 2H, -OCH2-(CH2N)-), 3.67-3.58 (m, 
14H, -CH2O- + -CH2N-), 3.55 (t, 2H, -CH2O-), 3.50-3.41 (m, 2H,-NCH2-), 3.27 (s, 6H, -
(CH3)2N-), 2.75 (s, 3H, CH3SO-3-), 2.21 (t, 2H, -SCH2-), 1.74-1.50 (m, 6H, -(NCH2)CH2-
) + (SCH2)CH2  + -CH2(CH2O)-), 1.42-1.11 (m, 20H, -(NCH2CH2-)CH2-) + -CH2-), 0.89 
(t, 3H, - CH3-). 
 
Compound Trt L2: 1H NMR (400MHz, CDCl3, TMS):  7.44-7.37 (m, 4H, HAr), 7.32-
7.23 (m, 9H, HAr), 7.22-7.16 (m, 2H, HAr), 3.99 (br, 2H, -OCH2-(CH2N)-), 3.67-3.58 (m, 
12H, -CH2O-), 3.57-3.54 (m, 1H, HCyclo), 3.51-3.39 (m, 4H, -CH2O- +-CH2N-), 3.19 (s, 
6H, -(CH3)2N-), 2.75 (s, 3H, CH3SO-3-), 2.12 (t, 2H, -SCH2-), 1.77-1.65 (m, 2H, HCyclo), 
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1.59-1.50 (m, 2H, HCyclo), 1.48-1.07 (m, 22H, HCyclo, -(SCH2)CH2 + -(SCH2)CH2CH2  + -
CH2(CH2O)- + -CH2(CH2CH2O)- + -CH2-). 
 
Compound Trit L3: 1H NMR (400MHz, CDCl3, TMS):  7.66-7.59 (m, 2H, HAr), 7.50-
7.36 (m, 7H, HAr), 7.32-7.23 (m, 9H, HAr), 7.22-7.16 (m, 2H, HAr), 4.80 (br, 2H,-NCH2-
Ar), 3.84 (br, 2H, -OCH2-(CH2N)-), 3.73-3.55 (m, 14H, -CH2O- + -CH2N-), 3.54-3.49 
(m, 2H, -CH2O-), 3.23 (s, 6H, -(CH3)2N-), 2.79 (s, 3H, CH3SO-3-), 2.12 (t, 2H, -SCH2-), 
1.57-1.48 (m, 2H, -(SCH2)CH2), 1.43-1.32 (m, 2H, -CH2(CH2O)-), 1.31-1.07 (m, 12H, -
CH2-). 
 
Compound Trit L4: 1H NMR (400MHz, CDCl3, TMS):  7.43-7.37 (m, 4H, HAr), 7.31-
7.24 (m, 9H, HAr), 7.23-7.17 (m, 2H, HAr), 3.95 (br, 2H, -OCH2-(CH2N)-), 3.77 (b, 1H, 
OH), 3.76-3.53 (m, 16H, -CH2O- + -CH2N- +  -CH2-OH), 3.51-3.44 (m, 2H,-NCH2-), 
3.42 (m, 2H, -CH2O-), 3.24 (s, 6H, -(CH3)2N-), 2.74 (s, 3H, CH3SO-3-), 2.13 (t, 2H, -
SCH2-), 2.09-1.99 (m, 2H, -(NCH2)CH2-), 1.59-1.51 (m, 2H, -(SCH2)CH2), 1.42-1.33 (m, 
2H, -CH2(CH2O)-), 1.33-1.10 (m, 14H, -CH2-). 
 
Compound Trit L5: 1H NMR (400MHz, CDCl3, TMS):  7.65-7.57 (m, 2H, HAr), 7.53-
7.35 (m, 7H, HAr), 7.31-7.23 (m, 9H, HAr), 7.21-7.15 (m, 2H, HAr), 3.97 (br, 2H, -OCH2-
(CH2N)-), 3.65-3.56 (m, 13H, -CH2O- + HCyclo), 3.57-3.53 (m, 1H, HCyclo), 3.50-3.39 (m, 
4H, -CH2O- +-CH2N-), 3.17 (s, 6H, -(CH3)2N-), 2.75 (s, 3H, CH3SO-3-), 2.13 (t, 2H, -
SCH2-), 1.77-1.64 (m, 2H, HCyclo), 1.59-1.49 (m, 2H, HCyclo), 1.47-1.05 (m, 22H, HCyclo, -
(SCH2)CH2 + -(SCH2)CH2CH2 + -CH2(CH2O)- + -CH2(CH2CH2O)- + -CH2-).  
 
Compound Trit L6: 1H NMR (400MHz, CDCl3, TMS):  7.43-7.38 (m, 4H, HAr), 7.36-
7.31 (m, 7H, HAr), 7.30-7.24 (m, 12H, HAr), 7.23-7.17 (m, 2H, HAr), 5.39 (s, 1H, CH-Ar-
), 3.99-3.93 (m and br, 2H, -CH2OCAr-), 3.92-3.87 (m and br, 2H, -OCH2-(CH2N)-), 
3.65-3.55 (m, 14H, -CH2O- + -CH2N-), 3.54-3.51 (m, 2H, -CH2O-), 3.49-3.44 (m, 2H, -
NCH2(CH2OCAr-), 3.37 (s, 6H, -(CH3)2N-), 2.74 (s, 3H, -CH3SO-3-), 2.13 (q, 2H, -CH2S-
), 1.59-1.50 (m, 2H, -(SCH2)CH2),  1.41-1.34 (m, 2H, -CH2(CH2O)-), 1.33-1.10 (m, 14H, 
-CH2-). 
 
Compound 5: Compound 4 was dissolved in dry dichloromethane (DCM) and an excess 
of trifluoroacetic acid (TFA, ~ 20 equivalents) was added. The color of the solution was 
turned to yellow immediately. Subsequently, triisopropylsilane (TIPS, ~ 1.2 equivalents) 
was added to the reaction mixture. The reaction mixture was stirred for ~5 h under Ar2 at 
room temperature. The solvent and most TFA and TIPS were distilled off under reduced 
pressure. The pale yellow residue was purified by hexane combining both heat and 
sonication and further dried in a high vacuum system. The product (L) formation was 
quantitative and their structure was confirmed by NMR showing a shift of the counter ion 
peak on the spectra to more down field ~2.98 ppm. The yields were >95.4%.  
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1H NMR and 13C of compound 5 (Figures 5.S5-5.S16) 
 
Compound L1: 1H NMR (400MHz, CDCl3, TMS):  3.95 (br, 2H, -OCH2-(CH2N)-), 
3.68-3.56 (m, 14H, -CH2O- + -CH2N-), 3.46 (t, 2H, -CH2O-), 3.40-3.33 (m, 2H,-NCH2-), 
3.19 (s, 6H, -(CH3)2N-), 2.87 (s, 3H, CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.76-1.53 (m, 6H, 
-(NCH2)CH2-) + (SCH2)CH2  + -CH2(CH2O)-), 1.41-1.22 (m, 21H, -SH + -(NCH2CH2-
)CH2-) + -CH2-), 0.89 (t, 3H, - CH3-). 13C NMR(400 MHz, CDCl3) δ(ppm): 71.59, 70.54, 
70.51, 70.44, 70.33, 70.15, 70.00, 66.42, 64.82, 63.50, 51.90, 34.07, 31.18, 29.59, 29.54, 
29.52, 29.49, 29.09, 28.39, 26.07, 25.84, 24.68, 22.71, 22.37, 13.85. 
 
Compound L2: 1H NMR (400MHz, CDCl3, TMS): ( 3.97 (br, 2H, -OCH2-(CH2N)-), 
3.69-3.55 (m, 14H, -CH2O- + -CH2N-), 3.54-3.48 (m, 1H, HCyclo), 3.44 (t, 2H, -CH2O-), 
3.13 (s, 6H, -(CH3)2N-), 2.86 (s, 3H, CH3SO-3-), 2.52 (q, 2H, -CH2S-), 2.25 (d, 2H, 
HCyclo), 1.99 (d, 2H, HCyclo), 1.73 (d, 2H, HCyclo), 1.78-1.52 (m, 4H, -(SCH2)CH2  + 
-CH2(CH2O)-), 1.51-1.12 (m, 19H, SH + -CH2- + HCyclo). 13C NMR(400 MHz, CDCl3) 
δ(ppm): 73.76, 71,02, 69.85, 69.82, 69.69, 69.61, 69.37, 64.16, 61.42, 48.29, 38.89, 
33.46, 28.98, 28.92, 28.87, 28.76, 28.48, 28.07, 27.94, 27.78, 25.75, 25.43, 24.68, 24.11. 
 
Compound L3: 1H NMR (400MHz, CDCl3, TMS):  7.56-7.45 (m, 5H, HAr), 4.60 (s and 
br, 2H,-NCH2-Ar), 4.03 (br, 2H, -OCH2-(CH2N)-), 3.75-3.50 (m, 14H, -CH2O- + -CH2N-
), 3.48-3.41 (m, 2H, -CH2O-), 3.14 (s, 6H, -(CH3)2N-), 2.91 (s, 3H, CH3SO-3-), 2.52 (q, 
2H, -CH2S-), 1.72-1.46 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.44-1.15 (m, 15H, -SH + 
-CH2-). 13C NMR(400 MHz, CDCl3) δ(ppm): 132.85, 130.97, 129.27, 126.51, 116.08, 
113.24, 71.52, 70.10, 70.05, 69.97, 69.90, 69.54, 64.53, 63.42, 50.68, 39.37, 33.84, 29.33, 
29.28, 29.19, 29.12, 29.01, 28.86, 28.17, 25.69, 24.46. 
 
Compound L4: 1H NMR (400MHz, CDCl3, TMS):  4.55-4.46 (m, 2H,-CH2-OH), 3.99 
(br, 2H, -OCH2-(CH2N)-), 3.85 (br, 1H, -OH), 3.79-3.52 (m, 16H, -CH2O- + -CH2N- + -
NCH2-), 3.47 (t, 2H, -CH2O-), 3.25 (s, 6H, -(CH3)2N-),  2.87 (s, 3H, CH3SO-3-), 2.52 (q, 
2H, -CH2S-), 2.35-2.26 (m, 2H, -(NCH2)CH2-), 1.70-1.49 (m, 4H, + (SCH2)CH2  + -
CH2(CH2O)-), 1.42-1.19 (m, 15H, -SH + -CH2-). 13C NMR(400 MHz, CDCl3) δ(ppm): 
71.12, 69.70, 69.66, 69.62, 69.58, 69.48, 69.15, 63.92, 63.15, 62.11, 51.75, 38.87, 33.46, 
28.94, 28.89, 28.80, 28.73, 28.64, 28.48, 28.34, 27.79, 25.29, 24.08, 21.45. 
 
Compound L5: 1H NMR (400MHz, CDCl3, TMS):  7.4-7.19 (m, 5H, HAr), 3.95 (br, 
2H, -OCH2-(CH2N)-), 3.79-3.52 (m, 15H, -CH2O- + -CH2N- + 1H, HCyclo), 3.45 (t, 2H, -
CH2O-), 2.81 (m and br, 6H, -(CH3)2N-), 2.87 (s, 3H, CH3SO-3-), 2.70 (q, 2H, -CH2S-), 
2.59-2.41 (m and br, 1H, HCyclo), 2.39-2.20 (m, 2H, HCyclo), 2.19-2.06 (m, 2H, HCyclo), 
1.96-1.84 (m, 4H, HCyclo), 1.72-1.53 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.42-1.1.19 
(m, 15H, -SH + -CH2-). 13C NMR(400 MHz, CDCl3) δ(ppm): 128.76, 128.73, 127.16, 
127.09, 126.72, 126.39, 71.65, 70.50, 70.41, 70.37, 70.31, 70.27, 70.00, 64.97, 62.34, 
62.07, 49.15, 48.81, 40.86, 34.16, 32.49, 32.13, 29.66, 29.58, 29.30, 28.68, 28.61, 27.77, 
26.79, 26.34, 26.10, 24.03.21.77. 
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Compound L6: 1H NMR (400MHz, CDCl3, TMS):  7.42-7.27 (m, 10H, HAr), 5.13 (s, 
1H, HAr), 4.12 (br, 2H, -CH2OCAr-), 3.96 (br, 2H, -OCH2-(CH2N)-), 3.75-3.51 (m, 16H, 
-CH2O- + -CH2N- + -CH2O-), 3.50-3.44 (m, 2H, -NCH2(CH2OCAr-), 3.28 (s, 6H, -
(CH3)2N-), 2.95 (s, 3H, CH3SO-3-), 2.38 (t, 2H, -CH2S-), 1.60-1.48 (m, 4H, -(SCH2)CH2  
+ -CH2(CH2O)-), 1.34-1.16 (m, 15H, -SH + -CH2-). -). 13C NMR(400 MHz, CDCl3) 
δ(ppm):  141.71, 128.61, 128.67, 127.18, 116.95, 114.10, 71.61, 70.51, 70.45, 70.32, 
70.19, 69.97, 67.14, 64.80, 59.91, 56.26, 55.98, 54.25, 53.09, 50.46, 43.72, 39.47, 32.43, 
29.63, 29.57, 29.52, 29.24, 29.09, 28.92, 26.08. 
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Figure 5.S5 400 MHz 1H NMR spectra of compound L1 in CDCl3 (D, 99.8%).  
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Figure 5.S6 400 MHz 13C NMR spectra of compound L1 in CDCl3 (D, 99.8%).  
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Figure 5.S7 400 MHz 1H NMR spectra of compound L2 in CDCl3 (D, 99.8%).  
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Figure 5.S8 400 MHz 13C NMR spectra of compound L2 in CDCl3 (D, 99.8%).  
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Figure 5.S9 400 MHz 1H NMR spectra of compound L3 in CDCl3 (D, 99.8%).  
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Figure 5.S10 400 MHz 13C NMR spectra of compound L3 in CDCl3 (D, 99.8%).  
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Figure 5.S11 400 MHz 1H NMR spectra of compound L4 in CDCl3 (D, 99.8%).  
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Figure 5.S12 400 MHz 13C NMR spectra of compound L4 in CDCl3 (D, 99.8%).  
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Figure 5.S13 400 MHz 1H NMR spectra of compound L5 in CDCl3 (D, 99.8%).  
 155
 
Figure 5.S14 400 MHz 13C NMR spectra of compound L5 in CDCl3 (D, 99.8%).  
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Figure 5.S15 400 MHz 1H NMR spectra of compound L6 in CDCl3 (D, 99.8%).  
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Figure 5.S16 400 MHz 13C NMR spectra of compound L6 in CDCl3 (D, 99.8%).  
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Scheme 5.S2 Synthesis of cationic gold nanoparticles NP1-NP6. 
 
1-Pentanethiol coated gold nanoparticles (d = ~2 nm) were prepared according to the 
previously reported protocol (See NMR Figure 5.S17).5 A place-exchange reaction6 of 
compound Ls dissolved in DCM with pentanethiol-coated gold nanoparticles (d~2 nm) 
was carried out for 3 days at room temperature. Then, DCM was evaporated under 
reduced pressure. The residue was dissolved in a small amount of distilled water and 
dialyzed (membrane MWCO = 1,000) to remove excess ligands, acetic acid and other 
salts present with the nanoparticles solution. After dialysis, the particles were lyophilized 
to obtain a brownish solid product. The particles (AuNPs) are redispersed in water and/or 
deionized water (18 M-cm). 1H NMR spectra in D2O showed substantial broadening of 
the proton signals and no free ligands were observed (see Figures 5.S18-5.S23). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
5 Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R. J. Chem. Soc., Chem. Commun. 1994, 801-802.  
6 Hostetler, M. J.; Templeton, A. C.; Murray, R. W. Langmuir 1999, 15, 3782-3789.  
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1H NMR spectra of AuS(CH2)4CH3 
 
 
 
 
Figure 5.S17 400 MHz 1H NMR of pentane-1-thiol capping the surface of the metal core gold 
nanoparticles. The average diameter of the metal core AuS(CH2)4CH3 is ~ 2 nm (2.15  0.31 nm). 
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1H NMR spectra of NP1 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S18 400 MHz 1H NMR of N-hexyl-23-mercapto-N,N-dimethyl-dimethyl-3,6,9, 12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP1 is ~ 2 nm (2.15  0.28 nm). 
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1H NMR spectra of NP2 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S19 400 MHz 1H NMR of N-cyclohexyl-23-mercapto-N,N-dimethyl-3,6,9,12-tetraoxatricosan-1-
aminium capping the surface of the metal core gold nanoparticles after place exchange. The average 
diameter of the metal core NP2 is ~ 2 nm (2.09  0.27 nm). 
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1H NMR spectra of NP3 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S20 400 MHz 1H NMR of N-benzyl-23-mercapto-N,N-dimethyl-3,6,9,12-tetraoxatricosan-1-
aminium capping the surface of the metal core gold nanoparticles after place exchange. The average 
diameter of the metal core NP3 is ~ 2 nm (2.12  0.21 nm). 
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1H NMR spectra of NP4 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S21 400 MHz 1H NMR of N-(3-hydroxypropyl)-23-mercapto-N,N-dimethyl-3,6,9,12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP4 is ~ 2 nm (2.14  0.25 nm). 
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1H NMR spectra of NP5 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S22 400 MHz 1H NMR of 23-mercapto-N,N-dimethyl-N-(4-phenylcyclohexyl)-3,6,9,12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP5 is ~ 2 nm (2.10  0.29 nm). 
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1H NMR spectra of NP6 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 5.S23 400 MHz 1H NMR of N-(2-(benzhydryloxy)ethyl)-23-mercapto-N,N-dimethyl-3,6,9,12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP6 is ~ 2 nm (2.11  0.22 nm). 
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Scheme 5.S3 Synthesis of tetraethylene glycol functionalized gold nanoparticles 
 
General procedure7: 60 mg of HAuCl4 were dissolved in a mixture of 100 ml of 2-
propanol and 1 ml of concentrated acetic acid (to prevent possible deprotonation of thiol 
molecules (II) after addition of excess NaBH4). Compound II (Yield 4.57 g, >95.4%, see 
NMR Figure S24) bearing both thiols and hydroxyls end groups (monohydroxyl(1-
mercaptounce-11-yl) was added under stirring conditions to the gold salt solution. 
HAuCl4 was reduced by rapid addition of 10 ml of freshly prepared 0.5 M solution of 
NaBH4 in methanol. The pale yellow gold solution turned black. After further stirring for 
3 h, the volume of 2-propanol was reduced to 5-10 ml using a rotavapor. The synthesized 
AuNP (III, NPOH) was precipitated by pouring the reaction mixture into hexane.  The 
tetraethylene glycol functionalized particles were cleaned several times in hexane and 
were separated by centrifugation. 1H NMR spectra in D2O showed substantial broadening 
of the proton signals and no free ligands were observed (See NMR Figure S25). Please 
notes that compound (I) was synthesized as shown in scheme I (Yield 7.83 g, >65 %, see 
NMR Figure S3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
7 A. G. Kanaras, F. S. Kamounah, K. Schaumburg, Ch. J. Kiely and M. Brust, Chem. Commun. 2002, 2294-2295. 
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Figure 5.S24 400 MHz 1H NMR spectra of compound II (23-mercapto-3,6,9,12-tetraoxatricosan-1-ol) in 
chloroform-D (D, 99.8%). 
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Figure 5.S25 400 MHz 1H NMR of 23-mercapto-3,6,9,12-tetraoxatricosan-1-ol capping the surface of the 
metal core gold nanoparticles after synthesizing them. The average diameter of the metal core NPOH is ~ 2 
nm (2.40  0.46 nm). 
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Figure 5.S26  Fluorescence titration curves for the complexation of -Gal with cationic gold nanoparticles 
(NP1-NP6).  The inhibition study was measured following the addition of cationic nanoparticles (0-100 
nM) with an excitation wavelength of 455 nm. The -Gal stock concentration was 275 nM, while the stock 
concentration of NP1-NP4 and NP5-NP6 were 100 nM and 50 nM, respectively. For the activity/inhibition 
studies, optimal concentrations of -Gal/ AuNP complexes were obtained (-Gal = 0.5 nM and NP1: 14 
nM, NP2: 5 nM, NP3: 6 nM, NP4: 32 nM, NP5: 6 nM and NP6: 10 nM).
(a) (d) 
(b) (e) 
(c) (f) 
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 Table 5.S1 Final and initial kinetics ratio of the fluorescence response patterns of -Gal and six AuNP 
(NP1-NP6) adducts against various target proteins  the standard deviation (SD).  Each value represents an 
average of six parallel measurements. 
 
 
Table 5.S2 Training matrix of activity response patterns generated from -Gal/AuNP sensor array (NP1–
NP6) and the fluorogenic substrate (4-Methylumbelliferyl-beta-D-galactopyranoside) against various types 
of proteins (concentration = 1 nM). Table continues on the next page. 
 
Protein NP1 NP2 NP3 NP4 NP5 NP6 
BSA 0.044053 3.214873 1.915919 3.019801 1.508394 2.596625 
BSA 0.001803 2.751742 1.862452 2.7310954 1.929778 2.125469 
BSA -0.029208 5.238646 4.532112 6.1428905 4.079058 8.703043 
BSA -0.005562 5.150131 2.309229 4.3265513 1.57304 2.363229 
BSA -0.002474 3.970872 1.487962 3.064843 3.281544 4.358388 
BSA -0.010731 5.38278 2.692894 4.6892543 1.484737 4.295396 
-Amy 0.030533 47.949173 2.694459 0.04751 0.971899 4.085935 
-Amy 0.030473 40.106219 1.095875 0.024666 0.872635 3.451511 
-Amy 0.037562 49.668787 1.225475 -0.038449 0.568434 3.20844 
-Amy 0.046226 48.437045 1.068158 -0.08928 0.49703 2.897434 
-Amy -0.000473 53.43828 1.464148 -0.123741 0.289909 2.854269 
-Amy 0.081295 39.644225 1.239895 -0.110541 0.630381 2.807335 
PhosB 0.026263 5.167704 5.097584 0.031897 0.506591 9.209252 
PhosB 0.085332 8.328736 7.486119 0.129765 0.59378 7.720325 
PhosB 0.091886 5.566015 8.598139 -0.00099 1.499621 8.635416 
PhosB 0.170683 8.147285 3.929951 0.010107 0.340704 6.876555 
PhosB 0.099291 13.73013 6.251962 0.077694 0.397096 9.220521 
PhosB 0.096983 6.576261 4.349083 0.094739 0.736506 7.02314 
Myo -0.033206 8.080209 2.630773 0.021627 2.082037 6.037168 
Myo -0.027848 4.615996 1.559139 0.044039 1.226572 7.504394 
Myo -0.033647 7.094949 2.565082 0.006033 2.241766 9.31948 
Myo -0.103298 5.823526 2.629196 0.006574 1.203914 9.472293 
Myo -0.060838 4.055951 0.713224 0.015152 1.29802 7.997081 
Myo -0.09288 0.960021 0.268708 -0.036356 1.105129 6.876726 
HSA 0.034241 11.695738 0.117799 0.01436 0.210229 9.729707 
HSA 0.030275 16.082641 0.27824 -0.000932 0.175173 12.303557 
HSA 0.030139 9.63946 0.161239 0.033209 0.13621 12.761519 
HSA 0.000204 14.385132 0.165391 0.013896 0.132509 13.612848 
HSA -0.040128 14.886227 0.246951 0.035259 0.184369 11.848571 
HSA -0.070378 11.715753 0.156712 -0.001143 0.183518 11.504987 
CytC 0.184217 3.334292 2.484168 0.00432 1.997726 3.585885 
Proteins (Vmax/Vo,max) 
  NP1 SD NP2 SD NP3 SD NP4 SD NP5 SD NP6 SD 
-Amy 1.032631 0.023070 49.826124 5.782580 2.521877 0.642766 0.956224 0.065155 1.605185 0.236992 3.685843 0.410927 
BSA 0.999694 0.021073 5.495259 1.192272 3.563111 1.135221 4.621077 1.189828 3.189334 1.045792 4.400572 2.060501 
CytC 1.099279 0.038270 7.035717 1.641028 4.688597 0.888432 1.047342 0.056569 3.059661 0.815755 3.247085 0.923202 
Fer 0.992357 0.013876 5.907556 1.403126 1.248837 0.077110 1.049945 0.240083 3.939724 1.574754 4.814340 1.156489 
HSA 1.022090 0.093190 0.578550 0.061970 0.593520 0.082680 1.053750 0.020060 0.198600 0.078690 1.067530 0.030660 
Lip 1.016972 0.022431 21.891588 7.816683 7.545811 1.491518 1.048292 0.028982 5.889066 2.165569 12.169190 1.601643 
Lys 1.033740 0.032185 25.554471 3.995886 2.064363 0.457939 1.033634 0.024631 1.208252 0.108581 7.644296 0.648020 
Myo 0.949131 0.028495 6.355809 2.647767 2.795169 1.091327 1.008620 0.023961 2.446874 0.481337 7.567806 1.130111 
PhosB 1.082503 0.045996 9.308256 3.585956 7.184626 1.906531 1.051838 0.048903 1.643739 0.450590 7.773445 0.881225 
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CytC 0.086233 6.881454 3.775898 0.058127 2.035972 3.80381 
CytC 0.093745 6.705778 2.958707 0.162795 1.009177 1.514039 
CytC 0.133485 4.480754 4.809584 0.022029 2.466796 2.025927 
CytC 0.059278 7.360435 3.126939 0.037145 1.892558 3.668159 
CytC 0.129476 5.756436 4.144335 0.029029 3.633607 1.553461 
Lip 0.03489 15.975745 6.129009 0.044412 3.649662 12.760949 
Lip -0.006349 14.685047 5.771155 0.049339 4.351439 11.519174 
Lip 0.059929 23.193191 7.965504 0.044512 7.374255 13.884153 
Lip 0.016398 33.350164 7.693391 0.116974 2.994633 14.215449 
Lip -0.008592 18.87153 6.235977 0.033004 3.938793 11.4049 
Lip 0.02107 13.406363 4.003451 0.03149 8.634694 16.495692 
Fer 0.015638 3.881425 0.250667 0.594025 0.91143 4.736998 
Fer -0.025041 3.76365 0.194659 -0.079998 2.743015 5.65528 
Fer -0.012179 6.219136 0.175432 -0.055006 2.912148 5.733982 
Fer -0.001526 4.868176 0.352427 -0.020403 5.77607 5.321418 
Fer -0.026687 6.258195 0.181103 -0.036432 4.048367 3.833469 
Fer -0.003048 3.076446 0.282612 -0.071511 2.21483 2.135025 
Lys 0.039216 18.908905 1.43748 0.02018 0.35339 8.155539 
Lys 0.021889 25.932638 1.674801 0.087391 0.089727 8.739942 
Lys 0.02705 23.321727 0.795414 0.033402 0.252776 6.517422 
Lys -0.011735 18.721133 0.953478 0.037755 0.091089 8.167482 
Lys 0.058959 25.967241 0.523449 0.007717 0.198486 7.764536 
Lys 0.097906 27.578963 0.761495 0.036241 0.332586 8.412007 
 
 
Table 5.S3 Accuracy of LDA classification of protein analytes (Conc. = 1 nM) from the complexes of the 
enzyme (-Gal) with individual cationic nanoparticles as sensors. The values are taken from the Jackknifed 
classification matrix based on LDA analysis of the raw data (6 replicates) listed in Table 5.S1. 
 
Protein NP1- 
(-Gal) 
NP2- 
(-Gal) 
NP3- 
(-Gal) 
NP4- 
(-Gal) 
NP5- 
(-Gal) 
NP6- 
(-Gal) 
-Amy 17% 100% 17% 67% 50% 33% 
BSA 17% 50% 33% 100% 0% 17% 
CytC 50% 33% 50% 0% 50% 50% 
Fer 50% 17% 50% 0% 33% 67% 
HSA 0% 83% 67% 33% 83% 50% 
Lip 33% 17% 50% 0% 50% 67% 
Lys 17% 67% 50% 50% 67% 0% 
Myo 50% 0% 0% 33% 50% 17% 
PhosB 67% 33% 17% 0% 17% 17% 
Total 33% 44% 37% 31% 44% 35% 
 
 
Table 5.S4  Identification of 60 unknowns protein samples with LDA using -Gal/AuNP sensor array. 
Table continues on the next page. 
 
Fluorescence response pattern Identification Accuracy
Entry NP1- 
(-Gal) 
NP2- 
(-Gal) 
NP3- 
(-Gal) 
NP4- 
(-Gal) 
NP5- 
(-Gal) 
NP6- 
(-Gal) Proteins YES/NO 
1 0.0249 5.0111 7.0148 0.0265 7.7240 6.0431 PhosB YES 
2 -0.0319 7.0499 1.0191 0.0454 2.0664 7.9505 Myo YES 
3 -0.0241 4.0722 0.2621 -0.0477 3.5312 2.8284 Fer YES 
4 0.0432 19.0053 0.9033 0.0577 0.3114 6.2252 Lys YES 
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5 0.0482 42.0235 2.0051 -0.1494 0.9479 2.6495 Amy YES 
6 -0.0532 20.0375 7.0020 0.0513 5.0730 14.7841 Lip YES 
7 -0.1396 4.0600 3.0306 0.0184 3.5895 2.9529 CytC YES 
8 -0.0477 10.1205 0.1779 -0.0306 0.1808 11.3290 HSA YES 
9 0.0490 22.0385 1.0080 0.0366 0.2627 7.9681 Lys YES 
10 -0.0159 3.0547 0.0240 -0.0401 2.4212 5.2937 Fer YES 
11 -0.0519 27.0321 6.0071 0.0481 5.1727 12.4804 Lip YES 
12 0.0406 6.0647 4.0280 0.0505 1.3679 7.6684 PhosB YES 
13 -0.0690 27.0339 7.0287 0.0546 4.0528 13.9802 Lip YES 
14 0.0669 25.0304 0.9457 0.0471 0.1769 8.4429 Lys YES 
15 0.0235 14.0188 0.2401 0.1601 0.1327 12.9316 HSA YES 
16 -0.0725 8.0147 1.0279 0.0063 1.6280 9.0444 Myo YES 
17 0.0947 5.0075 4.0441 0.0454 2.0443 2.8999 CytC YES 
18 0.0653 7.0399 3.1420 0.0542 1.6320 1.6501 Fer NO 
19 -0.0368 11.1823 0.1548 0.0364 0.2355 11.8070 HSA YES 
20 0.1032 4.0846 2.9033 0.0637 2.1633 1.9459 CytC YES 
21 0.0270 8.0277 4.3149 -0.0027 0.7895 7.4108 PhosB YES 
22 -0.0127 50.0125 2.0083 -0.0249 0.2990 2.6078 Amy YES 
23 0.0173 5.0105 3.0119 0.0290 2.3539 1.0394 CytC YES 
24 -0.0205 8.0175 2.0432 0.0410 1.5333 9.0862 Myo YES 
25 -0.0082 13.0109 0.2192 -0.0301 0.1516 11.8710 HSA YES 
26 0.0248 20.0153 7.0042 0.7316 5.4685 13.0649 Lip NO 
27 -0.0128 44.0447 1.8053 0.0241 4.2127 7.1356 Amy YES 
28 0.0985 8.1151 6.0505 0.1189 0.8590 6.8917 PhosB YES 
29 -0.0338 3.0126 1.0091 5.0363 1.5770 2.1641 BSA YES 
30 -0.0114 45.0051 1.0187 -0.0367 0.7776 2.5967 Amy YES 
31 -0.0702 0.0299 -0.1050 -0.0455 2.4480 2.2238 Fer NO 
32 -0.0356 13.1249 0.2015 -0.0542 0.1703 12.8905 HSA YES 
33 -0.0261 6.0661 0.3170 -0.0571 2.8549 4.5573 Fer YES 
34 -0.0291 5.1087 2.0284 -0.0303 1.6971 6.5164 Myo YES 
35 0.1081 4.4278 3.0256 0.0358 3.0605 1.9780 CytC YES 
36 -0.0332 0.2987 0.0992 -0.0133 8.2027 6.8927 Fer YES 
37 0.0514 2.8060 4.8809 6.0245 2.1747 8.1074 BSA YES 
38 0.1259 6.0918 3.9306 0.0217 1.4871 2.1888 CytC YES 
39 -0.0205 26.1369 5.5155 0.0530 4.1899 7.7610 Lys YES 
40 0.2482 21.5107 0.8112 0.0423 0.2183 14.3341 Lip YES 
41 -0.0620 7.7939 0.4299 0.0339 1.8662 6.7561 Fer NO 
42 0.3158 15.3109 0.2225 -0.0416 0.2131 14.1598 Lip NO 
43 0.0208 19.9544 6.2423 0.0622 7.4915 15.0587 Lip YES 
44 0.0391 26.8454 1.5656 0.0363 0.2279 7.7122 Lys YES 
45 0.0373 48.5690 2.0407 0.0460 0.9108 3.7984 Amy YES 
46 0.0305 3.2047 1.4620 3.0280 1.6631 2.9823 BSA YES 
47 0.0399 23.0935 1.0030 0.0393 0.3487 7.8088 Lys YES 
48 -0.0232 4.0325 0.0346 -0.0316 2.5385 5.0346 Fer YES 
49 0.0381 23.6552 7.0022 0.0383 3.0861 13.4142 Lip YES 
50 0.0367 3.2249 2.0097 4.0454 2.7286 4.4868 BSA YES 
51 0.0365 47.5912 1.0886 -0.0317 0.5385 2.8833 Amy YES 
52 -0.0249 5.3064 0.0251 -0.0541 3.0858 5.1605 Fer YES 
53 0.0265 25.0879 1.0192 0.0353 0.5735 7.2697 Lys YES 
54 -0.0217 4.1281 0.1720 -0.0463 5.0178 4.4913 Fer YES 
55 0.0197 18.1657 7.0109 0.0497 7.5318 11.8303 Lip YES 
56 0.0453 47.2604 2.0273 -0.0354 0.6315 3.3308 Amy YES 
57 -0.0195 3.7982 1.2125 4.0348 2.5901 2.6594 BSA YES 
58 -0.0167 14.0147 0.2106 -0.0469 0.1838 12.1914 HSA YES 
59 0.0454 4.0803 1.2043 5.0537 2.4238 3.1062 BSA YES 
60 0.0405 41.4076 1.1746 -0.0591 0.9762 2.8994 Amy YES 
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Figure 5.S27  These pictures compare the physical state and color of the concentrated human urine proteins 
with the original human urine samples (water is used as reference in terms of both turbidity and color). On 
the gel electroporesis8, no urine proteins are lost during the binding step, as can be seen by examining the 
binding flowthrough. Line U is 30 µL of input human urine, line F is the binding flowthrough, and line P is 
30 µL of the eluted protein.  
 
 
 
 
 
Figure 5.S28 Protein purification. Purification is based on spin column chromatography using Norgen’s 
property resin as an ion exchanger. The resin has poor affinity for monovalent and divalent cations, making 
it an effective resine removal of salts.  Urine proteins are preferentially purified from all other urine 
components including salts and other wastes. 
 
 
 
 
 
 
 
 
                                                 
8 Proteospin Urine Protein Concentration Kits, Norgen Biotek Corporation. 
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Table 5.S5 Sources of urine proteins including soluble proteins and protein components of solid phase 
elements.9  
 
 
 
 
 
 
 
 
 
 
                                                 
9 T. Pisitkun, R. Johnstonen, M. A.  Knepper   Molecular & Cellular Proteomics 5:1760-1771, 2006. 
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Figure 5.S29  Gel electrophoresis of -gal and nanoparticles NP1-NP6: a) before staining and b) after 
staining. The concentration of enzyme was fixed at 8 M as well as NP1-NP6 concentrations. The average 
size of the core metal was determined from a population of 200 nanoparticles by both TEM and image J 
and expressed in average diameter  its standard deviation between runnings. Zeta potential were 
measurements in 5 mM phosphate buffer, pH = 7.4. 
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Figure 5.S30  Zeta potential of -Gal was measured in 5 mM phosphate buffer at pH 7.4. The charge 
average of -Gal was -22.67  1.53 mV. 
 
 
 
 
Figure 5.S31  Zeta potential of NP1-NP6 was measured in 5 mM phosphate buffer at pH 7.4. The overall 
charges of these cationic AuNPs are on the range of + 20-25 mV. 
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Figure 5.S32  Dynamic light scattering (DLS) of -Gal was measured in 5 mM phosphate buffer at pH 7.4. 
The size average of -Gal was 18.55  1.71 nm. 
 
 
 
 
Figure 5.S33 Dynamic light scattering (DLS) of NP1-NP6 was measured in 5 mM phosphate buffer at pH 
7.4. The overall sizes of these cationic AuNPs are on the range of 10.57-17.81 nm. 
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Table 5.S6 Physical properties of the proteins used as sensing targets in phosphate buffer solution at pH 
7.4.  
 
Samples‡ 
(n = 6) 
DH 
 (nm) 
 Potential 
(mV) 
280 = M-1 cm-1 
-Amylase (-Am) 7.80.4 
(0.432) 
-8.60.9 130000 
Bovine serum albumin (BSA) 8.90.3 
(0.317) 
-10.30.1.4 46860 
Cytochrome c (CytC) 4.40.5 
(0.317) 
+6.291.5 23200 
Ferritin (Fer) 27.30.9 
(0.251) 
-21.73.2 950000 
Human serum albumin (HSA) 7.60.5 
(0.707) 
-8.80.1.8 37800 
Lipase (Lip) 4.90.8  
(0.493) 
-12.10.7 54350 
Lysozyme (Lys) 3.90.5 
(0.317) 
+4.50.5 38000 
Myoglobin (Myo) 4.60.3  
(0.668) 
-12.50.3 13940 
Alkaline phosphatase (PhosB)  13.10.7  
(0.459) 
-17.61.4 62780 
 ٭Note: The parenthesis adjacent to the hydrodynamic diameter (DH) is the corresponding polydispersity 
index. 
 ‡ Proteins in italics are found in human urine. 
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Figure 5.S34  Gel electrophoresis of -Gal and AuNPs with varying molar ratios (enzyme-AuNP adducts) 
of a) NP1, b) NP2, c) NP3, d) NP4, e) NP5, and f) NP6. The concentration of the enzyme was 2 M. 
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Figure 5.S35  As control experiment, gel electrophoresis of -Gal and both negative charge NPCO2 (26-
mercapto-3,6,9,12,15-pentaoxahexacosan-1-oate capping the metal core)10 and neutral charge NPOH (23-
mercapto-3,6,9,12-tetraoxatricosan-1-ol capping the metal core) with varying molar ratios (enzyme: NP) of 
a) before staining NPCO2, b) after staining NPCO2, c) before staining NPOH, d) after staining NPOH. The 
concentration of the enzyme was 2 M. As it can be seen on the gels b) and d) anionic AuNPs and neutral 
AuNPs do not interact strongly with the enzyme, -Gal. 
 
 
 
 
                                                 
10 R. Hong, N. O. Fischer, A. Verma, C. M. Goodman, T. Emrick, and V. M. Rotello J. Am. Chem. Soc., 2004, 126 (3), pp 739–743 
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Figure 5.S36 Fluorescence titration curves for the complexation of -Gal (0.5 nM) with cationic gold 
nanoparticles (NP1-NP6).  The inhibition study was measured following the addition of cationic 
nanoparticles (0-100 nM) with an excitation wavelength of 455 nm. 
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5.4.7 Thermodynamic parameters for the enzyme-nanoparticle conjugate 
 
Both the binding constant (Ks) and the binding ratio (n) between -Gal and AuNPs could 
be quantified using the activity titration curves through nonlinear least-squares curve 
fitting analysis combined with gel electrophoresis. The experimental ratios of 
nanoparticles to -Gal needed to yield ~1% enzyme activity ranged from 4.0 for NP2-
NP3 to 7.0 for NP1 (see Table S7 and Figure S36).  The inhibition of -Gal activity 
strongly depends on the chemical structural changes of the peripheral ligands on the 
AuNPs, as shown in Table S7. Complex stabilities vary within approximately one order 
of magnitude (G  9 KJ mol-1), and the binding stoichiometry (n) between each AuNP 
and the enzyme vary from 4 to 7, since they possess different affinity. These observations 
indicate that the subtle structural changes of the nanoparticles end groups significantly 
affect the affinity for the enzyme. Under these conditions, it is estimated that >80% of 
NP1-NP6 is bound to the -Gal, based on the binding constant listed on Table S7, 
allowing fluorescence enhancement through both subsequent displacement enzymatic 
reaction. 
 
Table 5.S7 Binding constants (KS) and binding stoichiometries (n) between -Gal and several cationic 
nanoparticles (NP1–NP6) in desalted urine as determined from both activity assays and gel. 
 
Nanoparticles KS (1010 M-1) -∆G (kJ mol-1) n 
NP1 1.30 57.3 6 
NP2 0.31 53.8 4 
NP3 0.65 55.6 4 
NP4 1.78 58.1 7 
NP5 12.94 63.0 6 
NP6 6.90 61.4 5 
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Figure 5.S37 Gel electrophoresis confirms the hypothesis that the displacement assays of the enzyme by 
proteins take place.  Agarose gel electrophoresis a) shows the displacement assay of -Gal by two 
proteins HSA (-) and lysozyme (+): i) 8 M -Gal, ii) 8 M HSA (notes that the broad peak is probably 
due to high concentration of the protein), iii) Lysozyme (notes that the broad peak is probably due to high 
concentration of the protein), iv) 8 M NP2, v) 2 M of -Gal and 8 M NPTOH, vi) 1:4 molar ratio 
(enzyme : NP2), vii)  1:4 molar ratio (-Gal : NP2) and 1 M HSA, viii) 1:4 molar ratio (enzyme : NP2) 
and 1 M lysozyme and ix) 2 M -Gal  and 1 M HSA confirming the no interaction between these two 
proteins. Agarose gel electroporesis b)  shows the displacement assay of -Gal by two proteins BSA (-) 
and Ferritin (-): x) 8 M -Gal, xi) 8 M BSA (notes that the broad peak is probably due to high 
concentration of the protein), xii) Ferritin (notes that the broad peak is probably due to high concentration 
of the protein), xiii) 8 M NP2, xiv) 2 M of -Gal and 8 M NPTOH, xv) 1:4 molar ratio (-Gal : NP2), 
xvi)  1:4 molar ratio (enzyme : NP2) and 1 M BSA, xvii) 1:4 molar ratio (enzyme : NP2) and 1 M 
Ferritin, xviii) 2 M -Gal  and 1 M BSA confirming that there is no interaction between these two 
proteins and xix) 2 M -Gal  and 1 M Ferritin confirming that there is no interaction between them. 
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Table 5.S8 Final and initial kinetics ratio of the fluorescence response patterns of -Gal and six AuNP 
(NP1-NP6) adducts against various target proteins  standard deviation (SD).  Each value represents an 
average of six parallel measurements. 
 
 
 
Table 5.S9 Training matrix of activity response patterns generated from -Gal/AuNP sensor array (NP1–
NP6) and the fluorogenic substrate (4-Methylumbelliferyl-beta-D-galactopyranoside) against various 
proteins (concentration = 1 nM). †  Table continues on the next page. 
 
Protein NP1 NP2 NP3 NP4 NP5 NP6 
-Amy 0.160975 3.393432 1.251925 -0.499563 0.072658 0.786185 
-Amy 0.119801 2.838373 1.658166 -0.359135 0.065237 0.664113 
-Amy 0.360905 3.525645 1.576092 -0.578533 0.042495 0.617349 
-Amy 0.123519 3.427957 1.378307 -0.575258 0.037157 0.557427 
-Amy 0.146484 3.781986 1.276771 -0.552547 0.021673 0.549194 
-Amy 0.119801 2.805677 1.594953 -0.614698 0.047126 0.540163 
BSA -0.524773 0.855423 0.368644 -0.042752 0.112765 1.699626 
BSA -0.407967 0.518049 0.358356 -0.212016 0.144267 0.408964 
BSA -0.435635 0.122587 0.872029 -0.177976 0.304944 1.674564 
BSA -0.425384 0.344485 0.444321 -0.122473 0.117598 0.454712 
BSA -0.440822 0.281023 0.286352 -0.129752 0.245323 0.838603 
BSA -0.510731 0.380946 0.518147 -0.113815 0.110997 0.826483 
CytC 0.035445 0.235972 0.477981 0.018681 0.149347 0.689965 
CytC 0.016592 0.487015 0.726525 0.010589 0.152206 0.731896 
CytC 0.018037 0.474577 0.569288 0.029653 0.175445 0.291318 
CytC 0.025684 0.317109 0.925419 0.040126 0.184414 0.389811 
CytC 0.011405 0.520908 0.601658 0.067659 0.141485 0.705795 
CytC 0.024912 0.407391 0.797416 0.005288 0.271643 0.298903 
Fer 0.003009 0.706992 0.048231 0.108201 0.175369 0.911452 
Fer -0.004823 0.685545 0.037454 -0.014575 0.527787 1.088146 
Fer -0.002341 1.132817 0.033757 -0.010029 0.560338 1.103283 
Fer -0.000267 0.886735 0.067819 -0.003723 1.111381 1.023901 
Fer -0.005135 1.139926 0.034846 -0.006647 0.778952 0.737603 
Fer -0.000593 0.560372 0.054377 -0.013032 0.426158 0.410803 
HSA 0.156082 -0.007475 -0.049664 0.065918 -0.173453 0.044086 
HSA 0.008484 -0.068359 -0.084735 0.041808 -0.152816 0.126597 
HSA 0.017289 -0.078791 0.045644 0.054551 -0.074029 0.069858 
HSA -0.050856 -1.088342 -0.127892 0.075639 -1.088317 0.034675 
HSA 0.114875 -1.690797 -0.146809 0.071153 -1.556754 0.071189 
Proteins (Vmax/Vo,max) 
  NP1 SD NP2 SD NP3 SD NP4 SD NP5 SD NP6 SD 
-Amy 1.162744 0.089064 3.828086 0.335818 2.401873 0.169194 0.482782 0.089669 1.045633 0.017870 1.581139 0.088925 
BSA 0.566856 0.045598 1.357927 0.215107 1.456985 0.202390 0.870069 0.056741 1.165084 0.078856 1.923542 0.538564 
CytC 1.020838 0.008033 1.349411 0.095001 1.657639 0.158399 1.027977 0.021659 1.171242 0.046114 1.486211 0.199757 
Fer 0.998399 0.002915 1.731210 0.209064 1.044367 0.013751 1.009791 0.047099 1.570519 0.305616 1.825326 0.250235 
HSA 1.022090 0.093190 0.578550 0.061970 0.593520 0.082680 1.053750 0.020060 0.198600 0.078690 1.067530 0.030660 
Lip 1.142678 0.111317 1.119827 0.032988 2.167052 0.265922 0.462804 0.448489 1.368664 0.163287 1.414100 0.097572 
Lys 1.214415 0.071499 2.421471 0.231323 1.189766 0.081647 1.006598 0.004832 1.015704 0.008186 2.421105 0.244526 
Myo 1.212988 0.055828 1.310051 0.153280 1.320058 0.194570 1.413432 0.059226 1.109101 0.036296 2.249909 0.278100 
PhosB 1.017318 0.008850 1.480974 0.207608 2.102657 0.339915 1.010170 0.009593 1.048541 0.033976 2.465599 0.190674 
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HSA -0.105869 -0.012866 -2.169627 0.021359 -1.983362 0.085226 
Lip 0.146105 0.110819 1.179293 -0.316738 0.272846 0.578538 
Lip 0.071871 0.119053 1.110435 -0.341516 0.325371 0.453623 
Lip 0.287884 0.188278 1.532652 -0.442879 0.551288 0.268081 
Lip 0.272863 0.189773 1.480295 -0.468783 0.223874 0.505244 
Lip 0.145567 0.110815 1.199872 -0.258125 0.294458 0.427209 
Lip -0.019982 0.119053 0.770309 -1.474511 0.645517 0.414082 
Lys  0.157841 1.338209 0.276587 0.003676 0.026419 1.161619 
Lys  0.345268 1.835289 0.322254 0.015918 0.006708 1.443934 
Lys  0.152547 1.650511 0.153046 0.006084 0.018897 1.793173 
Lys  0.187049 1.324925 0.183459 0.006877 0.006816 1.822576 
Lys  0.276511 1.837733 0.100717 0.001406 0.014839 1.538729 
Lys  0.239768 1.951802 0.146523 0.006601 0.024864 1.323167 
Myo 0.278681 0.571847 0.506194 0.510292 0.155658 1.569218 
Myo 0.278686 0.326684 0.299995 0.391116 0.091697 0.981664 
Myo 0.147753 0.502119 0.493531 0.378591 0.167591 1.254026 
Myo 0.213595 0.412139 0.505887 0.457545 0.090003 1.571516 
Myo 0.163881 0.287045 0.137232 0.455627 0.097038 0.993984 
Myo 0.267342 0.067942 0.051702 0.348509 0.082618 1.618565 
PhosB 0.005053 0.365723 0.980838 0.005815 0.037872 1.771964 
PhosB 0.016418 0.589436 1.440413 0.023637 0.044395 1.485478 
PhosB 0.017679 0.39391 1.654379 -0.000182 0.112109 1.661552 
PhosB 0.032841 0.576594 0.756166 0.001841 0.025471 1.323127 
PhosB 0.019104 0.971739 1.202948 0.014152 0.029686 1.774132 
PhosB 0.018667 0.465411 0.836812 0.017257 0.05506 1.351331 
†  -Gal: -galactosidase,  (280 nm) = 1128600 M-1 cm-1; BSA: bovine serum albumin,  (280 nm) = 46860 M-1 cm-1; 
-Amy: -amylase,  (280 nm) = 130000 M-1 cm-1; PhosB: alkaline phosphatase,  (280 nm) = 62780 M-1 cm-1; Myo: 
myoglobin,  (280 nm) = 13940 M-1 cm-1; HSA: human serum albumin,  (280 nm) = 37800 M-1 cm-1; CytC: 
cytochrome c,  (280 nm) = 23200 M-1 cm-1; Lip: lipase:  (280 nm) = 54350 M-1 cm-1; Fer: ferritin:  (280 nm) = 
950000 M-1 cm-1; Lys: lysozyme:  (280 nm) = 38000 M-1 cm-1. 
 
Table 5.S10 Accuracy of LDA classification of protein analytes (Conc. = 1 nM) from the complexes of the 
enzyme (-Gal) with individual cationic nanoparticles as sensors.  The values are taken from the 
Jackknifed classification matrix based on LDA analysis of the raw data (6 replicates) listed in Table S2. 
 
Protein NP1- 
(-Gal) 
NP2- 
(-Gal) 
NP3- 
(-Gal) 
NP4- 
(-Gal) 
NP5- 
(-Gal) 
NP6- 
(-Gal) 
-Amy 0% 100% 67% 17% 50% 33% 
BSA 100% 0% 33% 83% 17% 0% 
CytC 0% 17% 50% 33% 33% 0% 
Fer 100% 50% 100% 0% 67% 17% 
HSA 0% 33% 17% 67% 50% 100% 
Lip 33% 100% 17% 0% 33% 50% 
Lys 0% 100% 50% 83% 100% 17% 
Myo 0% 33% 17% 100% 67% 17% 
PhosB 67% 33% 17% 0% 17% 50% 
Total 33% 52% 41% 43% 48% 31% 
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Table 5.S11  Identification of 60 unknowns protein samples with LDA using -Gal/AuNP sensor array. 
 
Fluorescence response pattern Identification Accuracy 
Entry NP1- 
(-Gal) 
NP2- 
(-Gal) 
NP3- 
(-Gal) 
NP4- 
(-Gal) 
NP5- 
(-Gal) 
NP6- 
(-Gal) Proteins YES/NO 
1 0.014053 0.725769 1.387652 0.005863 0.038725 1.576353 PhosB YES 
2 0.258481 0.490884 0.268747 0.458737 0.092778 1.437691 Myo YES 
3 0.011883 0.521188 0.616283 0.059383 0.159981 0.757299 CytC YES 
4 0.014982 0.519524 0.837249 0.032874 0.198373 0.629875 CytC YES 
5 0.018655 0.578776 0.987652 0.002845 0.024236 1.654218 PhosB YES 
6 0.123629 3.417971 1.373303 -0.574268 0.031153 0.553475 Amy YES 
7 0.015273 0.435886 0.858873 0.032992 0.198745 0.498731 CytC YES 
8 0.153256 0.188375 0.476772 0.510535 0.126633 1.352787 Myo YES 
9 0.129887 -0.098539 -0.079845 0.057954 -0.398851 0.096358 HSA YES 
10 0.260995 3.124645 1.560927 -0.478231 0.062795 0.617343 Amy YES 
11 0.024187 0.693764 1.469739 0.017652 0.044163 1.678362 PhosB YES 
12 -0.498358 0.273985 0.862731 -0.182616 0.239642 0.947846 BSA YES 
13 0.136414 3.683982 1.275778 -0.392842 0.031974 0.657194 Amy YES 
14 0.028965 0.649875 0.997631 0.016238 0.054543 1.423162 PhosB YES 
15 -0.454561 0.231843 0.792837 -0.173653 0.291861 1.629482 BSA YES 
16 0.302952 1.629439 0.183849 0.006896 0.018905 1.239049 Lys YES 
17 0.150965 2.934324 1.351625 -0.593519 0.042638 0.563719 Amy YES 
18 0.017873 0.939473 1.202948 0.014322 0.032645 1.736251 PhosB YES 
19 0.184932 0.209837 0.197235 0.456526 0.153874 0.152663 Myo YES 
20 0.217752 0.146651 1.135246 -0.419791 0.257746 0.351247 Lip NO 
21 0.187493 2.965968 1.275778 -0.534757 0.057723 0.627548 Amy YES 
22 -0.503725 0.489471 0.629473 -0.122792 0.147662 0.793848 BSA YES 
23 0.009714 -0.059456 -0.048769 0.039845 -1.098469 0.118985 HSA YES 
24 0.293129 1.498453 0.307858 0.003982 0.013851 1.497034 Lys YES 
25 -0.013265 0.102732 0.936304 -1.498739 0.615528 0.317413 Lip YES 
26 0.023876 0.362539 0.918031 0.042857 0.298437 0.393148 CytC YES 
27 -0.002182 1.112349 0.039762 -0.015416 0.929874 0.577653 Fer YES 
28 -0.421627 0.497436 0.463785 -0.114537 0.182949 1.459478 BSA YES 
29 0.028768 0.470821 0.758837 0.007925 0.239754 0.621475 CytC YES 
30 0.199835 1.593782 0.153952 0.005039 0.007942 1.374757 Lys YES 
31 0.258763 0.175245 1.562535 -0.865528 0.638771 0.456171 Lip YES 
32 -0.453511 0.467336 0.518487 -0.172652 0.218672 0.635572 BSA YES 
33 0.128634 0.188264 1.329782 -0.562564 0.296625 0.498782 Lip YES 
34 -0.050942 -0.907456 -0.876578 0.079871 -1.548758 0.087461 HSA YES 
35 0.273827 1.358371 0.296496 0.014713 0.006183 1.320896 Lys YES 
36 -0.004126 1.076529 0.047659 -0.002942 0.987631 0.678657 Fer YES 
37 -0.504781 0.187457 0.638245 -0.115578 0.142746 1.538495 BSA YES 
38 -0.000318 0.981453 0.070842 -0.001639 0.887382 1.017295 Fer NO 
39 0.003155 0.936953 0.052171 -0.010561 0.176537 1.081474 Fer YES 
40 0.225627 3.383681 1.476634 -0.413654 0.042795 0.557614 Amy YES 
41 -0.000341 0.983735 0.042988 -0.018775 0.987663 0.654926 Fer YES 
42 -0.479739 0.180497 0.519372 -0.139839 0.169624 0.408965 BSA YES 
43 0.193275 0.502132 0.507256 0.377671 0.156627 1.275536 Myo YES 
44 -0.003987 0.749757 0.042145 -0.014287 0.538756 0.827541 Fer NO 
45 0.175627 0.168979 1.261547 -0.652531 0.342883 0.463789 Lip NO 
46 0.129301 2.893649 1.571664 -0.456148 0.055136 0.636467 Amy YES 
47 0.035294 0.479481 1.531231 -0.001693 0.112352 1.466216 PhosB NO 
48 0.223183 0.374849 0.372634 0.451267 0.142731 0.996628 Myo YES 
49 0.224348 0.394871 0.351719 0.376235 0.112835 1.618565 Myo YES 
50 0.179835 1.529733 0.164895 0.015324 0.008231 1.524564 Lys YES 
51 0.097657 -0.087756 -1.287873 0.048752 -1.246568 0.107367 HSA YES 
52 -0.414592 0.598458 0.628468 -0.198481 0.212453 0.683825 BSA YES 
53 0.013626 0.493882 0.721265 0.019386 0.247387 0.987563 CytC YES 
54 0.106479 -0.678467 -1.974631 0.057439 -0.74631 0.097364 HSA YES 
55 0.217583 1.712908 0.243952 0.009737 0.001754 1.684731 Lys YES 
56 0.259853 1.824312 0.168956 0.006139 0.021745 1.302892 Lys YES 
57 -0.431676 0.529435 0.618468 -0.151652 0.161652 1.605218 BSA YES 
58 0.011834 -0.087646 -1.098136 0.069973 -0.90853 0.084627 HSA NO 
59 0.115538 0.146251 1.987377 -0.252165 0.572532 0.476556 Lip YES 
60 0.118801 2.825617 1.514973 -0.615836 0.049129 0.582761 Amy YES 
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CHAPTER 6 
 
DETECTING PATHOGENS USING  
GOLD NANOPARTICLE-PPE BASED ARRAY SENSING 
 
 
 
6.1 Introduction 
 
Fast and efficient identification of pathogens in water and biological fluids is an 
important issue in medical, forensic and environmental sciences.1  We demonstrate herein 
that non-covalent conjugates of gold nanoparticles2 and a fluorescent polymer3 identify 
bacteria effectively within minutes. Nanoparticle-bacteria interactions release the bound 
fluorescent polymer from the gold nanoparticle quencher, resulting in a “turn-on” of the 
polymer’s fluorescence.  The fluorescence responses generated by the bacterial surfaces 
provide an efficient means of their discrimination.3b We have differentiated 12 bacteria 
by this method.  Both species of bacteria as well as strains of a single species were 
discerned, without the use of antibodies3cd or radioactive markers.3e 
Conventional plating and culturing4 is generally used to identify causative 
bacterial pathogens in clinical environments. While technologically advanced systems 
have been developed for specific microorganisms (Table 6.1),5 these methods are 
complex or require sophisticated instrumentation.  Plating and culturing is accurate, but 
requires >24 h.   
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Table 6.1 Common methods to detect bacteria.5 Current technologies for bacterial sensing: 1) plating and 
culturing, biochemical tests, microscopy and luminescence, 2) immunological approaches, 3) nucleic acid 
probe-based methods (PCR, LCR), 4) mass spectrometry, 5) microarrays 6) biosensors. Despite sensitivity 
and selectivity, high cost of production, extended and complicated preparation and the often lengthy 
processing time by skilled operators are common disadvantages. 
 
 
Point-of-care treatment decisions are therefore made without access to 
microbiological information, potentially leading to the prescription of a sub-optimal 
antibiotic.  An example is the treatment of keflex- or methicillin-resistant S. aureus 
strains (MRSA) in community-acquired infections that require treatment with either sulfa 
drugs or vancomycin.6  Reisner et al. have investigated >9000 cases of clinically reported 
bacterial infections4 and found that 85-90% were due to only seven pathogens with S. 
aureus and E. coli being responsible for half of all infections.  A simple and rapid test 
that could discern clinically prevalent pathogens would be of great value, increasing the 
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efficacy of therapy, and reducing the occurrence of drug-resistant bacteria arising from 
inefficient antibiotic prescription.  
The detection of bacteria and pathogens plays a crucial role in food safety.7  For 
example, E. coli O157:H7 is a world-wide cause of foodborne illness, responsible for 
more than 2000 hospitalizations and 60 deaths directly related to bacterial infection each 
year in the United States.3d,8  Major outbreaks were associated with the contamination of 
unpasteurized juice, vegetables, water, etc.9  However, testing food for contamination is 
difficult due to the complex and/or lengthy analysis protocols.  
To address the issue of rapid identification of bacteria, we developed a protocol 
for bacterial sensing using an array of gold nanoparticle-conjugated polymer constructs.10 
This ‘chemical nose’ combines a series of analyte receptors to differentiate targets 
according to their unique response diagrams.  An anionic conjugated polymer (Figure 
6.1) is initially associated with cationic gold nanoparticles to afford fluorescence-
quenched complexes.  In the presence of bacteria, the negatively-charged bacterial 
surface11 competitively interacts with the nanoparticles to release the semiconducting 
polymer, restoring fluorescence; 1.6 nm gold nanoparticles12 seem to recognize patches of 
hydrophobic/functional surfaces on microorganisms and poly(L-lysine)-coated gold nano-
particles self-assemble with live bacteria through complementary electrostatic 
interactions.13 The π-conjugated polymer used in this study provides both multivalency20 
and the molecular wire effect13d to facilitate efficient signal generation in the sensing 
process. As functional “patches” (e.g. the charged residues and hydrophobic “hot spots”) 
are prevalent on cell and microbial exteriors,13d this strategy has potential applications in 
the identification of a wide variety of microorganisms.  
 193
 
 
 
Figure 6.1 Design of the nanoparticle-conjugated polymer sensor array.  a) Schematic representation of the 
displacement of anionic conjugated polymers from cationic nanoparticles by negatively charged bacterial 
surfaces.  b) Schematic illustration of fluorescence pattern generation on a microplate.   
 
6.2 Results and Discussion 
For the fluorophore displacement strategy we chose Sw-CO213d and three 
hydrophobic ammonium-functionalized gold nanoparticles (NP1-NP3)10b as sensor 
elements (Figure 6.2).  Fluorescence titration studies revealed that the cationic gold 
nanoparticles (NP1-NP3) quench the fluorescence of Sw-CO2 through formation of 
supramolecular complexes (Figure 6.3 and Table 6.2).10a 
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Figure 6.2. Receptor and transducer components of the bacterial sensors.  a) structural representation of 
three cationic gold nanoparticles (NP1-NP3) with various hydrophobic tails.  b) chemical structure of the 
conjugated polymer (Sw-CO2) featuring a branched oligo(ethylene glycol) side chain to suppress non-
specific polymer-microorganism interactions. 
 
 
Quenching by the nanoparticle is efficient: typically, an aqueous solution of the 
polymer (100 nM, based on 12 repeat units/polymer) with a stoichiometric amount of 
nanoparticle displays approximately 20% of the initial fluorescence of Sw-CO2 ( = 
0.33). The polymer and a stoichiometric amount of nanoparticles (NP1-NP3) were mixed 
in 5 mM phosphate buffer (pH 7.4) to yield nanoparticle-Sw-CO2 constructs with final 
polymer and nanoparticle concentrations of 100 nM and 10-40 nM, respectively.   
 
 195
 
Figure 6.3  Fluorescence titration curves for the complexation of Sw-CO2 (100 nM) with cationic gold 
nanoparticles (NP1-NP3).  The changes in fluorescence intensity at 463 nm were measured following the 
addition of cationic nanoparticles (0-150 nM) with an excitation wavelength of 400 nm.  The solid lines 
represent the best curve-fitting using a calculation model of a single set of identical binding sites. 
 
 
Table 6.2 Binding constants (KS) and binding stoichiometries (n) between anionic polymer (Sw-CO2) and 
three cationic nanoparticles (NP1-NP3) as determined from fluorescence titration. 
 
Nanoparticle KS / 108 M-1 G / kJ mol-1 n 
NP1 1.12 45.9 2.67 
NP2 2.75 48.1 10.0 
NP3 2.71 48.1 6.71 
 
The exposure of these three nanoparticle-Sw-CO2 constructs towards bacteria 
(OD600 = 0.05) induced different levels of fluorescence changes (Figure 6.4).  In most 
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cases, the fluorescence of the solution increases upon addition of the microorganisms.  
Significantly, the fluorescence changes exhibit reproducible patterns that depend upon 
the strains and classes of bacteria, indicating differentiation in the fluorophore 
displacement.  
 
 
Figure 6.4 Fluorescence response patterns of nanoparticle-polymer constructs in the presence of various 
bacteria (OD600 = 0.05).  Each value is an average of six parallel measurements and the error bars are 
shown.   
 
 
The 12 different bacteria display excellent separation when the fluorescence 
changes were plotted in a three-dimensional graph with the fluorescence change of the 
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three nanoparticles (NP1-NP3) as the respective axes (Figure 6.5), explicitly 
demonstrating the ability of these particles to discriminate between bacteria.  
 
 
Figure 6.5  Fluorescence response patterns of nanoparticle-polymer constructs in the presence of various 
bacteria (OD600 = 0.05). Three-dimensional representation of the fluorescence intensity changes against the 
three nanoparticle-polymer constructs. 
  
 
Initially both hydrophilic and hydrophobic nanoparticles were tested for the array.   
Upon incubation with bacteria, however, only the hydrophobic ones (NP1-NP3) 
produced significant fluorescence recovery.  Since hydrophobic and hydrophilic 
nanoparticles exhibit comparable binding affinities to Sw-CO2, the difference in the 
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fluorescence recovery indicates that the former strongly interact with bacteria.  A 
plausible explanation is that the hydrophobic parts of the nanoparticles interact with 
hydrophobic regions on the surface of the bacteria (e.g. the alkyl chains in teichoic acid), 
enhancing the electrostatic nanoparticle-bacteria interaction and, thereby, the 
fluorescence regeneration.  Both electrostatic and hydrophobic interactions seem to play 
important roles in the complexation of these particles with bacteria.  We plan to engineer 
nanoparticles with varying size, shape and hydrophobicity to augment the diversity in the 
fluorescence response. 
The fluorescence response patterns were analyzed through linear discriminant 
analysis (LDA), a quantitative statistical method extensively used in pattern 
recognition.14 Discriminant functions were deduced by maximizing the separation 
between classes relative to the variation within classes; LDA (Figure 6.6) transformed the 
raw patterns to canonical scores which are clustered into 12 groups according to the 
individual bacteria.   
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Figure 6.6 Canonical score plot for the fluorescence response patterns as determined with LDA.  The first 
two factors consist of 96.2% variance and the 95% confidence ellipses for the individual bacteria are 
depicted. 
 
 
 
The Jackknifed matrix (with cross-validation) in LDA reveals a 100% 
classification accuracy. We can discern all 12 microorganisms, which contain both Gram-
positive (e.g. A. azurea, B. subtilis) and Gram-negative (e.g. E. coli, P. putida) species.  
The LDA plot does not place the Gram-negative bacteria into an identifiable part of the 
graph, suggesting that other effects are also involved in the discrimination process.  
Different strains of E. coli can be easily discerned with the current sensor array but the 
three E. coli strains are not grouped particularly close in the LDA plot, indicating that 
subtle differences in the bacteria generate marked changes in response.  While the herein 
introduced concept is useful, it should be noted that the present system can merely 
differentiate bacteria in a clean buffered solution.  Although, it is suitable to analyze 
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many biological samples (e.g. water), pre-separation is required for most biological fluids 
as the concomitant proteins may affect the analytical results.  In this regard, the 
introduction of recognition elements specific for a bacterial surface on the nanoparticles 
would greatly address this problem.   
With the patterns shown in Figure 6.4 as the training matrix (3 constructs  12 
bacteria  6 replicates), we can identify unknown solutions of bacteria, randomly selected 
from the 12 bacterial species grown in different batches. Fluorescence response patterns 
generated from the three nanoparticle-polymer constructs were analyzed by LDA.  After 
transformation of the patterns to the canonical scores using the discriminant functions 
established on the training samples, the Mahalanobis distances of the new case to the 
respective centroids of 12 groups were calculated.  The closer a specific data set is to the 
center of one group, the more likely it belongs to that group. This assignment is based on 
the shortest Mahalanobis distance to the 12 bacteria in a three-dimensional space 
(canonical factors 1 to 3).  For the 64 samples studied, 61 were correctly identified; a 
detection accuracy of >95% demonstrates expediency and reliability.  The differentiation 
of the three strains of E. coli suggests suitable identification of pathogenic strains of 
normally harmless bacteria. 
 
6.3 Conclusion 
The integration of cationic gold nanoparticles with conjugated polymers provides 
an easily accessible yet potentially powerful biodiagnostic tool, in which the functional 
nanoparticles and the fluorescent polymer serve as the recognition elements and the 
transducer, respectively. The efficient quenching ability of gold nanoparticles coupled 
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with the ‘molecular wire’ effect of conjugated polymers compound the pronounced 
fluorescence response, which is dictated by the binding strength of the bacterium to the 
gold nanoparticle.  Therefore, manipulating the surface chemistry of gold nanoparticles 
and the constitution of the conjugated polymer will result in constructs with expanded 
binding capabilities.  By investigating the mechanism of binding which occurs between 
the hydrophobic nanoparticles and the conjugated polymer, we should be able to gain an 
understanding of the specific factors which govern fluorescence recovery.  Based on our 
ability to readily differentiate 12 different bacteria using only three systems, we speculate 
that the detection of any microorganism including the differentiation of pathogenic and 
resistant strains will be possible with this approach.  
 
6.4 Experimental Section 
6.4.1 Instrumentation and Materials.  The number average molecular weight (Mn = 25 
kDa), polydispersity index (PDI = 1.8) and degree of polymerization (Pn = 12) of Sw-
CO2 were determined by gel permeation chromatography. The cationic gold 
nanoparticles (NP1-NP3, d ~ 2 nm)10b were synthesized according to published 
procedures.  The bacteria, including Amycolatopsis azurea (A. azurea), Amycolatopsis 
orientalis subsp. lurida (A. orientalis subsp. lurida), Bacillus lichenformis (B. 
lichenformis), Bacillus subtilis (B. subtilis), Escherichia coli (BL21(DE3)) (E.coli 
(BL21(DE3)),  Escherichia coli (DH5α) (E.coli (DH5α)), Escherichia coli (XL1 Blue) 
(E.coli  (XL1 Blue)), Lactococcus lactis (L. lactis), Lactococcus plantarum (L. 
plantarum), Pseudomonas putida (P. putida), Streptomyces coelicolor (S. coelicolor), and 
Streptomyces griseus (S. griseus), were graciously donated by Dr. A. Bommarius 
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(Georgia Institute of Technology) and Dr. J. Hardy (University of Massachusetts 
Amherst).  Fluorescence intensity changes at 463 nm were recorded in 96-well plates 
(300 µL Whatman Glass Bottom microplate) on a Molecular Devices SpectraMax M5 
micro plate reader with an excitation wavelength of 400 nm. 
6.4.2 Bacterial Stock Preparation. Bacterial cells were grown in LB medium (3 mL) at 
37 ºC to an optical density of 1.0 at 600 nm.  The cultures were centrifuged (4000 rpm, 
15 min) and washed with phosphate buffer (5 mM, pH 7.4) three times, resuspended in 
phosphate buffer and diluted to an absorbance of 1.0 at 600 nm.  
6.4.3 Fluorescence Titrations. Fluorescence titration experiments determined the 
complexation between nanoparticles and Sw-CO2.  Fluorescence intensity changes at 463 
nm were recorded with an excitation wavelength of 400 nm.   
6.4.4 Fluorophore Displacement. Sw-CO2 and stoichiometric amounts of NP1-NP3, as 
determined by the fluorescence titration study were diluted with phosphate buffer (5 mM, 
pH 7.4) to solutions with a final Sw-CO2 concentration of 100 nM.  Each solution (200 
L) was placed into a well on the microplate.  After incubation for 15 min, the 
fluorescence intensity at 463 nm was recorded with an excitation wavelength of 400 nm.  
Next, 10 L of a bacterial solution (OD600 = 1.0) was added to each well.  After 
incubation for another 15 min, the fluorescence intensity at 463 nm was measured again.   
6.4.5 LDA Analysis. The fluorescence intensity before addition of the bacteria was 
subtracted from that obtained after addition of the bacteria to record the overall 
fluorescence response (∆I).  This process was completed for 12 bacteria to generate six 
replicates of each, leading to a training data matrix of 3 constructs  12 bacteria  6 
replicates that was subjected to a classical linear discriminant analysis (LDA) using 
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SYSTAT (version 11.0).  The Mahalanobis distances of each individual pattern to the 
centroid of each group in a multidimensional space were calculated and the case was 
assigned to the group with the shortest Mahalanobis distance.  A similar procedure was 
also performed to identify 64 randomly selected bacterial samples based on their 
fluorescence response patterns.  The classification of new cases was achieved by 
computing their shortest Mahalanobis distances to the groups generated through the 
training matrix (3 constructs (NP1-NP3)  12 bacteria  6 replicates).  During the 
identification of unknown bacteria, the bacterial samples were randomly selected from 
the 12 respective bacteria and the solution preparation, data collection, and LDA analysis 
were each performed by different researchers, resulting in a double-blind process. 
 
Table 6.S1 Training matrix of fluorescence response patterns generated from NP-(Sw-CO2) sensor array 
(NP1-NP3) against various types of bacteria   (OD = 0.05 at 600nm)  
 
Bacteria NP1 NP2 NP3 
A. azurea 1.320 8.363 7.758 
A. azurea 1.875 8.085 11.318 
A. azurea 1.643 6.843 7.628 
A. azurea 1.810 8.313 14.915 
A. azurea 1.283 7.735 5.742 
A. azurea 1.305 9.253 8.243 
A. orientalis subsp. lurida 30.668 32.533 25.598 
A. orientalis subsp. lurida 33.398 35.758 34.093 
A. orientalis subsp. lurida 31.160 34.170 37.205 
A. orientalis subsp. lurida 24.005 42.848 29.438 
A. orientalis subsp. lurida 29.243 26.558 38.220 
A. orientalis subsp. lurida 38.018 29.803 41.178 
B. lichenformis 195.318 124.438 140.640 
B. lichenformis 164.993 136.788 142.965 
B. lichenformis 163.903 123.355 154.520 
B. lichenformis 167.495 120.315 152.213 
B. lichenformis 194.945 133.145 158.730 
B. lichenformis 196.840 125.638 152.393 
B. subtilis 235.218 174.260 196.053 
B. subtilis 232.040 174.323 198.023 
B. subtilis 235.505 164.763 190.720 
B. subtilis 227.188 153.493 185.988 
B. subtilis 222.990 172.223 189.518 
B. subtilis 232.705 156.003 198.215 
E. coli (BL21(DE3)) 17.443 -26.578 -4.338 
E. coli (BL21(DE3)) 14.325 -28.983 -3.265 
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E. coli (BL21(DE3)) 15.175 -18.655 -4.203 
E. coli (BL21(DE3)) 16.275 -21.973 -2.668 
E. coli (BL21(DE3)) 19.198 -20.328 -4.965 
E. coli (BL21(DE3)) 17.968 -19.300 -2.903 
E. coli (DH5α) 9.335 61.068 105.800 
E. coli (DH5α) 11.843 52.365 109.883 
E. coli (DH5α) 12.013 60.328 100.815 
E. coli (DH5α) 12.360 55.873 92.673 
E. coli (DH5α) 9.893 57.170 94.078 
E. coli (DH5α) 9.860 70.608 116.055 
E. coli (XL1 Blue) 158.553 6.858 105.023 
E. coli (XL1 Blue) 171.280 3.700 90.718 
E. coli (XL1 Blue) 164.298 9.120 94.633 
E. coli (XL1 Blue) 177.520 6.280 115.653 
E. coli (XL1 Blue) 185.140 6.520 128.793 
E. coli (XL1 Blue) 178.785 5.023 126.658 
L. lactis 83.708 80.135 123.985 
L. lactis 63.935 97.958 129.270 
L. lactis 61.988 70.870 145.810 
L. lactis 88.515 95.460 133.183 
L. lactis 64.880 83.260 140.150 
L. lactis 87.530 101.368 153.320 
L. plantarum -6.428 -15.945 -12.628 
L. plantarum -7.400 -10.255 -9.813 
L. plantarum -3.183 -8.055 -8.163 
L. plantarum -4.235 -11.848 -13.960 
L. plantarum -7.460 -11.235 -7.278 
L. plantarum -3.730 -16.715 -13.028 
P. putida 133.883 77.358 84.243 
P. putida 138.650 91.008 104.965 
P. putida 126.060 62.608 77.063 
P. putida 145.825 73.970 92.140 
P. putida 146.658 71.735 84.733 
P. putida 150.738 84.933 109.765 
S. coelicolor 45.600 14.303 12.790 
S. coelicolor 38.213 20.615 16.215 
S. coelicolor 50.170 21.460 14.265 
S. coelicolor 46.963 15.608 10.325 
S. coelicolor 53.710 10.520 15.943 
S. coelicolor 63.685 19.250 21.253 
S. griseus 153.198 100.128 147.823 
S. griseus 135.543 104.763 142.028 
S. griseus 134.793 94.068 173.475 
S. griseus 139.033 84.893 162.908 
S. griseus 126.708 96.993 143.033 
S. griseus 144.808 92.060 166.973 
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Table 6.S2 Accuracy of LDA classification of bacteria analytes (OD600 = 0.05) from the complexes of the 
fluorescent polymer (Sw-CO2) with individual cationic nanoparticles as sensors.  The values are taken from 
the Jackknifed classification matrix based on LDA analysis of the raw data (6 replicates) listed in Table 
6.S1. 
 
Bacteria NP1-      
(Sw-CO2) 
NP2-      
(Sw-CO2) 
NP3-     
(Sw-CO2)
(NP1-NP3)- 
(Sw-CO2) 
A. azurea 100 83 83 100 
A. orientalis subsp. 
lurida 
83 100 100 100 
B. lichenformis 50 100 33 100 
B. subtilis 100 100 100 100 
E. coli (BL21(DE3)) 100 100 100 100 
E. coli (DH5α) 100 83 33 100 
E. coli (XL1 Blue) 50 83 17 100 
L. lactis 83 17 50 100 
L. plantarum 100 100 83 100 
P. putida 33 50 67 100 
S. coelicolor 67 83 83 100 
S. griseus 50 67 33 100 
Total 76 81 65 100 
 
 
 
Table 6.S3 Identification of 64 unknown bacterial samples with LDA using assemblies of Sw-CO2 and 
NP1-NP3. From the unknown bacterial samples, 61 out of 64 were correctly identified, resulting in an 
accuracy of 95.3%. 
 
Fluorescence response pattern LDA Identification Correct Identification Entry 
NP1 NP2 NP3 Bacteria Yes / NO 
1 142.533 75.388 92.108 P. putida YES 
2 182.858 127.943 149.733 B. lichenformis YES 
3 77.468 88.975 138.883 L. lactis YES 
4 30.539 33.934 34.990 A. orientalis subsp. lurida YES 
5 18.646 -23.160 -3.736 E. coli (BL21(DE3)) YES 
6 11.639 57.813 101.611 E.coli (DH5α) YES 
7 49.205 16.395 15.680 S. coelicolor YES 
8 141.730 78.216 92.954 P. putida YES 
9 174.401 7.234 109.469 E. coli (XL1 Blue) YES 
10 31.039 32.559 33.740 A. orientalis subsp. lurida YES 
11 204.689 153.540 205.669 B. subtilis NO 
12 232.956 165.099 192.426 B. subtilis YES 
13 1.955 7.644 9.180 A. azurea YES 
14 137.791 95.444 157.609 S. griseus YES 
15 182.769 129.653 151.988 B. lichenformis YES 
16 -5.669 -12.276 -10.574 L. plantarum YES 
17 182.396 124.340 149.264 B. lichenformis YES 
18 17.094 -24.721 -4.388 E. coli (BL21(DE3)) YES 
19 11.456 56.974 104.551 E.coli (DH5α) YES 
20 30.545 35.691 32.033 A. orientalis subsp. lurida YES 
21 174.821 6.005 113.186 E. coli (XL1 Blue) YES 
22 47.008 17.113 15.470 S. coelicolor YES 
23 232.094 165.985 191.679 B. subtilis YES 
24 1.936 9.194 9.234 A. azurea YES 
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25 11.245 59.013 102.789 E.coli (DH5α) YES 
26 171.610 5.960 110.973 E. coli (XL1 Blue) YES 
27 32.531 32.886 33.358 A. orientalis subsp. lurida YES 
28 140.358 96.693 155.983 S. griseus YES 
29 204.960 155.854 174.626 B. subtilis NO 
30 13.996 -23.933 -3.560 E. coli (BL21(DE3)) YES 
31 47.584 17.030 15.216 S. coelicolor YES 
32 -4.958 -13.494 -11.673 L. plantarum YES 
33 1.496 8.318 9.690 A. azurea YES 
34 -5.145 -11.691 -10.746 L. plantarum YES 
35 230.105 165.309 191.754 B. subtilis YES 
36 139.821 95.380 156.686 S. griseus YES 
37 142.581 75.099 92.426 P. putida YES 
38 175.360 6.960 113.460 E. coli (XL1 Blue) YES 
39 175.956 6.429 110.243 E. coli (XL1 Blue) YES 
40 177.206 131.679 153.993 B. lichenformis YES 
41 1.730 8.059 9.379 A. azurea YES 
42 143.094 77.610 91.804 P. putida YES 
43 176.345 7.005 109.099 E. coli (XL1 Blue) YES 
44 231.541 165.444 193.734 B. subtilis YES 
45 138.209 94.530 155.216 S. griseus YES 
46 179.203 126.666 151.850 B. lichenformis YES 
47 -5.656 -11.515 -11.946 L. plantarum YES 
48 48.960 17.104 17.126 S. coelicolor YES 
49 50.358 16.068 15.233 S. coelicolor YES 
50 -4.895 -12.941 -10.746 L. plantarum YES 
51 15.855 -23.191 -3.371 E. coli (BL21(DE3)) YES 
52 48.326 16.870 15.005 S. coelicolor YES 
53 10.729 61.713 104.940 E.coli (DH5a) YES 
54 15.985 -23.040 -3.790 E. coli (BL21(DE3)) YES 
55 51.345 17.133 14.724 S. coelicolor YES 
56 232.371 166.068 192.690 B. subtilis YES 
57 17.031 -24.114 -4.018 E. coli (BL21(DE3)) YES 
58 11.475 60.711 102.038 E.coli (DH5α) YES 
59 1.716 8.224 8.881 A. azurea YES 
60 174.838 6.734 115.711 E. coli (XL1 Blue) YES 
61 1.920 9.241 7.370 A. azurea NO 
62 139.838 95.484 159.461 S. griseus YES 
63 17.225 -24.289 -2.963 E. coli (BL21(DE3)) YES 
64 11.541 60.444 102.609 E.coli (DH5α) YES 
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CHAPTER 7 
 
COLORIMETRIC BACTERIA SENSING USING  
A HYBRID ENZYMATIC NANOCOMPOSITE BIOSENSOR 
 
 
 
 
7.1 Introduction 
 
Pathogenic bacteria cause 300 million cases of severe illness and many varieties of 
infections (e.g. cholera, syphilis, leprosy, meningitis, and pneumonia)1 and are estimated 
to kill over 2 million children every year.2 The great majority of these deaths occur in 
emerging nations where bacteria are present in drinking water and food.3 Several 
techniques4,5 are available in laboratories for pathogenic bacteria detection and 
identification, including i) plating and culturing, 6,7,8,9,10,11,12 ii) luminescence,13 iii) 
immunological approaches,7,8 iv) nucleic acid probe-based methods 9 (PCR, LCR), v) 
mass spectrometry,10 vi) microarrays,11 and vii) biosensors.12 Despite the sensitivity and 
selectivity of these systems, their applications are restricted because 1) high cost of 
production, 2) extended and complicated preparation, 3) often lengthy processing time by 
skilled operators, and 4) their limited use as in-situ analysis tool. Therefore, the need to 
develop fast, sensitive and reliable detection methods for sensing bacteria in the field is 
crucial in order to safeguard public health. Recent advances in nanotechnology have 
enabled the development of new diagnostic platforms aimed at more sensitive and faster 
pathogen detection. For example, Ji et.al.14 used positively charged amine-terminated 
polyamidoamine dendrimers on a silica surface to capture bacteria in a flow system. In 
this sensor, the membrane-reactive fluorophore, FAST DiA, functions as the reporter 
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fluorophore to transduce signals for detection and quantification of bacteria. The sensor 
surface was then imaged using a charge-coupled detector, reporting a detection limit of 1 
x 104 cells/mL.15 Gold nanoparticles (AuNPs) have been used to detect bacteria,16 virus,17 
cancer cells,18 and proteins.19 In 2005, Murphy et al.20  showed that CTAB 
(cetyltrimethylammonium bromide)-functionalized gold nanorods or nanospheres can 
conformally deposit to form monolayer on Bacillus cereus by strong electrostatic 
interaction. More recently, our group16a has demonstrated how this electrostatic assembly 
can be used for bacteria sensing through a nanoparticle-fluorescent polymer conjugate 
system. We were able to differentiate between 12 bacteria streams, which contain both 
Gram-positive (e.g. A. azurea, B. subtilis) and Gram-negative (e.g. E. coli, P. putida) 
species. Of particular importance was the ability to distinguish between differing strains 
of the same bacteria i.e BL21(DE3), DH5, and XL1 Blue strains of E. coli at 2x105 
cells/mL. While this nanoparticle-fluorescent polymer method was quite effective for 
bacterial sensing, it had three key limitations for implementation in our desired goal of 
point-of-use drinking water analysis. First, the limits of detection (LOD) of the 
fluorophore displacement assay were 105 bacteria/mL, far higher than is required for 
application in either environmental testing (102 cells/mL)3,4a,5,15,21 or clinical 
applications, e.g. bacterial sepsis (<102cells/mL).15,22 Secondly the method was 
fluorometric, dependant upon instrumentation to read-out the sensor response. Finally, 
sensing was done in solution, requiring handling steps that would make the method 
cumbersome for in-field applications.  Therefore, we have designed and developed a fast 
and easy hybrid colorimetric enzymatic nanocomposite biosensor based on signal 
amplification schemes that provides high sensitivity for the detection and for the 
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recognition of pathogens in aqueous solutions. To test the robustness of our system, this 
approach is also translated to a test strip platform.  
The concept of enzyme amplified colorimetric sensing provides a platform with enhanced 
sensitivity. Our colorimetric sensor design features three main components: a) an enzyme 
to provide signal amplification (-Galactosidase, a tetramer 465 KDa (-Gal, 
1713.59.0 nm) with a pI value of 4.6, Figure 7.1b),23 b) a colorgenic substrate to 
provide color tuning i.e. chlorophenol-red--D-galactopyranside (CPRG), and c) a 
receptor to provide affinity binding with biomolecules (metal core gold nanoparticles ~2 
nm of diameter). Functionalized cationic AuNPs electrostatically bind to the anionic 
enzyme -Galactosidase, inhibiting the enzyme without denaturation (Figure 7.1a and 
Figure 7.S6 for more details). Displacement of the particle by bacteria restores -Gal 
activity towards the colorimetric substrate (CPRG) added to the system, generating a 
read-out signal that is amplified through enzymatic catalysis. We hypothesized that in 
this activity-turn-off system, the binding equilibrium between enzyme and AuNPs would 
be affected in the presence of bacteria, resulting from the competitive binding between 
enzyme/AuNPs complexes and bacteria. Released β-Gal from the complexes recovers its 
activity in the enzymatic reaction with CPRG, converting the binding event into a “turn 
on” fashion. During this process, the initial yellow color of the substrate is converted into 
a red color product, giving the colorimetric effect (Figure 7.1a). Since our sensor is based 
on enzymatic  colorimetric catalysis rather than indicator displacement assay (IDA)24 or 
analyte exchange our design should provide a fast, easy and sensitive biosensor able to 
detect bacteria a very low concentration. Our colorimetric sensor strategy provides two 
key advantages for on-site sensing: a) the use of enzyme-substrate as transduction 
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elements will amplify the response of the sensor, providing much greater sensitivity 
relative to simple colorimetric methods and b) appropriate choice of substrate will enable 
the colorimetric assay to provide direct visual output and eliminate the need for 
instrumentation. We do not discard the possibility that the size of our biosensors, which 
has smaller dimensions than a bacteria cell, could also contribute and make it possible to 
detect small quantities of bacteria in relatively large samples.23,25 
 
 
 
Figure 7.1  a) Design of enzyme-based sensing of bacteria: binding of nanoparticles to the bacteria surface 
activates the enzyme, generating a colorimetric response, b) Molecular structure of ligands attached to a 2 
nm core nanoparticles and enzyme structure used in this study.  
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7.2 Results and Discussion 
Most bacterial cell walls are negatively charged due to teichoic acids and 
lipopolysaccharides.26 The negative surface charge enables bacteria to bind with 
positively-charged materials, which subsequently provides a potential platform for 
bacteria sensors. As a starting point, we conducted an activity assay of -Gal-catalyzed 
hydrolysis of a colorimetric substrate at various concentrations of nanoparticles, showing 
a relative decrease in activity or no activity (color change) while mixed at appropriated 
stoichiometries (Figure. 7.2).  Typically, a concentrations of 0.5 nM of -Gal in 
phosphate buffer solution (5 mM, pH = 7.4) was incubated with various concentration of 
NP1-NP4 for 15 minutes and 1.5 mM of the chromogenic substrate (CPRG, max = 595 
nm) was added to NP-enzyme complexes (Figure 7.2 and Figure 7.S6). The normalized 
first-order rate of chromogenic substrate hydrolysis was plotted versus the molar ratio of 
nanoparticles to -Gal, and showed a tendency to decrease upon addition of 
nanoparticles, as shown for NP2 in Figure 7.2. To optimize the sensor response in 
solution, various ligand shells composed of different functional head groups where used 
for the designing of the cationic particles to optimize the supramolecular interactions i.e. 
hydrophobic interactions, π-π interactions and hydrogen bonding.19c These intrinsic 
physical properties can vary the affinity of NPs to both the enzyme and bacteria, giving 
various responses and limits of detection (LODs). After preliminary activity studies, NP2 
was chosen as our best enzyme inhibitor from the four cationic nanoparticles used in this 
experiment (Figure 7.2 and Figure 7.S6), inhibiting the -Gal activity at very low 
concentration.19  NP2 was also employed to give the lowest LOD among the NPs used on 
the bacteria detection (See Figure 7.S7). To verify this furthermore, inhibition of β-Gal 
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by NP2 was carried out and monitored by spectroscopy since the product, chlorophenol 
red, has maximal absorbance wavelength at 595 nm. As a control, the enzyme inhibition 
was also studied with neutral tetraethylene glycol (NPTEG) and carboxylate (NPCO2) 
functionalized nanoparticles. In addition, -Galactosidase (-Gal) was also used as a 
control to demonstrate that CPRG is specific only for -Gal. As seen in Figures 7.S8, 
only cationic particles i.e. NP2 nanocomposite sensor gave inhibition signals while 
neutral and negative particles, NPTEG and NPCO2, failed to inhibit enzyme initially due to 
lack of electrostatic interactions. As a consequence they are not able to block the active 
sites of the enzyme (Figure (s). 7.S6, 7.S7, and 7.S8). When -Gal was used with CPRG 
no activity was observed, confirming that the enzymatic colorimetric reaction is due to 
the specificity of CPRG to -Gal. This result clearly indicates that activity of -Gal is 
inhibited by nanoparticle binding. We observed that the inhibition depends on subtle 
structural changes of peripheral ligands on the AuNPs e.g. the linear end group (NP1) 
exhibited less suppression in activity than branched isomeric structure (NP2), See SI. 
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Figure 7.2 Inhibited activity assay of -Gal (0.5 nM) against 1.5 mM substrate CPRG upon addition of 
cationic NP2 in 5 mM phosphate buffer. The inset shows the kinetics of the absorption spectra before and 
after addition of NP2. The arrow in the inset indicates the direction of activity (0 nM indicates free enzyme 
and 5.95 nM indicates inhibited enzyme with NPs). 
 
As we addressed before, most bacterial cell walls are negatively charged due to teichoic 
acids and lipopolysaccharides.26 The negative surface charge enables bacteria to bind 
with positively-charged materials, which subsequently provides a potential platform for 
bacteria sensors. To address the objective of our study the negatively charged bacteria E. 
coli XL1 was chosen.32  Chromogenic substrate hydrolysis for the -Gal/AuNP 
conjugates against individual bacteria in buffer is summarized in Figure 7.3. The 
individual target bacteria, E. coli XL1, generated distinguishable and highly reproducible 
rates for the colorimetric effect, indicating the potential for the differentiation of bacteria 
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in terms of concentration (three replicates were carried out for each sample, and each 
sample was also replicated three times). The color changes were analyzed following the 
scheme depicted in Figure 7.3. Figure 7.3 presents the changes in kinetic absorbance of 
β-Gal/NP2 complex upon incubation with bacteria of different concentrations. Each 
concentration can be discerned not only by intensity curves and Vmax histogram but also 
by a well developed trend of color changes; Vmax is measured in units of CPRG quantity 
transformed per unit time related to 0.5 nM of β-Gal, see Figure 7.3a. The β-Gal/NP2 
complex was used here as a control experiment. Images were taken immediately after 
reading by an LCD camera to demonstrate this colorimetric effect, as well as by a 
fluorescence microscope to clarify a general idea of the bacteria density in solutions 
(Figure 7.3b). 
 
Figure 7.3 Limit of detection of E. coli using -Gal/NP2 nanocomposite. a) kinetic absorbance response 
upon addition of different bacteria concentrations, as control -Gal/NP2 nanocomposite was used without 
bacteria.  b) microplate wells showing the color change upon variation of bacteria concentrations. Phase 
contrast bright-field of the E. coli XL1 at different concentrations using fluorescence microscope at a 
magnification of 40X/0.55, ∞/1/FN22, using an Olympus inverted microscope at 400 nm wavelength. Note 
that the naked eye is extremely sensitive, able to detect concentration levels as low as 1x102 bacteria/mL. 
Scale bar is 10 m.  
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Upto this point, we have demonstrated that through appropriate choice of cationic gold 
nanoparticles we are able to completely inhibit -Gal activity through binding of the 
particles to the enzyme surface, and that afterward addition of bacteria restored enzyme 
activity, generating a colorimetric response. The high sensitivity of our -Gal/AuNP 
sensor can be attributed to signal self-amplification through the enzymatic reaction. 
As the colorimetric sensing system was optimized in aqueous solution with 
extremely low LOD of bacteria (1102 cells/mL), we investigated the application of our 
design to paper strips. As far as we know few colorimetric methods have been reported.27 
These can be semiquantitatively evaluated by visual read-out of the originated color in 
comparison to a reference color scale.28 A key issue is the response time. Rapid bacterial 
penetration occurs on highly porous papers while restriction of particle/enzyme 
conjugates to the surface takes place on less porous materials. Considering these issues, 
we explored a wide range of materials available to maintain the enzyme activity and the 
efficiency of enzyme inhibition and activity recovery process. GF/B binder-free 
microfiber filter (Whatman, cat. No. 1821021) was selected as the preliminary platform 
due to its high wet strength, high loading capacity and mainly binding-free property. 
Initial composition of our strip sensor was set up with 25 mM CPRG and 15 nM β-Gal, in 
a way to make the reaction take place at an appropriate speed at which the color 
converted from yellow to dark red within 10 minutes. Then inhibition studies, similar to 
the solution studies, were carried out to choose the stoichiometric amount of cationic 
particles (i.e. NP2) and β-Gal to form the hybrid enzymatic nanocomposite sensor [(β-
Gal/NP2) complex]. NPTEG and NPCO2 were also used, as control experiment and no 
inhibition was observed as expected (See Figure 7.4). β-Gal/NP2 complex was ultimately 
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induced by mixing β-Gal (15 nM) and NP2 (80 nM) and incubated for 15 minutes. To 
test the performance of our system on a paper strip, 3 L of CPRG (25 mM), complex 
solution and diverse solutions from 1108 to 1104 bacteria/mL of E. coli XL1 were 
spiked onto GF/B filter paper at pH 7.4. Results were taken 10 minutes later by an LCD 
digital camera and appropriate light sources were placed at fixed positions above the strip 
sensors. 
 
 
 
 
Figure 7.4 Enzymatic inhibition-colorimetric assay of β-Gal (15 nM) against 25 mM substrate CPRG upon 
addition of cationic, anionic and neutral nanoparticles. (a) carboxylate (NPCO2), (b) hydroxyl (NPTEG), and 
quaternary amine (NP2) functionalized gold on a platform testing. Inset shows total inhibition for the 
positive nanoparticle NP2 at 80 nM, while no inhibition was observed for both the anionic and neutral 
AuNPs even at 160 nM. 
 
The color changes on the strip platform were analyzed following the scheme depicted in 
Figure 7.5. The use of color imagery for sensing application has been previously 
reported.28 The RGB (red, green and blue) digital image features gradual changes in color 
of each spot correspondingly to the specific concentrations marked above the sensors. 
Though differences can be observed visually, splitting of channels into red, green and 
blue (Figure 7.5b) reveals the way how an individual spot is composed by these three 
additive primary colors. Consequently, this proves that different spots are colored 
differently due to our sensor response to different concentrations of bacteria. The plots of 
RGB colorimetric channels (all values were taken at least three times and error bars are 
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displayed as well) in Figure 7.5c helped to monitor the effect of color tunability of the 
biosensor on the platform testing, observing that 1×104 bacteria/mL can be distinguished 
from control (β-Gal/NP2 conjugate) and can be fixed as the limit of the detection of the 
platform testing. 
 
 
Figure 7.5 Schematic illustration of the RGB colorimetric analysis to monitor color changes on the GF/B 
filter paper spot at pH 7.4. a) imagine of the enzymatic activity response-colorimetric assay of the β-Gal-
NP2 complex upon addition of E. coli XL1 at different concentration, CPRG substrate was used as a 
control. b) red, green, and blue channels obtained from the original sample a) to differentiate between 
bacteria concentration. c) the extracted values of red, green, and blue channel from the original data a). This 
process is repeated at least three times for each measurement in a series of images. 
 
To further confirm this differentiation, a 3-D plot containing coordinates for each of the 
concentration RGB values are shown in Figure 7.6, displaying the colorimetric response 
that the β-Gal/NP2 conjugate experienced upon exposure to the respective bacteria 
concentration. It can be seen that the four concentration of E. coli XL1 could be readily 
discerned by the three RGB channel values as a resulted of the color tunability as well as 
the bacteria concentration. Clustering of raw RGB data of the colorimetric response allow 
the assessment of the discrimination capabilities of the sensor and demonstrates that the 
concentration of bacteria can be detected as low as 1×104 bacteria/mL, as shown in 
Figure 7.6.   
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Figure 7.6  Schematic 3-D illustration of the RGB colorimetric analysis showing the limit of detection on a 
platform testing spot. 
 
In order to test the generality and limitations of our sensor toward bacteria, three different 
bacteria strains of various sizes and surface properties (e.g. charge surface) were chosen.  
Gram-positive (i. e. S. griseus and B. subtilis) and Gram-negative bacteria (i. e. E. coli 
XL1) differ by their gross surface chemistries. Bacterial cell surfaces are inherently 
negatively charged. In Gram-negative bacteria,29,32  the outer cell wall is composed of a 
lipid membrane, lipopolysaccharides, and glycoproteins, which impart negative charge to 
the surface. In Gram-positive bacteria,29,32  the single-layer cell wall is comprised of a 
porous peptidoglycan layer30 with attached negatively charged31 teichoic acids, 
teichuronic acids, polyphosphates, and carbohydrates.32 
 221
Besides the relatively low LOD, our colorimetric sensing system also possesses a 
potential ability in discrimination of bacteria, proved in Figure 7.7. Both Streptomyces 
griseus (S. griseus) and Bacillus subtilis (B. subtilis), two gram-positive bacteria, are well 
separated from gram-negative E. coli XL1, no matter in more sensitive form of solution 
phase or on a platform testing. Our hypothesis is that Gram-negative cell contains an 
outer membrane composed by phospholipids and highly-charged lipopolysaccharides, 
resulting in a higher overall negative charge density on cell surface than that on Gram-
positive cell surface, for the overall charge on Gram-positive cell is due to the presence of 
phosphodiester bonds between teichoic acid monomers, as a result of these unique 
molecular signatures among bacteria strong or weak tunability of the color can be 
observed. 
 
 
Figure 7.7 Colorimetric differentiation of Gram-negative and Gram-positive bacteria species. a) in solution 
phase, b) on a platform testing spot. 
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7.3 Conclusion 
In this study, we have demonstrated that the appropriate choice of a hybrid enzymatic 
nanocomposite as an amplifier in a colorimetric sensor can dramatically increase the 
sensitivity of bacteria detection in solution as well as in a test strip platform, for example 
from 1105 to 1102 bacteria/mL (three order of magnitude in improvement), 
demonstrating the potential of this method for the detection of microbial contamination. 
Our current system changes from pale yellow to dark red color, providing highly visible 
response. However, the use of other substrates to optimize the read-out process can be 
explored. Greater sensitivity could be possible using other color combinations. We 
strongly believe that this colorimetric sensor with an appropriate number of receptors can 
generate an array that could be able to differentiate a very large number of bacteria 
species as well as bacteria strains. In our ongoing studies, we are exploiting both new 
alternative approaches for bacteria detection and new data analysis strategies to apply this 
methodology to more complex matrices featuring a large diversity of target analytes. 
 
7.4 Experimental Section 
7.4.1 Synthesis of Cationic Nanoparticles (AuNPs).  NP1-NP4, core diameter ~2 nm, 
were synthesized according to References,19 see SI for more details. The cationic AuNPs 
were very stable in aqueous solution. 
7.4.2 TEM Images: These images were obtained on a JEOL 100CX electron microscope 
operated at 100 keV and analyzed using Image J.  More than 200 AuNPs were taken as 
target samples to calculate the average diameters and size distributions (see Table 7.S1 
for more details). 
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7.4.3 Charges and Sizes: -Potential (ZP) and dynamic light scattering (DLS) were 
measured on a Malvern Zetasizer Nano ZS instrument. Each sample was scanned six 
times and an average value was reported (see Table 7.S1 for more details). 
7.4.4 Activity Assays: -galactosidase (-Gal) and the colorgenic substrate 
chlorophenol-red--D-galactopyranside, CPRG were purchased from Sigma-Aldrich.  In 
this study, nanoparticle and -Gal solutions were prepared in sodium phosphate buffer 
solution (5 mM, pH 7.4).  In the activity assay studies, -Gal (0.5 nM) was incubated 
with various concentrations of NP1-NP4 for 15 minutes and 1.5 mM of the colorgenic 
substrate (CPRG) was added.   As a control experiments, the enzymatic activity of -Gal 
was also monitored in the presence of neutral tetraethylene glycol and carboxylate 
functionalized nanoparticles as well as an enzymatic protein (-Gal). The -Gal stock 
concentration was 314 nM, while the stock concentrations of NP1-NP4 were prepared at 
100 nM. The inhibition studies in solution were carried out at pre-determined times by 
adding 5 L of CPRG (1.5 mM in PB buffer) and 5 L of PB buffer into 200 L -
Gal/AuNP solution.  The enzymatic activity was followed by monitoring product 
formation every 22 s for 15 minutes at 595 nm using a microplate reader (EL808 Bio-Tek 
Instruments, Inc.). The samples were measured in triplicate.  From the activity/inhibition 
studies, optimal concentrations of -Gal/AuNP complexes were obtained. Once the 
different inhibiting characteristics of the -Gal/AuNP complexes were established, 
stoichiometric amounts of -Gal and NP1-NP4 were used to the bacteria detection. In the 
case of the test strip platform, 25 mM CPRG and 15 nM β-Gal was set up in a way to 
make the reaction take place at an appropriate speed for tuning the color of the substrate 
from yellow to dark red within a pre-determined time i.e. 10 minutes. Once the different 
 224
inhibiting characteristics of the -Gal/NP2 complexes were established, stoichiometric 
amounts of -Gal and NP2 was used on the bacteria detection. NPTEG and NPCO2 were 
also used, as control experiment and no inhibition was observed as expected. The 
samples were measured in triplicate. 
7.4.5 Instrumentation.  Transmission Electron Microscopy (TEM) samples were 
prepared by depositing 3 L of a diluted aqueous solution of cationic gold nanoparticles 
(AuNPs, 5 M) onto a 300 mesh carbon-coated copper grid. The samples were dried in 
air at room temperature. TEM images were obtained on a JEOL 100CX electron 
microscope operated at 100 keV and analyzed using Image J.  More than 200 AuNPs 
were taken as target samples to calculate the average diameters and size distributions.  -
Potential (ZP) and dynamic light scattering (DLS) results were used to characterize the 
charge and the hydrodynamic diameter of both nanoparticles and proteins (Table 7.S1). 
Cationic gold nanoparticles were dissolved in sodium phosphate buffer (5 mM, pH 7.4) 
to make solutions at 5 M concentrations. The samples were filtered through a Millipore 
syringe-driven filter (0.22 μm) and injected into a folded capillary disposable cell.  In the 
case of the proteins, the samples were filtered through a Millipore syringe-driven filter 
(0.22 μm) and injected into the disposable cell. Both ZP and DLS were measured on a 
MALVERN Zetasizer Nano ZS instrument. Each sample was scanned six times and an 
average value was reported. 
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Table 7.S1 Characterization of NP1-NP4. The average size of the core metal was determined from a 
population of 200 nanoparticles by both TEM and image J and expressed in average diameter  its standard 
deviation between runnings. Zeta potential were measurements in 5 mM phosphate buffer, pH = 7.4. 
 
 
 
7.4.6 Synthesis of AuNPs 1-4.  Pentanethiol-coated AuNPs with core diameter 2 nm 
were synthesized using the Brust-Schiffrin two-phase synthesis method.1 Murray place-
exchange method2 was used to obtain the quaternary ammonium functionalized AuNPs 
1-4 (see Figures 7.S1-7.S4 for characterization).3  The cationic AuNPs were very stable 
in aqueous solution. 
 
 
 
 
 
 
 
 
 
                                                 
1 a) A. G. Kanaras, F. S. Kamounah, K. Schaumburg, C. J. Kiely, M. Brust, Chem. Commun. 2002, 2294. b) M. Brust, M. Walker, D. 
Bethell, D. J. Schiffrin, R. Whyman, J. Chem. Soc. Chem. Commun. 1994, 801. 
2 A. C. Templeton, M. P. Wuelfing, R. W. Murray, Acc. Chem. Res. 2000, 33, 27. 
3 a) C. C. You, O. R. Miranda, B. Gider, P. S. Ghosh, I. B. Kim, B. Erdogan, S. A. Krovi, U. H. F. Bunz, V. M., Nature Nanotech. 
2007, 2, 318-323. b) O. R. Miranda, H. T. Chen, C. C. You, D. E. Mortenson, X. C, Yang, U. H. F. Bunz, V. M., J. Am. Chem. Soc. 
2010, 132, 5285-5289 
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1H NMR spectra of NP1 after place exchange with AuS(CH2)4CH3 
 
 
 
Figure 7.S1 400 MHz 1H NMR of N-hexyl-23-mercapto-N,N-dimethyl-dimethyl-3,6,9, 12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP1 is ~ 2 nm (2.15  0.28 nm). 
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1H NMR spectra of NP2 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 7.S2 400 MHz 1H NMR of N-cyclohexyl-23-mercapto-N,N-dimethyl-3,6,9,12-tetraoxatricosan-1-
aminium capping the surface of the metal core gold nanoparticles after place exchange. The average 
diameter of the metal core NP2 is ~ 2 nm (2.09  0.27 nm). 
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1H NMR spectra of NP3 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 7.S3 400 MHz 1H NMR of N-benzyl-23-mercapto-N,N-dimethyl-3,6,9,12-tetraoxatricosan-1-
aminium capping the surface of the metal core gold nanoparticles after place exchange. The average 
diameter of the metal core NP3 is ~ 2 nm (2.12  0.21 nm). 
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1H NMR spectra of NP4 after place exchange with AuS(CH2)4CH3 
 
 
 
 
Figure 7.S4 400 MHz 1H NMR of N-(3-hydroxypropyl)-23-mercapto-N,N-dimethyl-3,6,9,12-
tetraoxatricosan-1-aminium capping the surface of the metal core gold nanoparticles after place exchange. 
The average diameter of the metal core NP4 is ~ 2 nm (2.14  0.25 nm). 
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7.4.7 Laser Desorption/Ionization Mass Spectrometry (LDI-MS).  
The LDI-MS analyses were done on a Bruker Autoflex III time-of-flight mass 
spectrometer (Autoflex III; Bruker Daltonics, Germany) using a Smartbeam laser 
(Nd:YAG, 355 nm). All mass spectra were acquired in reflectron mode. The ion source 
voltage 1 and 2 were set to 19.00 kV and 16.65 kV, respectively. The reflector voltage 1 
and 2 were set to 21 kV and 9.7 kV, respectively. The post ionization extraction delay 
was 10 ns. On this instrument, 100 laser shots were fired to acquire each spectrum, and 
positive ions were detected. A 2 μL of 1 μM AuNP water solution was applied to a MTP 
384 ground steel sample target and allowed to air-dry before LDI-MS. The calibration 
was done using positively charged gold clusters (i.e., Au+, Au2+, and Au3+). The LDI-MS 
results are consistent as previous reported research.14  
                                                 
4 a) Z.-J. Zhu, P. Ghosh, O. R. Miranda, R. W. Vachet, V. M. Rotello, J. Am. Chem. Soc. 2008, 130, 14139-14143 b) B. Yan, Z. J. 
Zhu, O. R. Miranda, A. Chompoosor, V. M. Rotello, R. W. Vachet, Anal. Bioanal. Chem. 2010, 396, 1025-1035. 
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Figure 7.S5 LDI mass spectra of AuNPs 1-4. The LDI-MS results are consistent as previous research.1 
Symbol key: @, Au2+ (m/z 393.9); #, Au3+ (m/z 590.9); MH+, the molecular ion corresponding to surface 
ligand; A, a fragment ion corresponding to a loss of H2S ([MH-H2S]+); B, ions corresponding to multiple 
losses of methylene groups from the alkane portion of the ligands; C, disulfide ions and their fragment ions 
forming from the initial pentanethiol capping group (i.e., C5H11S) and surface ligands; D, disulfide ions and 
their fragment ions forming from surface ligands.  
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Figure 7.S6  Inhibited activity titration for the complexation of -Gal (0.5 nM) with cationic gold 
nanoparticles (NP1-NP4).  The inhibition study was measured following the addition of cationic 
nanoparticles (0-100 nM) with an excitation wavelength of 595 nm. The -Gal stock concentration was 314 
nM, while the stock concentration of NP1-NP4 was 100 nM. For the activity/inhibition studies, optimal 
concentrations of -Gal/ AuNP complexes were obtained (-Gal = 0.5 nM and a) NP1: 12 nM, b) NP3: 9 
nM, and d) NP4: 35 nM). 
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Figure 7.S7 Change of the kinetic absorbance of several enzymatic nanocomposite sensors (β-Gal and 
NP1, NP2, NP3, and NP4) on the incubation of different bacteria concentrations. NP2 was employed to 
give the lowest limit of detection among the four nanoparticles used on the bacteria detection. In the inset, 
NPCO2  and NPTEG are negative and neutral nanoparticles used as references and no interaction is observed. 
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Figure 7.S8  a) Gel electrophoresis of -Gal and NP2 with varying molar ratios (enzyme-NP adducts, 1:4 
optimal molar ratio) after staining. The concentration of the enzyme was 2 M. b) As control experiment, 
gel electrophoresis of -Gal and NPTEG (23-mercapto-3,6,9,12-tetraoxatricosan-1-ol capping the metal 
core) with varying molar ratios (enzyme: NP) of after staining NPTEG. The concentration of the enzyme 
was 2 M. As it can be seen on the gel neutral NPs do not interact strongly with the enzyme, -Gal. 
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As a control, NPCO2 and NPTEG nanoparticles, bacteria, and -Gal in CPRG solutions 
were studied and no activity or colorimetric effect was observed as compared with NP2, 
confirming that the colorimetric sensing effect is only due to the hydrolysis of the 
substrate by the enzyme (Figure 7.4 and Figure (s). 7.S8 and 7.S9).   
 
Figure 7.S9 Change of the kinetic absorbance of several enzymatic nanocomposite sensors (β-Gal/NP2) on 
the incubation of different bacteria concentrations. In the inset, NPCO2  and NPTEG are negative and neutral 
nanoparticles used as references and no interaction is observed. Bacteria (E. coli XL1) and substrate as well 
as -Gal and substrate were also used as control experiments and no change of color was observed in the 
solutions. 
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CHAPTER 8 
 
SNIFFING CHANGES ON CELL SURFACES: DETECTION AND 
DIFFERENTIATION OF NORMAL, CANCEROUS, AND METASTATIC CELLS 
USING NANOPARTICLE-POLYMER SENSOR ARRAY 
 
 
 
8.1 Introduction 
 
Each cell type has unique molecular signatures that distinguish between healthy and 
diseased tissues.1 In the case of cancers, the distinctions between normal vs. tumor and 
benign vs. metastatic cells are often subtle.  The identification of cellular signatures for 
early cancer cell detection is a major hurdle for cancer therapy; the earlier these 
signatures can be established, the more effectively they can be treated.2 Cancerous cells 
are differentiated from non-cancerous ones on the basis of intracellular or extra cellular 
(cell surface) biomarkers. Detection methods based on intracellular biomarkers (e.g. 
DNA/RNA/Proteins) require the previous knowledge of specific mutations in 
DNA/RNA3 or changes in the regulation of protein expression inside the cells. Similarly, 
detection methods based on specific recognition of extracellular (cell surface) biomarkers 
such as histopathology,4 bioimaging,5 antibody arrays require previous knowledge of 
biomarkers on cell surfaces. Observation of over expressed antigens6 on tumor cells using 
antibody-based platforms have been explored using enzyme-linked immunosorbent assay 
(ELISA)7, surface plasmon resonance,8 nanoparticles,9 microcantilevers,10 carbon 
nanotubes,11 and expression microarrays.12 Antibody arrays provide an effective but 
complex approach for cancer detection, diagnosis and prognosis,13 however there is no 
single marker or a combination of biomarkers that has sufficient sensitivity and 
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specificity to differentiate between normal, cancerous, and metastatic cell types.14 Here 
we describe a detection system that is based on selective noncovalent interactions 
between cell surface components and nanoparticles-based sensor elements that does not 
require any previous knowledge of intracellular or extracellular biomarkers. 
The cell membrane surfaces consist primarily of a thin layer of amphipathic 
phospholipids, carbohydrates and many integral membrane proteins. The amount and 
types of which differ between species and according to function of cells.15,16 This results 
into distinct cell membrane composition in different cell types. Therefore, one can 
predict, however, that there will be physicochemical (i.e., charge, hydrophobicity etc.) 
differences between cell types and between healthy and cancerous cells. Such 
physicochemical differences could potentially be detected by an array-based “chemical 
nose” approach that relies on selective interactions between multiple reporter elements 
and the target cell. 
In chemical nose approach, an array of different sensors is used where every element in 
the sensor array responds to a number of different chemicals or analytes.17 A distinct 
pattern of responses produced from a set of sensors in the array provide a fingerprint that 
allows classification and identification of the analyte.18 The collection of sensors contains 
maximum chemical diversity as possible, so that array responds to largest possible cross 
section of analytes. The specific interactions involved between the reporter elements and 
the analyte are noncovalent and reversible. This approach provides an alternative to 
“lock–key” specific recognition19 and has been used to detect metal ions,20 volatile 
agents,21 aromatic amines,22 amino acids,23 and carbohydrates.24 In recent research we 
have demonstrated that the displacement of fluorescent polymers from differentially 
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functionalized gold nanoparticles with concomitant restoration of fluorescence provides 
an effective array-based method for the identification of proteins (Chapter 3).25  More 
recently, we have shown that this methodology can be used to differentiate between 
bacterial species, and even between different strains of the same species (Chapter 6).26 
We report here a particle-polymer array that distinguishes between healthy, cancerous and 
metastatic human breast cells, and differentiates isogenic healthy and transformed cells. 
  
8.2 Results and Discussion 
Our detection system is based on conjugates between three structurally related 
cationic gold nanoparticles (NP1–NP3, Figure 8.1a and Figure 8.S4) and the poly(para-
phenyleneethynylene) (PPE) polymer PPE-CO2 featuring charge multivalency27 and 
molecular wire properties28 (Figure 8.1a). In these noncovalent conjugates, the particle 
quenches the fluorescence of the polymer. In these non-covalent conjugates, the 
nanoparticle quenches the fluorescence of the polymer. The interactions between 
nanoparticles and anionic polymers are noncovalent, and predominantly electrostatic.  
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Figure 8.1 Molecular structures of nanoparticles and polymers, and schematic of fluorophore displacement 
cell detection array. a) molecular structures of the cationic gold nanoparticles (NP1-NP3) and the 
fluorescent polymer (PPECO2). b) displacement of quenched fluorescent polymer (dark green strips, 
fluorescence off; light green strips, fluorescence on) by cell (in blue) with concomitant.   
 
When mammalian cells were incubated with these nanoparticle-polymer complexes, 
there is competitive binding between nanoparticle-polymer complexes and cell types 
(Figure 8.1b). Because of their cationic surface, nanoparticles are expected to interact 
with phospholipids, membrane proteins and carbohydrates of the cell surface through 
both electrostatic and hydrophobic interactions. These interactions are responsible for 
displacement of the fluorophore polymer from the nanoparticle-polymer complexes 
generating a fluorescence response. The nanoparticles are expected to possess different 
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affinities for dissimilar cell surfaces depending on cell membrane composition and 
surface of nanoparticles. Selective displacement of the polymer from the particle by the 
cell surface regenerates fluorescence, transducing the binding event in a “turn on” 
fashion. 
The complex stability constants (KS) and association stoichiometries (n) for the particle-
polymer dyads were obtained through nonlinear least-squares curve-fitting analysis.29 
Complex stabilities vary within 1 order of magnitude (∆∆G  4.5 kJ mol-1), and the 
binding stoichiometry ranges from 2.5 for NP2 to 0.9 for NP3 (Figure 8.S3). After 
determining the saturation point for fluorescence quenching, (Figure 8.S3), the 
appropriate stoichiometries of particle and polymer were mixed in 5 mM phosphate 
buffer (pH = 7.4) to yield nanoparticle- PPECO2complexes with a final concentration of 
polymer of 100 nM and of nanoparticles 10-40 nM. The complexes of PPECO2 and NP1-
3 were then incubated with different cell types to determine changes in fluorescence 
intensities. We observed increases and decreases in fluorescence intensities depending on 
the cell type and the nature of nanoparticle-polymer complexes. Increased fluorescence 
intensities are due to the displacement of the PPECO2 polymer from the NP-PPECO2 
complexes by cell surfaces (Figure 8.1b), whereas decreases in the fluorescence 
intensities are due to the quenching of the residual PPECO2 fluorescence by the cell 
surfaces. These differences in the fluorescence patterns depend on the cell type and are 
reproducible. We have performed array-based s sensing using 9 gold nanoparticles that 
possess different head groups and interact differently with polymers (Figure 8.S4a). We 
studied their interactions with the different cell types listed in Table 8.1, focusing on 
which particle set can best differentiate between different particles (see below). From 
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studies, we have observed the maximum differentiation grouping using 3 nanoparticles 
NP1-NP3, as established through Jackknifed analysis (Figure 8.S4b). 
 
Table 8.1 Origin and nature of the normal, cancerous and metastatic cell lines used in 
this study (Color is only used to differentiate cell lines). 
 
 
8.2.1 Detection of Differences in Cell Types. As an initial test of our method we used 4 
different types of human cancer cells: HeLa (Cervical), HepG2 (Liver), NT2 (Testis) and 
MCF-7 (Breast). Fig. 8.2a presents the change in the fluorescence response for the 
nanoparticle-polymer supramolecular complexes upon addition of the different cancer cell 
types. Linear Discriminant Analysis (LDA) was used to statistically characterize the 
fluorescence changes. This analysis reduced the size of the training matrix (3 
nanoparticles x 4 cell types x 6 replicates) and transformed them into canonical factors 
that are linear combinations of the response patterns (3 factors x 4 cell types x 6 
replicates). The two canonical factors contain 96.6% and 3.3% of the variation, 
respectively as shown in Figure 8.2b.  In this plot, each point represents the response 
pattern for a single cell type to the NP-PPECO2 sensor array. In the canonical 
fluorescence response patterns, the different cell types are clustered into four non-
overlapping groups (95% level confidence ellipses, Figure 8.2b) with standard deviation 
of <5%. These initial results validate our ability to differentiate cancer cell types 
phenotypically based on their surface properties.  
Liver HepG2 Cancerous 
Cervix HeLa Cancerous 
Testis NT2 Cancerous 
MCF10A Normal Immortalized 
MCF-7 Cancerous 
Human cell lines 
Breast 
MDA-MB-231 Metastatic 
  
CDBgo Normal Immortalized  Mouse cell lines 
 
BALB/c mice 
(Breast) TD Cancerous 
 246
 
 
Figure 8.2 Detection of human cancerous cell lines. a) Change in fluorescence intensities (F − F0) for 4 
different cancer cell lines HeLa (Cervical), MCF7 (Breast), HepG2 (Liver) and NT2 (Testes) using 
nanoparticle-polymer supramolecular complexes. Each value is average of 6 parallel measurements. b) 
Canonical score plot for the two factors of simplified fluorescence response patterns obtained with NP–
PPECO2 assembly arrays against different mammalian cell types. The canonical scores were calculated by 
LDA for the identification of 4 cell lines. 
 
8.2.2 Detection of Normal/Cancerous and Metastatic Cells. An important issue in 
cancer therapy is assessing whether tissue/cells are healthy, or either benign or metastatic 
tumors. We chose three different human breast cell lines to test our sensor array in this 
application: MCF10A a normal breast cell line, MCF7 a cancerous but non-metastatic cell 
line, while MDA-MB-231 is a metastatic cancer cell line. The three cell lines show 
differential fluorescence patterns (Figure 8.3a); LDA of their response indicates a 100% 
accuracy of detection (Figure 8.3b).  
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Figure 8.3 Detection of normal, cancerous and metastatic human breast cells. a) Change influorescence 
intensities (F − F0) for 3 breast cell lines of different nature MCF10A (normal), MCF-7 (cancer) and MDA-
MB231 (metastatic) using nanoparticle-polymer supramolecular complexes. Each value is average of 6 
parallel measurements. b) Canonical score plot for the first two factors of simplified fluorescence response 
patterns obtained with NP–PPECO2 assembly arrays against different mammalian cell types. 
 
 
8.2.3 Detection of Isogenic Cell Types. The above studies suggest that we can 
differentiate normal, cancerous and metastatic cell types with our sensor array. Each of 
the three cell lines, however, came from different individuals. To provide a test bed where 
individual-to-individual variation is not present, we used three isogenic cell lines, 
CDBgeo, TD, and V14 cells. Each of these isogenic cells was developed from BALB/c 
mice, and therefore possesses the same genotypic background. CDBgeo cells were 
prepared by retroviral infection with a marker gene encoding the fusion of β-galactosidase 
and neomycin resistance. These cells exhibit normal outgrowths when transplanted into 
mammary fat pads.30 The TD cells were prepared by treating CDBgeo-cells with 10 
ng/mL TGF- for 14 days. Withdrawal for five passages resulted in a persistent epithelial 
to mesenchymal transformation: Tumorogenic growth resulted when transplanted. The 
V14 cell line was established from a primary mammary tumor arising in BALB/c-
Trp53+/- mice. The cells lack p53 protein and form aggressive tumors that are locally 
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invasive in mice.31 Figure 8.4a presents the change in fluorescence intensities of three 
isogenic cell types towards nanoparticle-polymer complexes. The differential response 
indicates that these supramolecular complexes can effectively differentiate isogenic cell 
types. LDA classifies the cell types into three distinct clusters with two canonical factors 
containing 83.0% and 17.0% of the variation, with 100% identification accuracy among 
these isogenic cell types (Figure 8.4b). Taken together, these studies indicate that our 
method rapidly and effectively differentiates cell lines based on cell type and disease 
state. 
 
 
Figure 8.4 Detection of Isogenic cell types. a) Change in fluorescence intensities (F − F0) for 3 cell lines of 
same genotype CDBgeo, TD cell and V14 using nanoparticle-polymer supramolecular complexes. Each 
value is average of 6 parallel measurements. b) Canonical score plot for the first two factors of simplified 
fluorescence response patterns obtained with NP–PPECO2 assembly arrays against different mammalian 
cell types. 
 
The efficacy of our approach indicates that there are distinct phenotypic differences in the 
physicochemical properties of cells. One question that arises is whether there is a 
response that is generally indicative of whether a cell is normal or cancerous. Meta-
analysis of our studies using LDA indicates that normal epithelial cell lines CDBgeo and 
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MCF10A were overlapping (Figure 8.5) even though both of these cell lines were isolated 
from mouse and human respectively. Likewise the metastatic murine (V14) and human 
MDMBA-231 metastatic cell lines were clustered, indicating a potential correlation 
between cell surface properties and disease states of cells.  
 
 
Figure 8.5 Detection of normal and cancerous cell lines. a) Changes in fluorescence intensities (F − F0) of 
noncancerous and cancerous cell types using nanoparticle-polymer supramolecular complexes. Each value 
is average of 6 parallel measurements. b) Canonical score plot for the first two factors of simplified 
fluorescence response patterns obtained with NP–PPECO2 assembly arrays against different normal and 
cancerous cell types. Further differentiation was observed in the third dimension, allowing discrimination 
each of the species. 
 
8.3 Conclusion 
In conclusion, we have developed a rapid and effective array-based approach to 
differentiate between normal and cancerous cell lines. Significantly, full differentiation 
was achieved using only three nanoparticle-polymer dyads, indicating that a simple 
sensor array has ample diagnostic capacity when exposed to mammalian cells. These 
systems have the potential to help us understand the physical changes that occur on the 
surfaces of cells in various disease states. Taken together, “nose” based sensor systems 
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are a fundamentally new way of looking into biodiagnostic and biophysical and surface 
science processes involving cell surfaces. 
 
8.4 Experimental Section 
Nanoparticles20,32 and polymers33 were synthesized as reported previously. All the cells 
except MCF10A, CDBgeo, TD and V14 were grown in DMEM media supplemented with 
10% FBS and 1% antibiotics in T75 flasks. NT2 cell line was obtained from Prof. R. 
Thomas Zoeller. CDBgeo, TD and V14 cells were grown in DMEM-F12 media 
supplemented with 2% ABS, 25mM HEPES, 10µg/mL insulin, 5ng/mL EGF, 15µg/mL 
gentamycin. Cells were washed with DPBS buffer, trypsinized with 1X trypsin and 
collected in the DMEM media. Fluorescence titration experiments determined the 
complexation between nanoparticles and PPE. Fluorescence intensity changes at 465 nm 
were recorded with an excitation wavelength of 430 nm. Polymer and stoichiometric 
amounts of NP1-NP3, as determined by the fluorescence titration study were diluted with 
phosphate buffer (5 mm, pH 7.4) to solutions with a final polymer concentration of 100 
nM.  Each solution (200 µL) was placed into a well on the micro plate. After incubation 
for 30 min, the fluorescence intensity at 465 nm was recorded with an excitation 
wavelength of 430 nm. Next, 100 µL of cell suspension (20,000 cells) was added to each 
well. After incubation for another 30 min, the fluorescence intensity at 465 nm was 
measured again. The fluorescence intensity before addition of the cells was subtracted 
from that obtained after addition of the cells to record the overall fluorescence response 
(DI). This process was completed for all cell lines to generate six replicates of each that 
was subjected to a classical linear discriminant analysis (LDA) using SYSTAT (version 
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11.0). The training matrix of fluorescence response patterns of NP-PPE sensor array 
(NP1-NP3 = Predictors) was generated from the addition of several normal and cancerous 
cell lines aliquots (Cell$ = Group variable) with identical cell numbers (6 replicates) 
coupled with Mahal statistics method using SYSTAT Program (version 11). As a 
result of running this program, statistical information was obtained,34 e.g. Group 
frequencies and group means, discriminat functions, classification matrix such as 
Jackknifed classification matrix, cumulative proportion of total dispersion, canonical 
scores of group means, etc. The Mahalanobis distance is the distance of a case to the 
centroid of a group in a multidimensional space (in the current case it is two-dimension). 
In a blind experiment, the rates of fluorescence patterns of new case were first converted 
to canonical scores using discriminate functions established on training samples. Then, 
Mahalanobis distances of the new case to the centroid of respective groups (Normal or 
cancerous or metastatic cells) of training samples were calculated.  The new case was 
assigned to the group with shortest Mahalanobis distance. This processing protocol could 
be automatically performed on SYSTAT 11 program. In this way, we have tested the cells 
blindly and have been able to assign them to specific groups. 
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Scheme 8.S1 Synthesis of ligands1,2,3  
 
General procedure: Compound II bearing ammonium end groups were synthesized 
through the reaction of 1,1,1-triphenyl-14,17,20,23-tetraoxa-2- thiapentacosan-25-yl 
methanesulphonate (I) with corresponding substituted N,N-dimethylamines during 48 h 
at ~35 oC. The trityl protected thiol ligand (II) was dissolved in dry DiChloroMethane 
(Methylene Chloride, DCM) and an excess of trifluoroacetic acid (TFA, ~ 20 
equivalents) was added. The color of the solution was turned to yellow immediately. 
Subsequently, triisopropylsilane (TIPS, ~ 1.2 equivalents) was added to the reaction 
mixture. The reaction mixture was stirred for ~5 h under Ar condition at room 
temperature. The solvent and most TFA and TIPS were distilled off under reduced 
pressure. The pale yellow residue was further dried in high vacuum. The product (L) 
formation was quantitative and their structure was confirmed by NMR. The yields were 
>95%.  
 
Compound L1: 1H NMR (400MHz, CDCl3, TMS):  3.95 (br, 2H, -OCH2-(CH2N)-), 
3.81-3.72 (m, 1H, HCyclo), 3.69-3.53 (m, 14H, -CH2O- + -CH2N-), 3.49 (t, 2H, -CH2O-), 
3.11 (s, 6H, -(CH3)2N-), 2.91 (s, 3H, CH3SO-3-), 2.52 (q, 2H, -CH2S-), 2.23 (d, 2H, 
HCyclo), 1.99 (d, 2H, HCyclo), 1.78-1.52 (m, 4H, -(SCH2)CH2  + -CH2(CH2O)-), 1.51-1.12 
(m, 21H, SH + -CH2-  + HCyclo). 
 
Compound L2: 1H NMR (400MHz, CDCl3, TMS):  8.37 (d, 1H, HAr), 7.98 (d, 1H, Ar-
), 7.69-7.61 (m, 3H, HAr), 7.59-7.48 (m, 1H, HAr), 4.38 (br, 2H,-NCH2-Ar), 3.76 (br, 2H, 
-OCH2-(CH2N)-), 3.72-3.62 (m, 14H, -CH2O- + -CH2N-), 3.61-3.55 (m, 2H, -CH2O-), 
3.23 (s, 6H, -(CH3)2N-), 3.07 (s, 3H, CH3SO-3-), 2.52 (q, 2H, -CH2S-), 1.67-1.51 (m, 4H, 
-(SCH2)CH2  + -CH2(CH2O)-), 1.35-1.21 (m, 15H, -SH + -CH2-). 
                                                 
1 Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R. J. Chem. Soc., Chem. Commun. 1994, 801-802.  
2 Hostetler, M. J.; Templeton, A. C.; Murray, R. W. Langmuir 1999, 15, 3782-3789.  
3 C.-C. You, O. R. Miranda, B. Gider, P. S. Ghosh, I.-B. Kim, B. Erdogan, S. A. Krovi, U. H. F. Bunz, V. M. Rotello, Nat. 
Nanotechnol. 2007, 2, 318-323. 
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Compound L3: 1H NMR (400MHz, CDCl3, TMS):  3.94 (br, 2H, -OCH2-(CH2N)-), 
3.78 (br, 1H, -OH), 3.75-3.52 (m, 16H, -CH2O- + -CH2N- +  -CH2-OH), 3.48 (t, 2H, -
CH2O-), 3.39-3.31 (m, 2H,-NCH2-), 3.25 (s, 6H, -(CH3)2N-), 2.89 (s, 3H, CH3SO-3-), 
2.52 (q, 2H, -CH2S-), 2.35-2.26 (m, 2H, -(NCH2)CH2-), 1.70-1.52 (m, 4H, + (SCH2)CH2  
+ -CH2(CH2O)-), 1.36-1.21 (m, 15H, -SH + -CH2-). 
 
 
 
 
 
Figure 8.S1 Dynamic light scattering (DLS) and zeta potential (ZP) of NP1-NP3 were measured in 5 mM 
phosphate buffer at pH 7.4. The overall size and charge of these cationic NPs were on the range of 10-12 
nm and ~21 mV respectively. 
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Figure 8.S2 Binding constants (log KS), binding stoichiometries (n) between polymer PPE-CO2 and 
fluorescence titration curves for the complexation of PPE-CO2 (100 nM) with various cationic gold 
nanoparticles as showed. The intensity changes at 465 nm were followed by adding several concentrations 
of NPs with an excitation wavelength of 430 nm.  The red solid lines represent the best curve-fitting. 
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Figure 8.S3  a) Chemical structures of the nine nanoparticles screened for cell sensing. B) Jacknifed 
classification matrix obtained through LDA analysis for nine nanoparticles for all cell sensing studies. 
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Table 8.S1 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1-NP6) against 
several normal and cancerous cell lines with identical cell numbers. 
 
 
Cell lines NP1 NP2 NP3 
HeLa 108.437 -22.619 131.272 
HeLa 96.849 -32.549 135.131 
HeLa 89.927 33.928 141.366 
HeLa 101.968 36.883 138.971 
HeLa 102.661 105.368 136.431 
HeLa 91.654 -38.012 134.211 
MCF7 88.523 -65.715 156.947 
MCF7 114.97 26.743 137.731 
MCF7 105.638 27.744 153.065 
MCF7 105.96 -26.903 142.949 
MCF7 117.061 17.557 155.298 
MCF7 114.596 6.609 150.304 
HepG2 47.544 -64.227 18.799 
HepG2 66.327 -21.701 23.522 
HepG2 80.899 26.59 23.866 
HepG2 64.620 7.153 17.854 
HepG2 62.46 26.967 19.176 
HepG2 56.912 -136.285 19.934 
NT2 19.087 -109.73 74.753 
NT2 8.361 -123.024 74.926 
NT2 73.837 -32.683 85.101 
NT2 58.277 -34.835 77.39 
NT2 22.529 -48.185 90.413 
NT2 -5.155 -77.017 56.566 
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Table 8.S2 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1-NP6) against 
several normal and cancerous cell lines with identical cell numbers. 
 
 
Cell lines NP1 NP2 NP3 
CDBgo 13.861 -24.620 51.592 
CDBgo 37.105 -21.639 59.431 
CDBgo 36.536 -36.333 68.922 
CDBgo 44.061 -26.607 55.739 
CDBgo 30.166 -17.268 56.664 
CDBgo 20.477 -29.478 48.557 
V14 35.127 -15.553 96.790 
V14 74.667 -26.552 90.021 
V14 77.513 -7.651 75.153 
V14 69.386 -23.164 69.885 
V14 73.883 -1.544 77.78 
V14 50.385 -19.679 82.247 
TD 39.278 -86.639 85.797 
TD 39.432 -90.846 71.702 
TD 36.815 -82.081 75.508 
TD 56.404 -74.041 75.384 
TD 32.872 -62.026 74.187 
TD 23.431 -64.688 58.341 
 
 
Table 8.S3 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1-NP6) against 
several normal and cancerous cell lines with identical cell numbers. 
 
Cell lines NP1 NP2 NP3 
MCF7 88.523 -65.715 156.947 
MCF7 114.97 26.743 137.731 
MCF7 105.638 27.744 153.065 
MCF7 105.96 -26.903 142.949 
MCF7 117.061 17.557 155.298 
MCF7 114.596 6.609 150.304 
MCF10A 36.403 -133.662 52.088 
MCF10A 38.125 42.26 50.506 
MCF10A 27.901 -41.355 60.088 
MCF10A 37.498 8.538 56.473 
MCF10A 25.869 -73.426 41.947 
MCF10A 30.117 -144.145 52.737 
MDMB231 49.212 -3.683 101.597 
MDMB231 78.188 0.156 111.938 
MDMB231 52.489 -40.314 100.431 
MDMB231 49.228 -5.52 105.549 
MDMB231 64.227 -23.985 102.052 
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Table 8.S4 Training matrix of fluorescence response patterns of NP-PPE sensor array (NP1-NP6) against 
several normal and cancerous cell lines with identical cell numbers. 
 
Cell lines NP1 NP2 NP3 
CDBgo 13.861 -24.620 51.592 
CDBgo 37.105 -21.639 59.431 
CDBgo 36.536 -36.333 68.922 
CDBgo 44.061 -26.607 55.739 
CDBgo 30.166 -17.268 56.664 
CDBgo 20.477 -29.478 48.557 
V14 35.127 -15.553 96.790 
V14 74.667 -26.552 90.021 
V14 77.513 -7.651 75.153 
V14 69.386 -23.164 69.885 
V14 73.883 -1.544 77.78 
V14 50.385 -19.679 82.247 
MCF10A 36.403 -133.662 52.088 
MCF10A 38.125 42.26 50.506 
MCF10A 27.901 -41.355 60.088 
MCF10A 37.498 8.538 56.473 
MCF10A 25.869 -73.426 41.947 
MCF10A 30.117 -144.145 52.737 
MDMB231 49.212 -3.683 101.597 
MDMB231 78.1889 0.156 111.938 
MDMB231 52.489 -40.314 100.431 
MDMB231 49.228 -5.52 105.549 
MDMB231 64.227 -23.985 102.052 
MDMB231 82.855 25.657 118.102 
TD 39.278 -86.639 85.797 
TD 39.432 -90.846 71.702 
TD 36.815 -82.081 75.508 
TD 56.404 -74.041 75.384 
TD 32.872 -62.026 74.187 
TD 23.431 -64.688 58.341 
MCF7 88.523 -65.715 156.947 
MCF7 114.97 26.743 137.731 
MCF7 105.638 27.744 153.065 
MCF7 105.96 -26.903 142.949 
MCF7 117.061 17.557 155.298 
MCF7 114.596 6.609 150.304 
CDBgo 13.861 -24.62 51.592 
CDBgo 37.105 -21.639 59.431 
CDBgo 36.536 -36.333 68.922 
CDBgo 44.061 -26.607 55.739 
CDBgo 30.166 -17.268 56.664 
CDBgo 20.477 -29.478 48.557 
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